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ABSTRACT 
 
 
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the five leading causes of 
cancer-related deaths in the West, and this, largely, is due to metastatic disease. In 
order to better understand PDAC metastatic spread and identify novel therapeutic 
targets, we analysed the proteome of primary tumours and matched lymph node 
(LN) metastases. As frozen specimens of metastatic lesions are scarce, we 
examined formalin-fixed paraffin-embedded (FFPE) tissues. Whilst such tissue is in 
routine diagnostic use, the cross-linkages induced by fixation have, in the past, 
precluded proteomic investigation for research purposes. Recent technological 
advances have, however, overcome this technical limitation.  
 
Using laser capture microdissection (P.A.L.M system), we isolated malignant 
epithelia from seven FFPE primary PDAC tumours and matched LN metastases. 
Following dissection, samples were analysed in duplicate using Multidimensional 
Protein Identification Technology (MudPIT); this resulted in the identification of 1504 
proteins, 854 of which were common to all samples analysed. Comparison of the 
obtained proteins with data from previous proteomics studies on pancreatic tissue, 
pancreatic juice, serum and urine resulted in a less than 30 % overlap, indicating that 
our study has expanded the current database of proteins expressed in this 
malignancy substantially. Statistical analysis further showed that 115/854 proteins 
(13.5%) were significantly differentially expressed (g-value ≥ 3.8). Two proteins, 
S100P and 14-3-3 sigma, with highly significant g-values were confirmed to be 
significantly differentially expressed (S100P: p = 0.05 and 14-3-3 sigma: p < 0.001) 
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in a larger series of 55 cases of matched primary PDAC and LN metastases using 
immunohistochemistry. 
 
 We chose to investigate further the roles of S100P in lymphatic invasion in vitro and 
in vivo. By co-culturing a Panc1 S100P-overexpressing clone (S5L), or a vector 
control clone (V3L), with human dermal lymphatic endothelial cells (HDLEC), we 
were able to show that different receptors mediate S5L adhesion to resting and 
activated HDLEC as opposed to V3L; and that the presence of S5L cells in these co-
cultures significantly increased permeability at one (p = 0.02), four (p = 0.002) and 
eight (p = 0.007) hours post-seeding, and significantly increased translymphatic 
endothelial migration at 72 hours (p = 0.006). Using the V3L and S5L cell lines, 
which were transduced to express luciferase, we also created an orthotopic mouse 
model of PDAC, as well as experimental metastatic mouse models, in CD1 nude 
mice. These models were used to evaluate the effects of S100P on primary tumour 
growth, metastasis and site-specific growth. S100P was only found to significantly 
increase primary tumour growth in this model (n = 10 animals/group), both by 
bioluminescence (p = 0.002) and tumour weight (p = 0.01). No metastases 
(spontaneous and/or experimental) were seen however. Thus, this model can be 
used to evaluate the anti-tumour efficacy of novel therapies to S100P in the future. 
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1. INTRODUCTION 
 
1.1  Pancreatic Ductal Adenocarcinoma 
 
Pancreatic Ductal Adenocarcinoma (PDAC) causes an estimated 227,000 deaths 
per year worldwide, and ranks as one of the five leading causes of cancer-related 
deaths in the Western world.  The five-year survival rate for PDAC is less than 5%, 
regardless of age, race and/or sex (1,2). These statistics reflect the fact that little 
progress has been made in the past 30 years in the management of this disease. 
Due to the latent, non-specific nature of the symptoms, most patients present late, 
once metastases already are present. Thus, there is an urgent need to increase our 
understanding of the pathogenesis of PDAC; improve our capacity both to diagnose 
this disease earlier and monitor its progression; and to develop novel therapies to 
treat metastatic disease. 
 
1.1.1 Multi-step Tumourigenesis 
 
The multi-step model of PDAC progression is well-established (Figure 1). It 
describes the histological and genetic changes that occur in the pancreatic ductal 
epithelia as cancer develops (3–5). 
 
Initially, the normal epithelium undergoes premalignant change, transitioning through 
three stages of ‘Pancreatic Intra-epithelial Neoplasia’ (PanIN). These lesions, 
characteristically, are contained by an intact basement membrane, and are classified 
according to the amount of cytological and architectural atypia present. The normal 
21 
 
pancreatic duct is lined by simple cuboidal epithelium. In PanIN-1, cells undergo 
metaplasia in which a change from cuboidal to columnar epithelium occurs (PanIN-
1A). In addition, cells adopt either a papillary, micropapillary or basally 
pseudostratified architecture (PanIN-1B). PanIN-2 lesions, by definition, show 
nuclear abnormalities, e.g. loss of polarity, hyperchromatism, nuclear crowding, 
enlarged nuclei and pseudostratification. Mitotic figures are rare at this stage but, if 
present, they should be nonluminal and not atypical. In PanIN-3 (carcinoma in-situ), 
the dysplasia is more pronounced at a cytonuclear level. Architecturally, cells begin 
budding into the lumen (cribriforming), and luminal necrosis may be present. 
Invasive cancer is defined by a breach of basement membrane, with cells moving 
out into the surrounding tissue (3–5).   
 
 
 
 
Figure 1 Progression model for the development of PDAC. Histological changes 
showing a progressive increase in cytological and architectural atypia are paralleled 
by a sequence of molecular alterations. These changes are thought to follow a linear 
temporal progression. However, the total number of mutations acquired is more 
important than the order in which they appear (Adapted from Robbins and Cotran 
Pathological Basis of Disease (5)). 
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Concurrent with these histological changes, a number of genetic changes occur.  
 
Telomere shortening is the earliest genetic change seen in PDAC (6).  These 
structures are located at the ends of chromosomes and in humans contain the 
tandemly repeated hexanucleotide sequence 5’-TTAGGG-3’ in conjunction with a 
number of telomere-binding proteins such as TRF1 and POT1 (7,8). These together 
form the functional telomere, which acts as a ‘protective shield’, preventing 
chromosomes from fusing with one another. Telomere loss occurs with every cell 
division, resulting ultimately in breakage-fusion-bridge cycles, and a resultant 
increase in chromosomal instability (9–13). Whilst it has been shown that telomere 
loss is important for the initiation of carcinogenesis, equally important is the 
emergence of the holoenzyme telomerase (hTERT) at a later stage in 
carcinogenesis, particularly at the point of conversion from a premalignant lesion to 
an invasive one (14). There are conflicting data at present as to the relevance of 
hTERT expression in PDAC. Current reports of hTERT mRNA quantification in 
PDAC tissues range from 41% to 83% (15,16). Whilst hTERT quantification in 
pancreatic juice indicates expression in the majority of PDACs, such tests currently 
are unable to distinguish benign from malignant disease (16,17). Furthermore, 
mouse data suggest that pancreatic carcinogenesis can progress in the absence of 
functional telomerase, raising the question of whether or not an alternative 
lengthening of telomeres (ALT) mechanism exists in PDAC (18). Finally, even in the 
absence of hTERT or ALT, the high prevalence of p53 mutations in PDAC (see 
below) may accelerate progression to invasive PDAC by allowing chromosomally 
unstable cells to proliferate by failing to initiate apoptosis and/or crisis (19). 
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In PanIN-1, the functional alteration of two proto-oncogenes, HER-2/Neu and KRAS, 
permanently activates intracellular signalling pathways, affecting proliferation, cell-
cycle, apoptosis, cell shape and motility. 
 
HER-2/Neu, a tyrosine kinase receptor of the epidermal growth factor receptor 
family, rarely is over-expressed in histologically normal pancreatic ducts, but is over-
expressed in 80% of PanIN-1 lesions (20).  However, the expression levels of HER-
2/Neu in PDAC are significantly lower, averaging across studies at less than 30% 
(20–24). These HER-2/Neu positive tumours typically result from increased 
transcription and translation of this receptor, with gene amplification being present in 
fewer cases; no mutations or receptor truncations have been identified, as yet 
(23,25). Several studies have shown that a positive HER-2/neu status significantly 
correlates with tumour stage, and negatively affects survival (23,26). However, no 
positive association with tumour grade has been demonstrated (26,27). In fact, HER-
2/Neu has been shown to be absent in poorly differentiated PDAC tumours, and 
strongly expressed in moderately or well differentiated tumours. The use of anti-
HER-2/Neu antibodies as adjuvant therapy for PDAC currently is under clinical 
investigation (28). 
 
KRAS undergoes a point mutation in 80–90% of PanIN-1 lesions - predominantly at 
codon 12, although codons 13 and 61 also can be affected (5,29). This results in 
constitutive activation of this GTP-binding protein. Furthermore, the expression of 
oncogenic KRAS in the pancreas of animal models, without other genetic 
abnormalities, is sufficient to induce the development of PanIN lesions which closely 
resemble human morphology (30,31). Interestingly, as oncogenic KRAS expression 
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in mouse models is driven by PDX-1 in the islet cells and P48/PTF-1A in the acinar 
cells of the pancreas, these models suggest that PDAC originates in the acinar, 
rather than the ductal, epithelia. Recently however, Shi et al. used the ‘almost 
ubiquitous’ expression of KRAS mutations in PDAC to trace the ‘cell of origin’ from 
which PDAC arises in human tissue samples (32). Acinar and stromal cells were 
found to express wild-type KRAS in this study, whilst cells from PanIN lesions 
expressed mutated KRAS. Of note, only acino-ductal metaplastic (ADM) lesions 
associated with PanIN, and not isolated ADM, harboured KRAS mutations. 
Furthermore, each ADM mutation found was identical to the mutation found in the 
associated PanIN lesion(s). Thus, the authors suggest that pancreatic neoplasia 
does not originate in acinar cells, in contrast to data obtained from mouse models 
 
Activation of tumour oncogenes is followed by loss of tumour suppressor genes in 
PanIN-2 and PanIN-3. This allows cells to overcome senescence, resulting in 
unopposed proliferation. The three most common tumour suppressor genes 
inactivated in PDAC are CDKN2A/p16ink4A, TP53 and DPC4/SMAD4. Furthermore, 
for all three of these genes, inactivation is due largely to loss of heterozygosity 
(LOH). A summary of these genes, including chromosomal location, mechanism of 
action and prevalence can be found in Table 1 (5).  
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Table 1 The chromosomal location, normal mechanisms of action, and prevalence of 
three tumour suppressor genes commonly affected in PDAC (5).  
 
Gene Location Mechanism of Action 
(in normal cells) 
Prevalence in PDAC 
CDKN2/p16INK4A 9p21  Cell cycle arrest 
(via CDK4/6) 
 95% of PDAC 
TP53 17p13  Cell cycle arrest 
 DNA repair 
 Apoptosis 
 Blocks 
angiogenesis 
 50-70% of PDAC 
DPC4/SMAD4 18q21  TGF-β induced 
growth inhibition 
 55% of PDAC 
 
 
The gene CDKN2/INK4A encodes the protein p16, which inhibits cell cycle 
progression from G1 into S phase by binding to the cyclin-dependent kinases Cdk4 
and Cdk6, thus preventing these molecules from binding to cyclin D1 (33). 
Mechanisms of p16 loss include homozygous deletion, intragenic mutation with loss 
of the second allele and epigenetic silencing by promoter methylation (34–36). Loss 
of nuclear p16 is found in PanINs associated both with cancer and chronic 
pancreatitis, although the frequency is lower in chronic pancreatitis (37).  
 
The bi-allelic inactivation of the TP53 gene almost always is due to a combination of 
intragenic mutation with loss of the second allele (38). Loss or alteration of p53 
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protein allows cells to bypass DNA damage checkpoints and evade apoptosis (39). 
In addition, as mentioned above, there is now evidence that p53 loss may contribute 
to the genomic instability seen in PDAC (19,40). Generally, p53 loss is considered to 
be a late event in PDAC progression, with accumulation of this protein being seen in 
advanced PanIN 3 lesions (41). 
 
Lastly, loss of the Deleted in Pancreatic Cancer 4 or DPC4 gene (also known as 
SMAD4 or MADH4) results in an interference with intracellular signalling downstream 
of the transforming growth factor β (TGF- β) family of cell surface receptors, 
decreasing growth inhibition and increasing proliferation (33,42). DPC4 loss is a late 
event in PDAC progression, and is evident only in PanIN 3 lesions (43). 
 
Interestingly, the combination of each of these tumour suppressor genes with KRAS 
mutations in mice results in the development of invasive pancreatic cancer; a 
phenomenon whose utilisation has increased the number of mouse models available 
for preclinical investigation (40,44,45).  
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1.2  Metastasis 
 
1.2.1  Tumour Evolution and Spread 
 
Metastasis has been defined as ‘the spread of cells from the primary neoplasm to 
distant organs, and their relentless growth’ (46).  
 
It has long been thought that tumours invade and spread through a series of 
sequential steps termed ‘the invasion-metastasis cascade’ (Figure 2) (46). 
According to this model, locally invasive cancer cells gain entry into blood or 
lymphatic vessels (intravasate), survive and travel in these vessels to distant sites, 
where they move out of the vessels (extravasate) into foreign environments. 
Secondary tumour growth (colonisation) occurs initially as micrometastases (i.e. 
single or small clumps of cells) which, over time, adapt and grow into 
macrometastases (> 2 mm in diameter).  
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Figure 2 The ‘invasion-metastasis cascade’. a. Cellular transformation and primary 
tumour growth. b. Extensive vascularisation (angiogenesis) must occur for the 
primary tumour to exceed 1-2 mm in diameter. c. Intravasation. d. Survival inside the 
lymphatic and blood circulatory systems. e. Extravasation. f. Colonisation (46) 
 
 
According to the classic theory of metastasis (46), metastatic tumours are derived 
from a single clone. As a tumour grows, the tumour population becomes increasingly 
genetically unstable, giving rise to ‘intra-lesional heterogeneity’. Within this evolving 
population, selection pressures and epigenetic mechanisms then govern which 
clone(s) will be able to metastasise. Thus, each metastatic tumour arises from a 
single progenitor cell (inter-lesional heterogeneity) which then establishes a 
heterogenous metastatic tumour via the same process that occurred in the primary 
tumour. This theory was founded largely on the work of Fidler and Kripke, and is 
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based on data obtained from experiments in which cell lines (predominantly 
melanoma) were grown and/or injected into mouse models (46–48). A variety of 
techniques were used in order to create clones with varying metastatic capacities, 
including the in vitro and in vivo selection of clones from parental cell lines, and 
radiation-induced genetic  instability. An intriguing finding of these studies, and one 
which often is forgotten, is that tumour heterogeneity exerts a stabilising effect on the 
tumour population. Indeed, a parental cell line maintains its metastatic capacity for 
years in vitro, whilst individual clones which are either isolated from this parental 
population or subjected to a strong selection pressure, e.g. chemotherapy, show an 
increased metastatic potential. When these clones are once again merged into a 
polyclonal population however, equilibrium is restored. Thus, ‘the society of tumour 
cells imposes regulatory constraints upon its individual members’. For Fidler and 
Hart, the very existence of this phenomenon argues against the random nature of 
metastasis, and suggests that, as this process is regulated, it can be successfully 
manipulated by therapeutic intervention (46–48). 
 
The advent of sequencing technology has allowed for these analyses to be extended 
to human tissues. Using ‘comparative lesion sequencing’ in colorectal cancers, in 
conjunction with a mathematical model derived from the passenger mutation rate, 
Jones et al. have proposed that it takes approximately 17 years for benign adenomas 
to develop into advanced carcinomas whilst, thereafter, the ability to metastasise is 
acquired fairly quickly though a relatively small number of additional mutations (49). 
Based on sequencing data obtained from 13 patients, the authors propose two 
evolutionary models: in model A, none of the cells within the primary tumour are able 
to metastasise, but require only a few genetic alterations in order to gain that 
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capacity; and in model B, all of the cells within the primary tumour have the ability to 
metastasise, without any further genetic alterations being required. Whilst it could be 
argued that model A represents the classic theory of metastasis, model B could 
represent an alternative theory - that of the early ‘metastatic gene signature’. In 
contrast to the classic theory, this suggests that metastatic potential is a pre-
ordained feature of certain primary solid tumours, and is not governed by selection 
pressures. In 2003, Ramaswamy et al. published a 17 metastatic gene signature that 
could be associated with medulloblastomas and a number of adenocarcinomas 
(lung, breast, prostate), but not with diffuse large B cell lymphomas (50). This 
signature comprised genes originating from both the epithelial and stromal 
compartments of the analysed tumours, and reflects the fact that tumours were not 
laser capture microdissected before profiling. Thus, the authors emphasise that 
metastasis arises from the interplay of various cell populations within the tumour 
mass, and not from the epithelial component in isolation; a concept which reflects the 
hallmarks of cancer as proposed by Weinberg and Hanahan (51). Ramaswamy’s 
paper raises an interesting question: does ‘heterogeneity’ exist in the epithelial 
population, as originally thought, or is ‘heterogeneity’ a product of crosstalk between 
a community of varied cell populations? For Fidler and Kripke, the divergence of 
these two models represents our inability to monitor the development of tumour 
heterogeneity in real time (52). If one concedes that gene expression signatures 
represent a snapshot in primary tumour evolution, then one cannot rule out the 
possibility that, if profiling were performed on a polyclonal epithelial tumour 
population in aggregate, some clones within the tumour mass could show a change 
in metastatic genes, whilst other clones simultaneously could show a change in 
genes governing proliferation. Thus, whilst comparing primaries and their 
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metastases provides us with clues as to how metastasis occurs, it cannot accurately 
quantify its kinetics. What is perhaps of more practical significance, however, is that 
analysing primary tumours for such ‘signatures’ increases our capacity to predict 
which tumours are most likely to metastasise, and therefore, to stratify patients in 
terms of risk and treatment. Thus, a move towards the molecular classification of 
solid tumours was established.  
 
According to Bernards and Weinberg, one of the major implications of the ‘metastatic 
gene signature’ theory is that metastatic genes do not exist per se, but rather, that 
metastasis is governed by the same oncogenes and tumour suppressor genes which 
have been studied for years (53). The authors reason that if this were not the case, 
then cells with a metastatic phenotype would constitute only a small proportion of the 
primary tumour, which, if one considers the low success rate of individual cells trying 
to metastasise, would make metastasis almost impossible. Thus, the mutations that 
confer a replicative advantage to tumours early in tumourigenesis, must also confer 
a metastatic advantage later on in tumour evolution. In essence, this paper 
emphasises the importance of the genomic instability generated by increased 
proliferation, rather than tumour size, as the driver behind metastasis. 
 
This view has been challenged by the parallel progression model (54). According to 
this theory, the early dissemination of cancer cells from primary tumours to various 
mesenchymal tissues in the body allows for the simultaneous growth of primary 
tumours and metastases. Evidence for this model derives, in part, from the whole 
genome analysis of disseminated tumour cells (DTC) isolated from pre-operative 
patients with breast, prostate and oesophageal cancers (55–61). In these studies, 
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DTCs from patient bone marrows harboured fewer genetic aberrations than their 
matched primary tumours. Thus, the authors conclude, dissemination must have 
occurred prior to the acquisition of whole genome instability. Further evidence for the 
early escape of cancer cells from premalignant lesions came from Husemann et al. 
who used transmission electron microscopy to capture cells escaping from atypic 
ductal hyperplastic (ADH) lesions in a Balb-NeuT transgenic mouse model; dormant 
cells with malignant potential were also demonstrated in the bone marrows and 
lungs of these mice at this premalignant stage (62). These findings were extended to 
607 human breast cancer samples, in which the number of DTCs found in patient 
bone marrows did not correlate with tumour size, and thus, stage. The final paper 
challenging Weinberg’s ‘progression puzzle’ was published in 2008 by Podsypanina 
et al., and showed that oncogene expression does not affect survival and 
extravasation of DTCs, but rather that these genes are required only for secondary 
tumour growth (63). These experiments were conducted in experimental metastatic 
mouse models; untransformed mouse mammary cells in which the transgenes MYC 
and KRAS, or polyoma middle-T, could be expressed inducibly, were injected into 
the tail veins of Rag1-/- mice. Lung tumours developed in the recipient mice only 
upon doxycycline administration at various time-points. Thus, the untransformed 
cells were able to survive in the bloodstream and extravasate into the lungs, 
remaining dormant without oncogene activation.  
 
Finally, the ‘seed and soil’ theory, as originally proposed by Paget in 1889, 
emphasises the importance of the tumour microenvironment in the metastatic 
process (64). By recognising the importance of ‘congenial soil’ in determining the 
growth of a metastatic clone, Paget was the first to highlight the intricacies of the 
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colonisation step in the metastatic cascade. By acknowledging the importance of the 
‘seed’, he recognised the importance of tumour as heterogenous tissue. And by 
emphasising the interaction of seed with soil, he recognised the selective nature of 
the metastasic process. His observations still hold true today. 
 
1.2.2  Metastasis in PDAC 
  
Little is known about the metastatic process in PDAC. This is largely due to the 
limited availability of tissue samples for analysis, as patients with metastatic disease 
are not amenable to surgery. Access to tissue samples has improved since the 
establishment of the Johns Hopkins Gastrointestinal Cancer Rapid Medical Donation 
Program (GICRMDP) which harvests rapid autopsy frozen samples for research 
(65); however access to surgically resectable PDAC samples and/or metastases 
remains difficult. Prior to the GICRMDP, only two studies had analysed the gene 
expression profiles (GEP) associated with PDAC metastases by correlating data 
obtained from fresh frozen primary tumours with clinicopathological parameters; the 
metastatic tissue itself was not analysed. In 2004, Nakamura et al. compared the 
GEP of laser microbeam microdissected PDAC to that of adjacent histologically 
normal ductal epithelia (n = 18 in total; n = 13 with known lymph node status) (66). 
Of the 606 differentially expressed genes found, 76 genes (35 up–regulated and 41 
down-regulated) showed a positive association with lymph node (LN) metastases. In 
2007, Kim et al. analysed the GEP of 10 macrodissected PDAC samples, five of 
which had positive LNs (67). In this study, 194 differentially expressed genes (66 up–
regulated and 128 down-regulated) were found to positively correlate with LN 
metastases. Comparison of the gene sets obtained from these two studies showed 
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virtually no overlap, which most likely reflects the technical differences between the 
two studies. Firstly, Nakamura et al. isolated a pure population of cancer cells using 
laser microbeam microdissection, whereas Kim et al. analysed whole tissue samples 
which contained stromal tissue; secondly, the DNA microarray used by Kim et al. 
contained approximately 15,000 more genes than that used by Nakamura et al.; and 
lastly, Nakamura et al. analysed their data by first comparing all pancreatic cancer 
samples to adjacent histologically normal pancreatic tissue, and then stratified the 
cancer samples into those with or without LN metastases, whilst Kim et al. only 
compared the GEP of PDACs with LN metastases to those PDACs without LN 
metastases.  
 
In 2008, Jones et al. sequenced 24 autopsy-derived primary PDAC samples, 
obtained from seven patients, in order to catalogue the somatic mutations found in 
PDAC (68). Of the 69 altered gene sets found, 31 were validated at a transcript level 
using serial analysis of gene expression (SAGE). Importantly, this transcriptome 
could be classified into 12 core signalling pathways, which are now considered to be 
central to PDAC pathogenesis. Although not stated in the article, these 12 pathways 
can, in turn, be classified into the six hallmarks of cancers (51). Importantly, the 
authors suggest that future therapies should aim to target the point at which these 
aberrations converge (i.e. the processes which they affect), rather than the genetic 
defects themselves.  
 
In the same year, Campagna et al. found that very few changes occur between the 
transcriptomes of primary pancreatic tumours and their metastases (69). As RNA 
from half of the 60 available samples had degraded following macrodissection, 30 
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matched and unmatched frozen tissue samples ultimately were analysed, 
representing five surgically-resected primary PDACs; five autopsy-derived primary 
tumours; and 20 autopsy-derived metastases from liver, lung, peritoneum and lymph 
nodes. Interestingly, although no appreciable change was demonstrated between 
primary tumours and metastases when analysed en masse, differential expression 
was found between each matched pair, suggesting that tumours did evolve within 
each patient. Furthermore, 242 genes were found to be differentially expressed 
between the primary tumours obtained from surgery (pT2 or pT3), and the primary 
PDACs with co-existent metastatic disease (pT4) obtained at autopsy. Thus, it is 
possible that early stage primary lesions do differ significantly from metastatic 
lesions. As the surgical lesions were unmatched however, such a comparison was 
not possible in this study. 
 
More recently, Yachida et al. (70) sequenced autopsy-derived PDAC metastases 
from seven patients, whose primary tumours previously had been sequenced by 
Jones et al. (68). Using comparative lesion sequencing, in conjunction with the 
mathematical model previously established for colorectal cancer (49), the authors 
propose a linear clonal evolution model for PDAC, in which, a ‘therapeutic window of 
opportunity’ of approximately 10 years exists during which metastasis may be 
prevented. A caveat to this model however, is that the kinetics are calculated using 
data obtained from patients with advanced metastatic disease, and may not 
accurately reflect the spatio-temporal evolution of metastases in real time. 
Furthermore, if at least 5 years are needed for metastasis to develop, as is 
suggested in this paper, why then do most patients with PDAC die within 5 years of 
diagnosis?  The answer to this is not clear at present: either this model accurately 
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reflects the kinetics of metastasis in real time, and mortality is compounded by other 
factors e.g. late presentation, or the fact that the pancreas is a vital organ, loss of 
which results in pathophysiological disturbances which accelerates disease 
progression; or this model fails to include a variant of PDAC which metastasises at a 
faster rate.  
 
In 2010, Campbell et al. (71) showed that genomic instability persists after 
dissemination in PDAC; emphasising the importance of selection and adaptation of 
cancers to new ‘soils’ as originally proposed by Paget. As in the above-mentioned 
studies, comparative lesion sequencing was performed on rapid autopsy-derived 
samples. However, for 10 of the 13 patients recruited to this study, sequencing was 
performed on cell lines derived from patient tissues - three representing resected 
primary tumours and seven representing index metastases. It could be argued, 
therefore, that this is the reason why the data obtained from this study match data 
derived from mouse studies, i.e. does altering the ‘seed’, for example by deriving cell 
lines in vitro from human tissue, alter the manner in which it interacts with the ‘soil’ in 
mouse models, and/or the sequencing data obtained ex vivo? However, evidence of 
clonal selection did extend to the two patients in which actual tissues (three 
metastases per patient) were sequenced.  
 
To date, only one proteomic study analysing 10 primary pancreatic cancers with or 
without LN metastases has been performed on fresh frozen, needle microdissected 
samples using 2D-DIGE combined with MALDI-TOF (72). When the results of this 
study were correlated to clinicopathological parameters, 18 up- and 15 down- 
regulated proteins were found; of these, moesin, radixin and c14orf166 were 
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confirmed, by Western blot (WB) and Immunohistochemistry (IHC), to be up-
regulated in primary PDAC with associated LN metastasis. No therapeutic targets 
were identified. And, most importantly, the LN metastases themselves were not 
analysed. 
 
Although fresh frozen PDAC/metastatic tissues are limited in supply, a substantial 
archive of formalin-fixed paraffin-embedded (FFPE) tissues exists that is more 
readily accessible. These tissues traditionally have been considered sub-optimal for 
proteomic analysis; however, there is now mounting evidence that valuable 
information, comparable to data obtained from frozen specimens, can be retrieved 
from FFPE samples from a variety of human tissues (73–77), including the pancreas 
(78).  
 
Whilst this ‘equivalence of fresh/frozen and FFPE proteomes’ was initially reported 
on prostatic tissues (73), the most comprehensive analysis was performed by 
Sprung et al. in 2009 (77). In this study, colon adenoma samples of a fixed 
dimension (60 µm diameter) were either snap-frozen or fixed in 10% formalin for 24 
hours. All samples then underwent tryptic digestion, with subsequent iso-electric 
focusing in order to separate the complex peptide mixtures into 20 fractions, each of 
which was analysed using LC/MS/MS. The rationale behind using tissues of fixed 
dimensions was to ensure that equal, accurate quantities of protein were analysed 
between fresh frozen and FFPE samples, as it is known that those amino acids 
which contribute to copper reduction in bicinchoninic acid (BCA) assays are also 
modified by formalin during fixation. Indeed, this study showed that protein 
measurements of FFPE samples were consistently 56% lower than that of their fresh 
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frozen counterparts (77). Thus, a corrective factor was introduced prior to tryptic 
digestion to ensure equal protein loading. Furthermore, as formalin induces intra- 
and inter-molecular cross-linkages at the primary amines of lysine side-chains, the 
authors questioned if C-terminal lysine-containing peptides would be under-
represented following shotgun proteomics; a hypothesis which proved to be true 
upon further analysis. However, this qualitative difference in peptide production was 
not found to alter protein identification; rather, it was shown that data analysis is the 
most important determinant of protein identification. The authors showed that a 
combined database search of both fresh frozen and FFPE inventories 
simultaneously yielded better results (90% overlap) than separate database 
searches (67% overlap) (77). The reason for this discrepancy lies in the two peptide 
requirement for peptide identification i.e. at least two fragmented peptides (see 
below) which are obtained via MudPIT must be realigned or matched to the parent 
protein in order for that to count as a positive result.  Whilst this reduces the number 
of false positives, it can increase the number of false negatives. If, for example, a 
protein is identified by two peptides in fresh frozen tissue, but produces only a single 
peptide for identification in the FFPE tissue, then it would incorrectly be logged as 
being present in fresh frozen tissue but absent in FFPE tissue. If the data sets are 
analysed simultaneously however, the fresh frozen dataset ‘rescues’ that FFPE 
single peptide in terms of protein identification, correcting this error. Thus, whilst the 
two peptide criteria serve to increase the sensitivity of MudPIT, simultaneous 
searches using multiple databases aim to improve its specificity. In addition to the 
significant overlap found between the two tissue types using this method, the 
subcellular compartmental distributions of proteins found from both fresh frozen and 
FFPE tissues were nearly identical. Thus, the authors conclude that human FFPE 
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proteomes are equivalent to human fresh frozen proteomes. Finally, this study 
examined the effects of the duration of formalin fixation and storage on protein yield, 
proving that a fixation time of up to 2 days, and long-term storage of up to 10 years 
duration, did not affect proteomic analysis adversely (77).  
 
These findings were extended to the human pancreas in 2009 by Reimel et al. (78), 
who showed a 69% overlap in peptide identification between frozen (340 proteins in 
total) and FFPE (370 proteins in total) human pancreatic samples. These samples 
had been macrodissected, digested in trypsin and analysed using nano-LC/MS/MS 
(78). The authors do not specify how the data were analysed in this study however; it 
would be interesting to note if the fresh frozen and FFPE data had been analysed 
simultaneously or not, as this would explain why only a 68% overlap was obtained 
(77). Nevertheless, these data are particularly relevant to the current study, as they 
validated, for the first time, the use of FFPE pancreatic tissues for proteomic 
analysis. The study also widened the scope of PDAC research; as patients with early 
stage PDAC who are amenable to surgery routinely have metastatic lymph node 
tissue processed for diagnostic purposes, these tissues now were considered 
eligible for research proteomics. Any data obtained from such FFPE samples also 
could be crucial to both understanding and potentially preventing metastasis.  
 
A number of technological advances which increase the number of proteins that can 
be recovered from FFPE have emerged in the past decade. The Liquid Tissue MS 
Protein Prep Kit, which has been available commercially since 2005 (79), has been 
shown to retrieve unique peptides reproducibly from laser capture microdissected 
(LCM) FFPE specimens for downstream ‘shotgun’ proteomics (73,80). 
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Improvements to this reagent over the past few years have resulted in a 10-fold 
decrease in the amount of starting material required for proteomic analysis (200,000 
LCM cells to 20,000 LCM cells over a period of three years) (73,80), which is of great 
benefit in diseases where specimens are scarce, like metastatic PDAC.  
 
The parallel development of large-scale, high-throughput proteomic technologies has 
further increased the amount of data that can be obtained from relatively small 
amounts of tissue. Multidimensional Protein Identification Technology (MudPIT) is 
one such technique that separates peptides in a complex mixture in two dimensions; 
first on the basis of charge, and then on the basis of hydrophobicity (81) (Figure 3). 
This added dimension, or ‘pre-fractionation’ step, further reduces sample complexity; 
thus MudPIT has been shown to considerably increase the number of proteins 
identifiable by mass spectrometry (82–84). The principle behind MudPIT is basically 
one of fragmentation. A protein is fragmented, both enzymatically (trypsin) and via 
collision-induced dissociation (CID) (mass spectrometry), in order to decrease the 
likelihood that mistakes are made during the in silico analysis when the peptide is 
realigned for identification. Theoretically, as the length of the fragmented peptide 
increases, the margin of error for realignment (and thus identification) decreases 
(85). If one considers that there are 20 amino acids, and if one assumes that all 
amino acids are equal in terms of their capacity to bind each other (which is not 
necessarily true), then the probability of a single amino acid occupying a particular 
position in a peptide sequence is 1 in 20. Thus, for a peptide that has six amino 
acids residues, the theoretical probability of an amino acid occupying a particular 
position in a peptide is 1 in 206 (or 1 in 64,000,000). Even with these odds however, 
false positives do occur (85).  
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Figure 3 Multidimensional protein identification technology (MudPIT). Total cell 
lysate (e.g. laser capture microdissection PDAC tissue) first undergoes enzymatic 
digestion (e.g. using trypsin). This produces a complex peptide mixture, which 
subsequently is separated in two dimensions: first on the basis of charge via strong-
cation exchange (SCX), and then on the basis of hydrophobicity using reverse-phase 
(RP) liquid chromatography. The resulting simplified or ‘fractionated’ peptide mixture 
then is analysed using mass spectrometry. The fragmented peptides resulting from 
this process are then realigned in silico in order to determine the protein composition 
of the starting material (Adapted from Whitelegge et al. (86)).  
 
 
This is largely because protein identification is further complicated by the concept of 
‘peptide detectability’ (87,88). This refers to the likelihood of observing a peptide in a 
standard proteomics experiment, and is determined by four factors: the chemical 
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properties of the peptide (and the parent protein); the limitations of the peptide 
identification method – including sample processing and digestion, the MS 
instrumentation, and the database(s) used; the abundance of the peptide in the 
sample; and the other peptides in the sample which compete with the peptide in 
question during the identification procedure. It could be argued, therefore, that the 
likelihood that a peptide will be seen in a sample is an intrinsic property of the 
peptide – determined directly by its primary amino acid sequence, and the location 
that it occupies within the composite protein. Thus, abundance alone does not 
determine detection (87,88). Rather, it is the quality of the method, as well as the 
quantity of starting material, which determines the output. 
 
The stochastic nature of data acquisition during mass spectometry was carefully 
studied by Liu et al. in 2004, in order to determine the optimum conditions for sample 
analysis (89). Nine LC/LC/MS/MS experiments were performed on the soluble 
fraction of whole cell yeast lysates, during which the experimental conditions were 
held constant across all sample runs i.e. samples did not differ in complexity, 
separation resolution, and data acquisition. Even having corrected for all these 
variables, inter-sample reproducibility was only 76%. It was determined that, in light 
of this limited reproducibility, the same data could be acquired from three sample 
replicates as from nine, irrespective of sample origin (89). The authors also 
investigated how best to quantitate protein abundance in these samples by spiking 
four different mixtures with known quantities of six proteins. Spectral counting was 
shown to be an accurate measure of relative protein abundance, with a linear 
correlation over a dynamic range of two orders of magnitude. Spectral counts reflect 
the number of matched peptides, and the number of times those peptides were 
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observed. Thus, spectral counts can be used as a semi-quantitative measurement of 
protein concentrations in unlabelled protein mixtures, as well as to evaluate any 
changes in protein composition between different samples (89).  
 
There has been little consensus on the statistical analysis of label-free proteomics 
data, particularly with regards to calculating differential protein expression. In 2006 
however, Zhang et al. compared five statistical tests in evaluating differential protein 
expression, namely the G-test, AC test, Fisher’s exact test, t-test and Local-Pooled-
Error (LPE) test (90). This was done by comparing the false positive rates obtained 
with each statistical test when one to three sample replicates of S. Cerevisiae cell 
lysates, which had been spiked with six proteins of known concentration, were 
analysed using LC/MS/MS. It was found that when a large fold-change (i.e. five- to 
ten-fold) in protein concentration was present, the G-test, AC-test and Fisher’s exact 
test yielded false positive rates of < 0.7%. However, when a two-fold change in 
differential expression was present, the t-test yielded the lowest false positive rates 
when > 3 replicates were used, whilst the G-test, AC-test and Fisher’s exact test 
were superior when ≤ 2 replicates were used. Thus, the authors conclude that the t-
test should be used when three or more replicates are analysed, whilst the G-test, 
AC-test or Fisher’s exact test should be used when less than three replicates are 
available (90). 
 
1.2.3 S100P in PDAC 
 
S100P, a 10.4 kDa EF-hand calcium-binding protein, has been a long-standing focus 
in our laboratory. A number of previous studies have investigated the importance of 
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this protein in PDAC (91–97). We have shown that S100P (transcript and protein) is 
absent in normal pancreatic ductal epithelia, progressively increased in PanIN 
lesions, and is expressed in > 90% of primary PDACs in human tissue samples 
(91,92). In a similar study performed by Logsdon et al., S100P was confirmed to be 
expressed exclusively in the neoplastic epithelial compartment of PDAC, using GEP 
with subsequent IHC validation (93). Importantly, analysis of S100P expression in 
this study included a comparison with tissue samples of chronic pancreatitis, a 
condition which is often difficult to differentiate from PDAC (93). In 2004, Arumugam 
et al. showed that S100P binds to the receptor for advanced glycation end-products 
(RAGE), hereby increasing the proliferation and survival of NIH3TC fibroclasts (97). 
The authors went on to investigate the effects of S100P expression in pancreatic cell 
lines and in orthotopic mouse models of PDAC (95,96). They showed that S100P 
increased pancreatic cancer growth, survival and invasion both in vitro and in vivo; a 
mechanism of action which could be targeted using cromolyn, or analogues thereof 
(95,96). In 2007, we showed that S100P increases invasion by mediating changes in 
the actin cytoskeleton and up-regulating cathepsin D in vitro (94). These experiments 
were conducted using a Panc-1 cell line, which was engineered in-house to over-
express S100P or a vector control (S5 and V3 cell lines respectively). Finally, we 
recently have found S100P to be a potential candidate gene involved in the 
haematological dissemination of PDAC (Sayka Barry, PhD Thesis 2009). These data 
were obtained from GEP experiments performed on unmatched human PDAC and 
liver metastases, with subsequent in vitro (transendothelial migration assays) and in 
vivo confirmation (Zebrafish model of metastasis). Thus, evidence for a causative 
role for S100P in PDAC metastasis is accumulating. However, the potential role of 
this protein in lymphatic metastasis has not been investigated to date.  
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1.3  The Biology of the Lymphatic Vasculature  
 
The lymphatic system regulates fluid homeostasis, immune function and fat 
absorption. It also is involved in a number of pathological processes, including 
tumour metastasis. Despite this, our understanding of the molecular mechanisms 
controlling the lymphatic system is still in its infancy. This is due to a historical lack of 
defining molecular markers to establish unequivocal provenance of putative cells of 
the lymphatic system, as well as to the fact that lymphatic cells are difficult to 
observe and manipulate both in vitro and in vivo. Whilst much progress has been 
made in this field of late, the precise molecular features that determine cellular and 
fluid entry into lymphatics remain poorly understood (98,99). 
 
1.3.1  Lymphatic Markers 
 
Several lymphatic markers have been identified recently, although few if any are 
expressed exclusively by the lymphatic endothelium. The three most commonly used 
markers are the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1); the 
transmembrane glycoprotein, podoplanin (PDPN); and the homeobox transcription 
factor, Prox-1 (98–100).  
 
The transmembrane glycoprotein, LYVE-1, first described by Banerji et al. in 1999, is 
a member of the Link protein superfamily, which binds hyaluronic acid (HA) via a 
conserved link module domain (101). Developmentally, LYVE-1 is expressed as the 
lymphatic system starts to sprout from a subpopulation of endothelial cells in the 
cardinal vein (98,99). In adult tissues, it is expressed on lymphatic endothelial cells 
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(LEC), liver sinusoidal endothelial cells and some populations of tissue macrophages 
(102). However, despite its expression in lymphatic progenitor cells, the absence of 
LYVE-1 in mice does not impede lymphatic development; indeed, knockout mice 
have a normal structural and functional lymphatic system (103). LYVE-1, therefore, 
does not appear to be essential for lymphatic specification or lymphangiogenesis. 
Furthermore, LYVE-1 null mice are comparable to wild type controls in a number of 
pathophysiological processes, including leukocyte development and 
compartmentalisation; dendritic cell trafficking/migration; acute inflammation; tumour 
growth; tumour-associated lymphangiogenesis and HA turnover (103). A possible 
explanation for the latter is that LYVE-1 is ‘functionally silenced’ in normal LEC by 
autoinhibitory glycosylation, and requires activation in order to bind HA (102). 
Despite this, the receptor itself can still be endocytosed and degraded without 
binding HA (104). These contradictory findings illustrate the complexity of LYVE-1, 
which requires further investigation. 
  
PDPN (podoplanin), a 38 kDa membranous glycoprotein, is expressed by lymphatic, 
but not blood vascular, endothelium. However, in normal human tissues, it also is 
expressed in kidney podocytes, skeletal muscle, in the placenta, lung and heart, in 
myofibroblasts of the breast and salivary glands, in osteoblasts and in mesothelial 
cells (105). Developmentally, like LYVE-1, PDPN is up-regulated in a subpopulation 
of progenitor cells in the cardinal vein, under the control of Prox-1 (see below) 
(98,99). In contrast to LYVE-1 however, the homozygous deletion of PDPN in mice is 
embryonically lethal; mice die of respiratory failure due to a shortage of type I 
alveolar epithelial cells (106). In addition, these mice show extensive cutaneous 
lymphoedema due to lymphangiectasia. Recently, it has been shown that PDPN 
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interacts with the platelet membrane lectin, CLEC-2, during lymphatic development, 
inducing platelet aggregation, which allows for the separation of lymph sacs from the 
cardinal vein (107,108). PDPN has also been shown to promote LEC adhesion to 
fibronectin (FN) and type I collagen, as well as to increase LEC migration towards 
fibronectin (106). Interestingly, PDPN is expressed at the invasive front in a number 
of squamous cell carcinomas, ovarian cancers, mesotheliomas and a subset of CNS 
tumours (109–114). However, contradictory evidence exists at present as to the 
molecular mechanisms underlying tumour migration as a consequence of podoplanin 
expression (105). In the Rip1Tag2 transgenic mouse model, progression of benign 
adenomas to carcinomas in the pancreas has been shown to involve a switch from 
E-cadherin to N-cadherin. This ‘cadherin switch’ is considered to herald epithelial-
mesynchymal transition (EMT), and thus, single cell migration of cancer cells. 
Trangenic expression of podoplanin in these β–islet cell tumours was shown to 
prevent this ‘cadherin switch’ from occurring, and to promote collective cancer cell 
migration as opposed to single cell migration (105). Similar results were found when 
podoplanin was over-expressed in both human keratinocytes and MCF-7 breast 
cancer cells (105). In the latter, podoplanin expression resulted in a down-regulation 
of RhoA activity, which resulted in an increase in collective cell migration (114). 
Conversely, the expression of podoplanin in MDCK cells has been found to increase 
RhoA activation, resulting in an EMT, and increased single cell migration (115). 
Thus, it would appear that podoplanin can modulate cell migration in two different 
ways by modulating RhoA (114,115).  
 
Finally, the homeobox transcription factor, Prox-1, has been described as the 
‘master control gene’ of LEC (100). Prox-1 has been conserved throughout 
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evolution; its expression heralds lymphatic specification in mice, zebrafish, frogs and 
chicks (98). Loss of Prox-1 expression results in lymphatic agenesis, whilst over-
expression of Prox-1 in blood vascular endothelial cells results in conversion to a 
lymphatic phenotype (98–100). Although the initial cues governing Prox-1 up-
regulation require further elucidation, there is evidence that SOX-1 (SRY-related 
HMG domain transcription factor), MYC, Slug and Twist can induce Prox-1 
expression, whilst TGFβ can inhibit its expression (98). Prox-1 has also been shown 
to up-regulate a number of lymphatic markers, including LYVE-1, podoplanin, 
VEGFR-3 and α9 integrin (98–100). In fact, it has been shown that LEC migration 
towards VEGF-C and VEGF-D is mediated by the integrin α9β1 and VEGFR-3, and 
that the expression of both these receptors is dependent on Prox-1 expression (116). 
This was shown in a series of experiments on human umbilical venous endothelial 
cells (HUVECS) and mouse embryonic stem cell derived endothelial cells, which 
utilised adenoviruses encoding wild-type and mutant Prox-1 and VEGFR-3 
constructs, siRNA knockdown of Prox-1 and neutralising antibodies to the integrin 
α9β1 to study the effects of Prox-1 on LEC migration  (116). 
 
1.3.2  The Anatomy of the Lymphatic System 
 
Most human tissues are drained by a network of blind-ending lymphatic capillaries, 
with the exception of the CNS and bone marrow; these initial lymphatics also are 
absent between striated muscles fibres and within hepatic lobules (117). A recent 
ultrastructural study by Baluk et al. has challenged the traditional view that 
lymphatics display little or no intercellular junctions (118). This study, which was 
conducted in mice, showed that lymphatic capillaries consist of an oak-leaf shaped 
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endothelium, which is secured to the surrounding extra-cellular matrix (ECM) by 
anchoring filaments comprising emilin and fibrillin. In contrast to blood vessels, these 
capillaries lie on a discontinuous basement membrane (BM), and lack pericytes. In 
addition, these capillaries are considerably larger than venules in size (both in terms 
of the dimensions of the constituent cells, as well as in vessel diameter). Uniquely, 
these initial lymphatics have discontinuous ‘button-hole’ junctions which contain 
parallel segments of VE-Cadherin. These buttons act as specialised anchoring 
junctions, allowing for the interdigitation of the adjacent cell membranes in between 
these buttons. These interdigitations or ‘flaps’ effectively function as one way valves, 
allowing for the easy passage of fluid and macromolecules (Figure 4). Thus, the 
repeated assembly and disassembly of cell junctions is avoided as fluid moves 
passively through these ‘flaps’ which then close, preventing the fluid from escaping 
out into the surrounding tissue. PECAM-1 (or CD31), a molecule common to both 
blood and lymphatic vasculature, also is expressed on the tips of these flaps. 
Functional studies in PECAM-1 null mice, however, showed that PECAM-1 was not 
essential for vessel function and leukocyte migration (118).  
 
These initial lymphatics drain into collecting lymphatics, which have continuous 
‘zipper’ junctions, again expressing VE-Cadherin (118). The LEC become spindle-
shaped, and pericytes are recruited to assist with the propulsion of lymph against 
gravity. Initially, these pericytes form a thin monolayer around lymphatic vessels, but 
as the vessels enlargen, more pericytes are recruited, resulting in a more complex 
multilayer, which is arranged in a basket-weave fashion around the lymphatic 
endothelial monolayer (117,119). These smooth muscle cells have been shown to 
stain positive for c-kit and vimentin, suggesting that they share a common origin with 
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the pacemaker cells of the gastrointestinal tract (the interstitial cells of Cajal) (119). 
In fact, there is evidence that these cells are able to contract independently, initiating 
contraction in sheep lymphatics over a distance of at least 80 mm (117,120,121). 
Thus, collecting vessels may possess an intrinsic pump, and may not be wholly 
dependent on the action of the muscles surrounding them for the maintenance of 
lymph flow (117). Collecting vessels also contain bi-leaflet valves which prevent 
backflow of lymph (117,118).   
 
Lymph passes from the periphery through a series of LNs (117). Before entering the 
LN, these afferent lymphatic vessels divide into smaller ducts, which enter through 
the lymph node capsule into the cortical sinuses. From here, lymph drains through 
the medullary sinuses to the LN hilum, where lymph then enters the efferent 
lymphatic vessels (117). This ‘percolation’ of lymph allows for the interaction of 
antigens with immune cells, leading to an appropriate immune response when 
necessary. Eventually, the lymphatic system drains into the thoracic duct and the 
right lymphatic duct, which drain into the blood circulatory system at the left 
brachiocephalic vein in the angle between the left subclavian vein and left internal 
jugular vein, and the right subclavian vein, respectively (122). 
 
 
 
 
 
 
 
51 
 
 
 
 
 
 
Figure 4 Schematic diagram (A) showing the two types of junctions between 
lymphatic endothelial cells. Initial lymphatics (B; dashed lines in A) are distinguished 
by oak-leaf endothelium with button-hole junctions, which contain VE-Cadherin (red). 
In between these junctions, the tips of the flaps (C and D) formed by adjacent cells 
express PECAM-1 (green) and function as one-way valves allowing for the easy 
passage of fluid and macromolecules from the interstitium into lymphatic vessels. 
Collecting lymphatics are distinguished by spindle-shaped endothelium with 
continuous zipper junctions. These collecting vessels are also surrounded by 
pericytes (not shown) (Adapted from Baluk et al. (118)). 
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1.3.3  Developmental Lymphangiogenesis  
 
The rate of LEC turnover in adults in vivo is extremely low; Tritiated thymidine 
incorporation rates of 0.6% have been observed in LEC, implying that LECs have a 
half-life in the range of several years (117). Although these rates increase during 
embryogenesis (11.5%) and wound healing (6.8%), lymphangiogenesis, or the 
growth of lymphatic vessels, usually occurs slower and later than haemangiogenesis 
(117). In the developing human, the first lymphatic structures, the lymph sacs, can 
be observed at 6 to 7 weeks gestation, approximately a month after the first blood 
vessels are seen to develop (117,123).   
 
Molecular profiling recently has validated the ‘centrifugal’ theory of 
lymphangiogenesis as originally proposed by Sabin in 1902 (99,100,118,124). As 
mentioned above, lymphangiogenesis begins with cells in the venous system. These 
cells begin to express Prox-1, which commits them to a lymph lineage. Once 
specified, LEC must proliferate and migrate into the surrounding tissue to form 
functional vessels. This process is governed by VEGF-C and its receptor, VEGFR-3, 
although a minor role for VEGF-D also has been shown (98–100,125). Both these 
growth factors exist as either full-length or mature forms; only the full-length forms 
can activate VEGFR-3, whilst only the cleaved, mature forms can activate VEGFR-2 
(126). Upon activation, VEGFR-3 can form either homodimers or heterodimers with 
VEGFR-2 and Neuropilin-2 (98,125). Thus, mutations in these co-receptors can 
affect lymphangiogenesis adversely. Furthermore, the integrin α9β1 has also been 
shown to be a receptor for VEGF-C and VEGF-D, and is important for the structural 
integrity of forming lymphatics (127).  
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In contrast to this ‘centrifugal’ theory, lymphangiogenesis has also been described to 
originate in the mesenchyme, in which cells fuse with each other and lymphatics 
form in a ‘centripetal’ manner (98,117,128). This theory has been largely supported 
by work conducted on avian embryos (98,117,129,130). 
 
Once formed, vessels undergo remodelling and expansion. A number of genes have 
been found to be important in this process, including FOXC2, EFNB2, ANGPT2 and 
EMILIN1 (98). Podoplanin has been shown to be important for the adhesion and 
migration of LEC, as well as in the formation of connecting lymphatics between the 
superficial and deep lymphatic plexuses (106–108). 
 
1.3.4  Interaction of Lymphatic Capillaries with the Tissue Interstitium  
 
As lymphatic capillaries have a discontinuous BM, LEC are in direct contact with the 
ECM and interstitial fluid. Thus, lymphatic organisation and function is directly 
influenced by ECM components, by the presence or absence of growth factors within 
the matrix, and by changes in lymph flow (131). 
 
Fibrillar collagens (types I, II, III, V and XI), which entrap proteoglycans and 
glycoproteins, provide the primary scaffold for this surrounding matrix. It has been 
shown that, unlike blood vascular endothelial cells, LEC can survive and form tubes 
in collagen type I matrices in vitro, even in the absence of growth factors (131,132). 
Under experimental conditions of flow, however, LEC organise better in a fibrin-only 
matrix (131,133). The high expression of collagen I and fibrin during wound healing 
has been shown to increase lymphangiogenesis in vivo. However, it has also been 
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shown that fragments of other collagens, such as endostatin and neostatin 7 
(fragments of collagen XVIII), can inhibit lymphangiogenesis (131,134,135).  
 
HA is a polymer of repeating D-glucuronic acid and D-N-acetylglucosamine 
disaccharides, ranging from 104 to 107 Da in size (136). Due to its hygroscopic 
properties, HA plays a key role in regulating matrix turgor and stability. There is a 
rapid turnover of HA in the body, with one third of HA being degraded in lymph 
nodes following its removal by lymphatic vessels. HA is made intracellularly, under 
the control of HA synthases, after which it can be extruded through the plasma 
membrane into the ECM, firmly anchored in the plasma membrane via synthases, or 
linked to cell surface receptors, like LYVE-1 or CD44 (136). By binding these 
receptors HA has the potential to initiate a number of signalling pathways in various 
cell types. The pathophysiological effects of HA are complex, and depend 
predominantly on the size of the HA polymer involved. With regards to LEC however, 
HA-rich stroma tends to stimulate lymphangiogenesis (131). 
 
Lastly, LEC are surrounded by patches of FN. By virtue of the fact that it binds 
VEGF-C, trapping it within the ECM, FN has been shown to increase LEC 
proliferation (131,137,138). There is evidence that the splice variant, EDA FN (139), 
is important for normal lymphatic valve development in vivo through its interaction 
with α9 integrin (127), as well as evidence that EDA FN stimulates lymphatic 
tubulogenesis in tumour stroma (137). Importantly, there is an emerging role for the 
fibronectin-binding integrins, α9β1, α5β1, and α4β1 in the lymphatic vasculature. 
These dynamic heterodimeric glycoproteins play a crucial role in relating changes in 
the extracellular microenvironment to the intracellular space, and vice-versa (140–
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143). Thus, integrins mediate adhesion, proliferation and migration of LEC under 
both physiological and pathological conditions. In addition to FN, α9β1 is known to 
bind VEGF-C, VEGF-D, tenascin C, collagen, laminin, thrombospondin and VCAM-1 
(131). The RGD binding integrin, α5β1, has been shown to be involved in 
inflammation-induced lymphangiogenesis. It has also been shown to associate 
constitutively with VEGFR-3 in vitro, thus increasing VEGFR-3 mediated 
lymphangiogenesis (138). Finally, it has been reported that α4β1 mediates the 
adhesion, migration, invasion and survival of proliferating lymphatic endothelial cells 
(144). Conversely, inhibition of this integrin decreases both lymphangiogenesis as 
well as lymph node metastasis in vivo (144).  
 
1.3.5  The Biology of Tumour Lymphatics 
 
Whilst lymphatics represent a common route of spread for most cancers (99), 
including PDAC (145,146), little is known about the mechanisms underlying this 
process. In terms of collective cell migration, it is known that pre-existing lymphatics 
can serve as a conduit for cancer cells (147). However, the detailed mechanisms 
determining both single cell and collective translymphatic migration have yet to be 
elucidated.  
 
While the concept of endothelial cell activation is well-established for blood vascular 
endothelium, the importance of activation for lymphatic endothelium is still unclear. 
Activation of blood vascular endothelium is defined by five core changes: expression 
of adhesion molecules; increased cytokine production; a loss of vascular integrity; 
up-regulation of HLA molecules and a change from anti- to pro-thrombotic activity 
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(148–150). At present, only  the up-regulation of adhesion molecules and an 
increase in cytokine production have been shown to occur following activation of the 
lymphatic vasculature (99,125,151–158). 
 
In 2006, Johnson et al. showed that the stimulation of LEC by a number of cytokines, 
particularly TNF-α (10 ng/ml) and IFN-γ (100 ng/ml), resulted in the up-regulation of 
ICAM-1, VCAM-1 and E-selectin (151). However, this study only investigated the 
importance of these adhesion molecules in immune function, and not in the context 
of cancer i.e only the effects of exogenous commercially available cytokines (and not 
conditioned media from cancer cells) on human dermal lymphatic endothelial cells 
(HDLEC) was investigated in vitro; the in vitro co-cultures experiments assessed 
only the interactions of dendritic cells, and not cancer cells, with activated HDLEC; 
and the in vivo experiments evaluated the presence of antigen-presenting cells 
attracted to the ear skin of mice following oxalozone-induced hypersensitivity; no 
mouse models of carcinogenesis were used in this study (151).  
 
It was only two years later that Kawai et al. showed that conditioned media from 
metastatic MDA-MB-231, but not non-metastatic MCF-7, breast cancer cells 
increased ICAM-1 expression on human LEC (152). Furthermore, the up-regulation 
of ICAM-1 led to the increased adhesion of MDA-MB-231 cancer cells to human 
LEC, potentially through the paracrine effects of cancer cell ATP production or 
leakage (152). However, no other adhesion molecules were evaluated in this study. 
 
Another molecule, the common lymphatic endothelial and vascular endothelial 
receptor, CLEVER-1 (also known as FEEL-1 and Stabilin-1), has been shown to be 
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expressed in peritumoural and intratumoural lymphatics in head and neck, and 
breast cancers (153). Furthermore, the intensity of CLEVER-1 expression in 
peritumoural lymphatics in breast carcinoma was shown to correlate positively to 
tumour grade (n = 72; p = 0.025) (153). However, its expression on intra- and peri- 
tumoural lymphatics in both head and neck (n = 17), and breast cancers (n = 72) 
showed no association with lymph node infiltration at the time of diagnosis (153). 
CLEVER-1 is a large glycoprotein which is expressed on lymphatics and high 
endothelial venules, and has been shown to be involved in scavenging, cell adhesion 
and angiogenesis (154). Exon 27 of this gene can be alternatively spliced in various 
tissues; however, once translated, CLEVER-1 contains 7 fasciclin domains, a 
proteoglycan link protein-like sequence, 22 EGF repeats and 2 RGD motifs. Most 
published studies on CLEVER-1 have been aimed at understanding its role in 
leukocyte trafficking, and not in cancer (153,154).  Although blocking CLEVER-1 has 
been shown to decrease the transmigration of peripheral blood mononuclear cells 
(PBMC) in vitro, CLEVER-1 blockade tended to increase the adhesion of PBMC to 
lymphatics in static conditions (154). This raises an important question regarding the 
interplay between adhesion and transmigration: if PBMC binding to lymphatics 
decreases upon CLEVER-1 blockade, does this suggest that PBMC preferentially 
bind to LEC receptors for which they have a weaker affinity in order to transiently 
‘stick’, thus facilitating migration through the lymphatic endothelium? This possibility 
has yet to be explored. 
 
An emerging concept in the context of LEC activation in cancer is that of tumour-LEC 
crosstalk. Shields et al. have shown that the migration of the metastatic melanoma 
cell line A375 is dependent on CCL21 secretion by LEC (155). In addition, A375 cells 
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were shown to express CCR7, the receptor for CCL21 (155). This migration was 
proven both in vitro and in vivo. Notably, A375 cells only migrated towards LEC and 
not towards blood vascular endothelial cells. Furthermore, the non-metastatic 
melanoma subclone A375P did not migrate towards LEC. Thus, the authors suggest 
that CCR7 is up-regulated on melanoma cells during metastasis in response to 
CCL21 secretion by lymphatics, resulting in the migration of cancer cells towards 
lymphatics. In addition, A375 cells were found to produce VEGF-C, which induced 
LEC migration towards cancer cells. It was found subsequently that VEGF-C 
secretion by cancer cells stimulates the secretion of CCL21 by LEC via VEGFR-3. 
CCL21 in turn attracts cancer cells expressing the receptor CCR7 (159). Thus, 
chemokine crosstalk between LEC and cancer cells is a potentially important cause 
of lymphatic invasion as it induces the migration of cancer cells towards existing 
lymphatics; an action independent of their role in stimulating lymphangiogenesis 
(Figure 5).  
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Figure 5 Cross-talk between melanoma cells and lymphatic vessels. Melanoma cells 
secrete VEGF-C which binds to VEGFR3 on lymphatic cells, stimulating 
lymphangiogenesis and inducing lymphatic endothelial cell migration. This also 
stimulates lymphatics to secrete CCL21, which causes cancer cells expressing the 
cognate receptor CCR7 to migrate towards the lymphatic vasculature (Adapted from 
Issa et al. (159)).  
 
 
These data are in keeping with a number of other studies which have demonstrated 
a positive role for VEGF-C and VEGF-D in inducing lymphangiogenesis and 
lymphatic metastasis  in melanoma (156), breast (157) and pancreatic cancer (158).  
With regards to the latter, it could be argued that some of these studies were sub-
optimal, since they were performed in the Rip1Tag2 mouse model of pancreatic 
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cancer (160,161), which is representative of endocrine neoplasms and not PDAC per 
se, and/or using pancreatic cancer cell lines in vitro (162). Furthermore, the role of 
VEGF-induced lymphangiogenesis in human tissue studies remains unclear. In 
2004, Kurahara et al. evaluated 58 PDACs (pancreatic head), from patients who had 
undergone curative resection without neoadjuvant therapies, for VEGF-C and VEGF-
D expression using IHC (163). Expression of both VEGF-C (p = 0.015) and VEGF-D 
(p = 0.02) at the tumour margins, but not at the centre of the tumours, was found to 
be associated with a higher incidence of LN invasion. It was also shown in this study, 
by Kaplan-Meier analysis, that tumours expressing both VEGF-C and VEGF-D at the 
tumour margins had a worse prognosis than those expressing only one or none of 
these growth factors (p = 0.017). In 2005 however, Schneider et al. showed that 
whilst VEGF-C mRNA expression was significantly higher in PDAC (n = 36) than in 
normal pancreatic tissue (n = 30; p < 0.001; with expression being confirmed at a 
protein level by IHC), no association was found in this study between VEGF-C 
expression in PDAC and survival (164). Finally, Sipos et al. showed in a study 
involving 98 PDAC samples, that VEGF-C and VEGF-D were not up-regulated in 
primary PDAC (165). Even though the mRNA quantification and ELISAs  were 
performed on a subset of these 98 cases, IHC confirmation of VEGF-C (but not 
VEGF-D) protein expression was performed on all 98 cases, and showed that only 
six of these expressed VEGF-C. Thus, these findings contradict those of the 
previous studies, concluding that VEGF-C does not influence lymphatic metastasis in 
PDAC. 
 
Whilst it has been shown that lymph node metastasis correlates to intratumoural 
lymphatic vessel density (LVD) for some tumours, such as thyroid carcinoma, 
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melanoma, and head and neck cancers (99,166–168), there are conflicting reports 
for other cancers, including PDAC. Both Sipos et al. and Schneider et al. 
demonstrated a paucity of intra-tumoural lymphatics in PDAC, with a relative 
predominance of peri-tumoural lymphatics (164,165). Furthermore, no correlation 
between LVD and patient survival was seen in either study. Thus, the authors 
conclude that lymphangiogenesis did not contribute to lymphatic metastasis in PDAC 
(164,165).  Sipos et al. confirmed these findings in three orthotopic mouse models of 
pancreatic cancer, in which the HPAF2, PancTu1 and PT45P1 cell lines were used, 
all of which showed high rates of lymphatic invasion and LN metastasis, but not 
increased LVD. The findings in these mouse models thus mirrored those found in the 
human tissue samples, supporting the conclusion that lymphangiogenesis does not 
contribute to lymphatic metastasis in PDAC (165). 
 
In contrast, Bailey et al. have shown that Sonic Hedgehodge (SHH) paracrine 
signalling increases lymphangiogenesis in an orthotopic mouse model of pancreatic 
cancer, resulting in an increase in primary tumour growth, as well as an increase in 
both vascular and lymphatic metastasis (169). This occurs via paracrine signalling; 
the pancreatic cancer cells secrete SHH, a morphogenic signalling protein, which 
binds to a 12-pass transmembrane protein called Patched (Ptch). This binding 
releases the inhibitory effects of Ptch on the serpetine receptor Smoothened (SMO), 
which is expressed on primary cilia in the surrounding stromal cells. Primary cilia are 
microtubule-based organells that project into the extracellular environment from the 
centriole of quiescent cells. In this paper, the authors demonstrate the presence of 
SMO on LYVE-1 positive cells in mouse orthotopic tumours containing hTERT-
HPNE pancreatic cells that had been engineered to over-express SHH. These 
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findings were confirmed in four human tissue samples from patients with PDAC. 
Furthermore, treating the orthotopic tumours with a neutralising antibody to SHH 
decreased lymphangiogenesis and tumour size, and decreased the number of 
metastatic LN. Thus, the authors suggest that SHH increases lymphangiogenesis, 
directly influencing metastasis, and that targeting the SHH pathway would decrease 
metastatic disease (169). Shultz et al. have reported that inducible re-expression of 
p16 decreases lymphangiogenesis and lymph node metastasis in an orthotopic 
mouse model of PDAC, providing further evidence for a direct association between 
lymphangiogenesis and LN metastasis (170).  
 
Taken together, these data highlight the lack of consensus regarding the importance 
of lymphangiogenesis with regards to lymphatic invasion in PDAC, as well as to the 
molecular mechanisms underlying lymphangiogenesis in PDAC (160–162,169,170). 
However, it is clear that at present, data from human tissue samples do not seem to 
support a direct association between lymphangiogenesis and lymphovascular 
invasion in PDAC (164,165). 
 
1.3.6  Lymph Node Status in PDAC 
 
Although the molecular mechanisms underlying lymphatic metastasis are currently 
unclear, it is recognised that lymph node status is an important predictor of survival 
in PDAC (146). 70% of PDAC patients will have positive LNs at the time of 
presentation, and will benefit from extended lymphadenectomy during surgery (145). 
However, as sentinel lymph node mapping is not feasible for pancreatic cancer, we 
currently are unable to identify the 30% of patients who are LN-negative, and who 
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would thus unnecessarily experience the morbidity associated with extensive LN 
dissection (145). Importantly, for the vast majority of patients who are LN-positive, 
the pattern of lymph node involvement has recently been shown to correlate with 
survival (146).  
 
In a retrospective analysis of 380 patients with pT3 invasive PDAC, patients with 
direct invasion of ≤ 2 peripancreatic LN (n = 35) showed the same overall survival as 
patients with node-negative disease (n = 97) (146) (The American Joint Committee 
on Cancer TNM classification of pancreatic cancer is shown in Table 2). However, 
patients in whom true lymphatic invasion was seen in LN (n = 248), as opposed to 
those patients whose tumours had directly invaded into the surrounding LNs, 
showed a worse overall survival when compared with patients with node-negative 
disease (p < 0.001), regardless of the number of LNs involved. Thus, the ability of 
cancer cells to enter into and travel through lymphatics negatively affects prognosis. 
Interestingly, there was a trend towards patients bearing tumours with direct LN 
invasion (n = 35) having an improved survival compared with patients who had true 
lymphatic metastasis in one or two LN (n = 42). However, this did not reach 
statistical significance (p = 0.056).  
 
These data highlight the importance of identifying molecular markers that 
differentiate true lymphatic invasion in PDAC from direct extension into the 
surrounding LN, as these patients clearly are at higher risk and require more 
aggressive therapies. They also highlight the importance of determining what 
facilitates lymphovascular invasion in PDAC, as targeting the molecules involved 
potentially could prevent metastasis, and significantly decrease mortality. Finally, the 
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data also suggest, as Hart and Fidler concluded earlier, that the nature of lymphatic 
invasion in PDAC is not entirely stochastic, and that by virtue of this fact, it is both 
preventable and controllable (48). 
 
 
Table 2 American Joint Committee on Cancer TNM classification of pancreatic 
cancer. 
 
  
 Tumour Node Metastasis 
X Primary tumour cannot be assessed   
0 No evidence of primary tumour Regional LN cannot 
be assessed 
No distant metastases 
Tis Carcinoma in situ   
1 Limited to pancreas; ≤ 2 cm in its 
greatest diameter  
No regional LN 
positive 
Distant metastases  
2 Limited to pancreas; ≥ 2 cm in its 
greatest diameter 
Regional LN positive  
3 Extends beyond the pancreas but 
without involvement of the celiac axis 
or the superior mesenteric artery. 
  
4 Involves the coeliac axis or the superior 
mesenteric artery (unresectable 
primary tumour). 
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1.4  Orthotopic Mouse Models of PDAC 
 
The orthotopic mouse model has, for many years, served as a translational bridge 
which allows for the preclinical evaluation of primary tumour growth, metastasis, and 
potential drug therapies. The first orthotopic pancreatic xenograft model was 
performed in 1989, and characterised the differences between MIAPaCa2 cell 
growth in the pancreata of young and old nude mice over a period of two years 
(171).  This study concluded that orthotopic implantation was feasible and superior to 
subcutaneous implantation in terms of tumour growth; pancreatic tumour growth was 
more reproducible in younger nude mice; spontaneous liver metastases were more 
likely to occur in experiments that lasted longer than 45 days; and primary tumour 
growth most often resulted in local invasion rather than haematological 
dissemination to the lungs and liver (171).  
 
Subsequent experiments have shown that the rate of primary pancreatic tumour 
growth and the development of spontaneous metastasis is largely cell-line 
dependent (172). Thus, a limitation of these models is that primary orthotopic 
tumours do not often metastasise spontaneously. However, various ways of 
circumventing this problem have emerged over the past few years e.g. the inclusion 
of synthetic ECM (e.g. Matrigel) into the injected cell suspension (173) and/or the co-
injection of pancreatic stellate cells (174,175), with such modifications being shown 
to enhance the development of spontaneous metastasis; and the implantation of 
tumour fragments, preferably from human pancreatic tumours but also from 
subcutaneous xenografts, has been shown to better simulate the clinical 
development of metastatic PDAC and create a more relevant model for drug testing 
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(176).  In addition, a number of experimental metastasis models, largely based on 
the work of Nicolson, Hart and Fidler have been developed to evaluate the 
extravasation and colonisation steps of the metastatic cascade (177–179). In such 
experiments, cells are injected into the tail veins of nude mice in order to ‘seed’ these 
cells into the vasculature. Thus, intravasation from the primary tumour site is 
obviated, and any subsequent tumour development is seen as a direct result of the 
interaction of ‘seed’ with ‘soil’ (64). The technique has been modified to include intra-
splenic injections (180,181), which seed cancer cells to the liver, and more recently, 
the intranodal injection of cancer cells into the right axillary LN  for imaging purposes 
(182).  
 
In addition to these models, a number of transgenic models of PDAC are available, 
in both zebrafish and mice (30,31,40,45). One of these mouse models, developed in 
2003, targeted mutated KRASG12D to the mouse pancreas (30). This mutation is 
commonly found in human PDAC, and results in a glycine to aspartic acid 
substitution, resulting in constitutive activation of the GTPase protein. These mice 
develop PanINs which are histologically similar to those premalignant lesions seen in 
humans (30). When these KRASG12D mice were crossed with mice containing the Li 
Fraumeni mutant TP53 allele, mice developed invasive PDAC with widespread 
metastatic disease (40). It has also been shown that concommitent expression of 
KRASG12D and the tumour suppressor gene DPC4/SMAD4 in mice results in 
mucinous cystic neoplasms of the pancreas, a distinct class of pancreatic tumours 
(45). Whilst these transgenic models provide us with an invaluable tool for the 
evaluation of novel therapeutic agents, they are costly to implement. Furthermore, 
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the ‘human element’ of the orthotopic transplantation model is lost, which could 
affect the evaluation of specific types of novel therapies e.g. antibody therapies. 
 
Finally, the emergence of various imaging techniques has allowed for the real-time 
imaging of primary tumour growth and metastasis in small animal models. As these 
models can be used to monitor and quantify any responses to novel therapies using 
imaging data, they provide an alternative to the more traditional method of killing 
animals at specific time-points with subsequent histological examination. In other 
words, they reduce and refine the evaluation of carcinogenesis and novel therapies 
in small animal models. Imaging modalities can broadly be divided into two 
categories: those which have been modified and adapted from the clinic for 
application in small animals; and those based on macroscopic imaging using 
photonics (183). With regards to the latter, both fluorescence and bioluminescence 
have been used previously for the real-time evaluation of primary orthotopic 
pancreatic tumour growth (96,184,185). However, it has been shown that image 
resolution is complicated by tissue depth and photon scattering; this is of particular 
relevance to the retroperitoneal pancreas (183). Bioluminescence imaging relies on 
the conversion of an administered substrate (luciferin) to light in the presence of 
ATP, whilst fluorescence emits light following excitation of a fluorochrome at a 
particular wavelength. The gut, in particular, shows a high level of auto-fluorescence 
due to endogenous chromophores (e.g. elastin, collagen, porphyrins, tryptophan and 
NADPH), and chlorophyll from alfalfa, a common ingredient in laboratory murine food 
(186). This results in lower imaging contrast than that seen with bioluminescence 
(183). Thus, although both techniques will allow for adequate visualisation of the 
pancreas, bioluminescence is superior.  
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2. AIMS AND OBJECTIVES OF THE STUDY 
 
1. To compare the proteins expressed in the epithelia of primary PDAC to the 
proteins expressed in LN metastatic PDAC epithelia using laser capture 
microdissection and MudPIT. This analysis would be performed in matched 
samples, i.e. primary PDAC and LN metastases were to be taken from the 
same patient. 
2. To validate candidate proteins that are differentially expressed between 
primary PDAC and matched LN metastases using IHC in a larger series of 
matched cases. Of note, S100P would be given preference as a candidate 
protein should it be found to be differentially expressed. 
3. To investigate the potential effects of a selected candidate protein (potentially 
S100P) on lymphatic invasion both in vitro and in vivo. 
4. To create an orthotopic mouse model for future use in the preclinical 
evaluation of potential therapies that will be developed based on the 
proteomic screen.  
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3.  MATERIALS AND METHODS 
 
3.1 Cell lines  
 
Both vector control (V3), and S100P over-expressing (S5), Panc-1 cell lines which 
had previously been engineered in our laboratory (94), were further engineered to 
stably express luciferase using a lentiviral vector by Dr David Gould (Bone and Joint 
Research Unit, William Harvey Research Institute, John Vane Science Centre, 
London, UK). These new cell lines, termed V3L and S5L, subsequently were used in 
all the in vitro and in vivo experiments. 
 
Cells were grown in Dulbecco’s Modified Eagle’s Media (DMEM) high glucose 4.5 
g/L (PAA Laboratories, Somerset, UK), supplemented with 10% heat-inactivated 
foetal calf serum (FCS; PAA Laboratories, Somerset, UK) and 
Penicillin/Streptomycin (PAA Laboratories, Somerset, UK) at a 1:100 dilution. 
Selection of stable cell lines was established with G418 as previously described (94). 
Human Dermal Lymphatic Endothelial Cells (HDLEC; PromoCell, Heidelberg, 
Germany), were grown in Endothelial Cell Basal Media MV2 (PromoCell, Heidelberg, 
Germany), supplemented with Supplement Mix (PromoCell, Heidelberg, Germany); 
Penicillin/Streptomycin (PAA Laboratories, Somerset, UK) at a 1:100 dilution and 
VEGF-C (R & D Systems, Abingdon, UK) at 5 ng/100 ml. Cells were grown in a 
humidified atmosphere (5% CO2 at 37
oC).  
 
During passage, cells were harvested from subconfluent cultures in exponential 
growth phase by overlaying the cells with a thin layer of trypsin EDTA (1% trypsin 
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EDTA for V3L and S5L cells; 10% trypsin EDTA for HDLEC; PAA Laboratories, 
Somerset, UK). Following a 3 minute incubation in a humidified atmosphere (5% 
CO2 at 37
oC), the 75 cm2 flask or 10 cm plate (see below) was tapped sharply to 
dislodge any adherent cells. An equal volume (to that of trypsin) of DMEM 
supplemented with 10% FCS then was added in order to inactivate the trypsin. Cell 
suspensions subsequently were transferred to 15 ml Falcon tubes (Becton-
Dickinson, Oxford, UK), and centrifuged at 12,000 x g for 3 minutes in order to 
produce a pellet; the overlying media was aspirated off, and the pellet was 
resuspended in 10 ml of the appropriate growth medium. V3L and S5L cells were 
passaged into 75 cm2 flasks (Becton-Dickinson, Oxford, UK). HDLEC were 
passaged into 10 cm plates (Becton-Dickinson, Oxford, UK) which had been coated 
with 0.5 mg/ml of FN. Cell passage was performed routinely every third day. 
 
For the in vivo experiments, V3L and S5L viability was assessed prior to injection 
using trypan blue. Cells were resuspended at a 1:1 ratio with trypan blue, after which 
viability was assessed by counting the number of cells that were able to exclude 
trypan blue using a haemocytometer, and multiplying by a dilution factor of 2. Only 
cell suspensions that were > 90% viable were used in the in vivo experiments. 
  
For long term storage, cells were centrifuged at 12,000 x g for 3 min, after which the 
pellet was resuspended in freezing media: for V3L and S5L cells, this contained 90% 
FCS and 10% dimethyl sulphoxide (DMSO); for HDLEC cryomedia (PromoCell, 
Heidelberg, Germany) was used. Cell suspensions were transferred to cryovials, 
frozen overnight at -80˚C, and then transferred to liquid nitrogen for storage. Cell 
pellets were produced by washing cells in PBS and then detaching using trypsin 
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EDTA. Detached cells were spun at 12,000 x g for 3 min to produce a pellet, any 
remaining PBS was removed and the pellets snap-frozen on dry ice. Pellets were 
stored at -80˚C until use.  
 
3.2 Human Tissues 
 
In total, 55 FFPE blocks of matched primary PDAC and LN metastases were 
obtained from the Pathology Departments of the General Hospital of Osijek, Croatia 
(17 cases) and Barts and the London (BTL) NHS Trust (38 cases). All tissues were 
obtained with full ethical approval from the host institutions. Clinicopathological data 
pertaining to all the used specimens (which I collected and collated from the two 
pathology departments) are shown in Table 3. 
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Table 3 Clinicopathological data. Relevant clinical and pathological parameters for 
the 55 cases of primary PDAC and matched LN metasatases; 38 of which were 
obtained from Barts and the London Hepato-Biliary Centre, London, UK, and 17 of 
which were obtained from the Clinical Hospital Centre Osijek, Croatia. (*grade not 
specified for two cases; IQR = inter-quartile range). 
 
 
3.3 Mice  
 
Female CD1 nude mice (Charles River Laboratories, Kent, UK) were purchased at 
four weeks of age. All animals were maintained in a sterile environment on a daily 
12-hour light/dark cycle. Surgical procedures were conducted when animals were 
five weeks of age, under aseptic conditions in a laminar flow hood. All animal work 
was conducted in accordance with the Animal (Scientific Procedures) Act of 1986.  
 
  
 BTL (n = 38) CROATIAN (n = 17) 
AGE (Median (IQR)) 67 (58.25-71) 64 (52.33-70.11) 
T1/T2/T3/T4 0/13/22/3 0/8/8/1 
LN METASTASIS 38/38 17/17 
RESECTION MARGIN POSITIVE  17/38 3/17  
WELL/MODERATELY/POORLY 
DIFFERENTIATED 3/23/12 5/9/1* 
PERINEURAL INVASION 27/38 11/17 
LYMPHOVASCULAR INVASION 30/38 11/17 
MALE/FEMALE 23/15 9/9 
SURVIVAL (Median (IQR)) 418.5 (300.5-527.75) Unknown 
ALIVE/DEAD/CENSORED 22/12/04 Unknown 
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3.4 RNA Isolation  
 
3.4.1 Cell Lines 
 
RNA was isolated from cell line pellets using the RNAqueous Total RNA isolation kit 
(Ambion, California, USA) according to the manufacturer’s instructions. Briefly, 5 x 
106 cells were lysed in 700 μl of lysis/binding solution and cells were passed through 
a 25 gauge needle (Becton-Dickinson, Oxford, UK) in order to shear DNA. An equal 
volume (700 μl) of 64% ethanol was then added to precipitate the RNA out of 
solution, and this mixture was transferred to spin columns. Following centrifugation 
for 1 minute at 12,000 x g, columns were washed with Wash Solution and 
centrifuged for 1 minute at 12,000 x g three times. The flow-through was discarded 
after each spin. RNA was then eluted in 40 μl of pre-warmed elution solution (at 
75˚C) into a fresh collection tube by centrifuging at 12,000 x g for 30 seconds.  
 
3.4.2 Mouse Tissue 
 
For each sample, 50-100 mg of frozen mouse tumour was homogenised in 1 ml of 
TRIzol Reagent (Invitrogen, Paisley, UK) using a power homogeniser (IKA ULTRA-
TURRAX, T25 basic, IKA, Staufen. Germany). Following centrifugation at 12,000 x g 
for 10 minutes at 4oC, the supernatant was transferred to a fresh tube and incubated 
for 5 minutes at room temperature to permit the complete dissociation of 
nucleoprotein complexes. Chloroform (0.2 ml) was then added and mixed into the 
solution with vigorous shaking for 15 seconds. This mixture was incubated at room 
temperature for 3 minutes and centrifuged thereafter at 12,000 x g for 15 minutes at 
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4oC. Chloroform separates the mixture into two phases: the colourless upper 
aqueous phase (containing RNA) and the pink organic phase (containing proteins).  
The colourless upper aqueous phase (containing RNA) was transferred to a new 
tube. In order to precipitate RNA isopropanol alcohol (0.5 ml) was then added; 
incubated at room temperature for 10 minutes; and centrifuged at 12,000 x g for 10 
minutes at 4oC. The RNA pellet was then washed with 1 ml of cold 75% ethanol, air-
dried for 5-10 minutes, and dissolved in diethyl pyrocarbonate (DEPC) treated water 
in order to inactivate RNase enzymes and prevent RNA degradation. 
 
3.5 RNA quantification 
 
Samples were assessed and quantified using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Thermoscientific, Wilmington, USA), 
with an A260/A280 ratio of > 1.95 being considered acceptable. In addition, RNA 
quality was assessed by gel electrophoresis for the presence of 28S and 18S rRNA 
(ratio 2:1). Briefly, 500 ng of the RNA was diluted in 6x blue gel loading dye (Sigma-
Aldrich, Poole, UK) and run on a 1% agarose gel containing 0.5 μg/ml GelRed 
(Sigma, Poole, UK) at 60V for 20 minutes. Gels were visualised using a UVidoc 
system (UVitec, JENCONS PLS, Cambridge, UK).  
 
3.6 Quantitative Real Time (qRT) PCR 
 
cDNA was synthesised from 1 µg of total RNA using QuantiTect Rev. Transcription 
Kit (Qiagen, West Sussex, UK). Briefly, 2 µl of gDNA Wipeout Buffer (7x) was added 
to 1 µg of RNA and RNase-free water to a final volume of 14 µl. Following incubation 
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at 42oC for 2 minutes, the samples were placed immediately on ice. 5 µl of master 
mix (containing 1 µl Quantiscript Reverse Transcriptase, 1 µl RT Primer Mix and 4 µl 
of Quantiscript RT Buffer, 5x) was then added, resulting in a 20 µl final reaction 
volume. This was incubated at 42oC for 15 minutes, followed by a 3 minute 
incubation at 92oC to inactivate Quantiscript Reverse Transcriptase. qRT-PCR was 
then performed on approximately 20 ng of cDNA per sample using the QuantiTect 
SYBR Green PCR Kit (Qiagen, West Sussex, UK) according to the manufacturer’s 
instructions. Briefly, a total reaction volume of 20 µl was used containing the 
following:  10 µl of SYBR MM Buffer; 0.6 µl of each primer (at a final concentration of 
0.3 µM); 2 µl cDNA (approximately 20 ng) and 6.8 µl of RNase-free water. Primers 
for S100P (Sigma, Poole, UK) were forward 5’ TGCAGAGTGGAAAAGACAAGGAT 
3’ and reverse 5’ CCACCTGGGCATCTCCATT 3’; primers for the human ribosomal 
gene S16 (Sigma, Poole, UK), which was used as a control, were forward 5’ 
GTCACGTGGCCCAGATTTAT 3’ and reverse 5’ TCTCCTTCTTGGAAGCCTCA 3’. 
The PCR was run on the ABI7500 detection system (Applied Biosystems, California, 
USA). Relative quantification was performed using Ct values. 
 
3.7 Protein Isolation 
 
Cell line pellets were lysed in 200 µl of NP40 lysis buffer (50 mM Tris pH 7.4, 150 
mM NaCl, 1 % NP40, 2 complete, EDTA-free protease inhibitor cocktail tablets 
(Roche Applied Sciences, Mannheim, Germany). Following lysis, samples were 
centrifuged at 10,000 x g for 1 minute, after which the supernatant was collected and 
stored at -20oC until analysis. 
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3.8 Protein Quantification 
 
Proteins were quantified using Pierce Coomassie Plus Assay Reagent 
(Thermofischer Scientific, Leicestershire, UK), according to the Bradford method. 
Briefly, 2 µl of sample was added together with 198 µl of Pierce Coomassie Plus 
Assay Reagent in a 96-well plate (Becton-Dickinson, Oxford, UK). Samples were 
always quantified in triplicate in relation to a BSA standard curve. Absorbance was 
read at 595 nm using the Dynex Revelation 4.04 program (MTX Lab Systems Inc., 
Virginia, USA). 
 
3.9 Laser Capture Microdissection (LCM) 
 
This protocol was optimised in a series of experiments performed over a period of 
two months, using PDAC sections that had been fixed in the same manner as the 
tissue which I was going to use for the final LCM. Over that time, various conditions 
were changed: 
-  I cut sections ranging in thickness from 4 to 10 µm, using the Leica RM2255 
rotary microtome (Leica Microsystems, Milton Keynes, UK), in order to 
determine the optimal thickness for LCM; 
- I changed the dehydration and rehydration times of the recommended 
protocol, ranging from 1 to 5 minutes in each ethanol solution, in order to 
decrease staining time in an effort to decrease contamination;  
- I tried varying concentrations of ethanol in different combinations in order to 
improve the quality of staining;  
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- I tried staining with haematoxylin (1-5 minutes) and crystal violet (1–5 
minutes), alone or in combination with eosin (10-60 seconds) in order to 
optimise the visualisation of sections on the P.A.L.M. system (P.A.L.M. 
Microlaser Technologies AG, Bernried, Germany). LCM was also attempted 
on unstained sections; 
- I practised LCM area estimation on the P.A.L.M. system intra-dissection in 
order to improve my ability to dissect the same number of cells between 
cases.  
 
The final LCM was performed over a period of three months, which included 
administrative delays e.g. booking times for use of the P.A.L.M. system. On average, 
three slides per day were dissected. Sections were cut the day before dissection; 
staining then commenced at 8 am in order to allow sections to air-dry adequately in 
order to commence LCM at midday. Thereafter, over a period of 8–10 hours, at least 
10,000 cells/slide could be captured. 
 
The final protocol can be described as follows: 
 
Following histological examination of haematoxylin and eosin (H&E) sections, seven 
cases (i.e. seven primary PDAC and seven matched LN metastases) were selected 
for LCM. 8 m sections were dewaxed in xylene twice, initially for 4 minutes followed 
by a second incubation for 3 minutes, and rehydrated through a series of graded 
alcohols (1 minute in 100% ethanol, 1 minute in 85% ethanol and 1 minute 70% 
ethanol). After staining with Mayer’s haematoxylin for 2 minutes, sections were 
dehydrated (1 minute in 70% ethanol, 1 minute in 85% ethanol and 1 minute in 
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100%) and cleared in xylene for 2 minutes. Sections were then left to air-dry in a 
fume hood until LCM. 
 
Approximately 10,000 to 15,000 cells per block were microdissected using the 
P.A.L.M. system (P.A.L.M. Microlaser Technologies AG, Bernried, Germany). 
Initially, four matched cases were dissected and pooled (PDAC1 and LN1, 
respectively), followed by the remaining three cases (PDAC2 and LN2, respectively). 
This resulted in two sample groups (PDAC and LN Metastasis), each represented by 
two pools; each pool comprising 40,000 to 45,000 cells. The samples were 
processed using Liquid Tissue (Expression Pathology Inc., Maryland, USA). Briefly, 
they were heated in 20 l Liquid Tissue Buffer at 95oC for 90 min. 1 l of proteomics 
grade porcine trypsin was then added to each sample, after which samples were left 
to digest overnight in a waterbath at 37oC. The peptide mixtures were then quantified 
using MicroBCA Assay Kit (Thermofischer Scientific, Leicestershire, UK). 2 l of DTT 
was then added; samples were heated at 95oC for 5 minutes before being stored at -
20oC.  
 
 3.10 Multidimensional Protein Identification Technology (MudPIT)  
 
The MudPIT experiment was performed in duplicate; the first experiment was 
performed on PDAC1 and LN1 and the second on PDAC2 and LN2. 10 μg of each 
sample was diluted 20-fold in 5% acetonitrile (0.1% FA) and injected onto a 100 μm 
x 6 cm SCX column. The flow-through and nine subsequent fractions were collected 
during a 20 minute gradient separation. Buffer A was 5% acetonitrile (0.1% FA) and 
buffer B was 1M ammonium acetate, 5% acetonitrile (0.1% FA). Each fraction was 
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analysed using LC/MS/MS with a 1 hour gradient on a LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, California, USA). MS/MS data were 
searched against the concatenated forward and reverse IPI Human v3.53 database 
using the Mascot (www.matrixscience.com) search engine. The database was 
appended with the common Repository of Adventitious Proteins (cRAP) to prevent 
false assignment of peptides derived from those proteins. This repository aims to 
identify proteins that are commonly observed in proteomics experiments, and which 
are classified into three general categories: common laboratory proteins; 
contaminant proteins which are added accidentally through dust and/or physical 
contact; and proteins used as molecular weights or mass spectrometry quantitation 
standards. Mascot output files were parsed into the Scaffold program for collation 
into non-redundant lists per sample (i.e. to avoid repetition of proteins in the final 
output) and filtering to assess false discovery rates to allow only correct protein 
identifications. Parameters for LTQ Orbitrap XL data require a minimum of two 
unique peptides matching per protein with minimum probabilities of 95% at the 
protein level and 50% at the corresponding peptide level. Spectral counts per protein 
were the output; these represent a semi-quantitative measure of abundance across 
samples (89). Spectral count reflects the number of matched peptides and the 
number of times those peptides were observed. The mass spectrometry experiments 
were performed at NextGen Sciences (Ann Arbor, Michigan, USA) by Dr Richard 
Jones. 
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3.11 Western Blotting 
 
50 µg of protein per sample were incubated with 5x Laemmli buffer (0.225 mM Tris 
pH 6.8, 50% glycerol, 5% SDS, 0.05% bromophenol blue, 0.25 mM DTT) at 95oC for 
5 minutes. Samples were then loaded onto NuPAGE 4-12 % Bis-Tris gels 
(Invitrogen, Paisley, UK). Following transfer onto polyvinylidene difluoride Immobilon-
P membrane (Millipore, Watford, UK), non-specific binding was blocked by 
incubating in 3% BSA in TBS-T for 30 minutes. Membranes were then incubated 
with anti-V5 antibody (1:1000; Invitrogen, Paisley, UK) overnight at 4oC, followed by 
a 30 minute incubation with horseradish peroxidase (HRP)-conjugated goat anti-
mouse immunoglobulin (Ig) (1:2000 Santa Cruz Biotechnology, Heidelberg, 
Germany) at room temperature. Bound immunocomplexes were visualised using 
enhanced chemiluminescence reagent (GE Healthcare, Hertfordshire, UK). HSC-70 
was used as a loading control. 
 
3.12 Immunocytochemistry (ICC) 
 
5 x 104 HDLEC were seeded onto 13 mm coverslips (Sigma, Poole, UK) in a 24-well 
plate (Becton-Dickinson, Oxford, UK) and left to settle overnight. The next day, 
following fixation in 4% paraformaldehyde and permeabilisation with 0.1% Triton X-
100, non-specific binding sites were blocked with 2% bovine serum albumin. Cells 
were then incubated with commercially available primary antibodies at the following 
dilution: anti-human LYVE-1 (RELIATech, Wolfenbüttel, Germany) 1:1000; and anti-
human PDPN (Abcam, Cambridge, UK) 1:1000. Secondary antibodies were Alexa 
Fluor 488–conjugated donkey anti-rabbit IgG (1:1000; Invitrogen Molecular Probes, 
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Paisley, UK), and Alexa Fluor 568–conjugated goat anti-mouse IgG, respectively. All 
experiments were conducted in the absence of primary antibody as a negative 
control. 
 
3.13 Flow Cytometry (FC) 
 
V3L and S5L cells were grown to confluency in 75 cm2 flasks, trypsinised, 
centrifuged and re-suspended in FC media (DMEM with 0.1 % BSA) to a 
concentration of 4 x 106 cells/ml. 50 μl of cell suspension was then added to a series 
of 1.5 ml Eppendorf tubes (Sigma, Poole, UK) on ice, to which 50 μl of FC media 
containing either a primary antibody (Table 4); isotype control (Dako, 
Cambridgeshire, UK) or no primary antibody (negative control), were added. 
Following a 45 minute incubation on ice, cells were washed with FC media and 
recovered by centrifugation at 10,000 x g for 5 minutes. Following the removal of FC 
media, 50 μl of a 1:125 diluted, Alex-488 conjugated secondary antibody (Invitrogen 
Molecular Probes, Paisley, UK) was added and the suspension was incubated for a 
further 30 minutes on ice, in the dark. Following a second wash with FC media and 
recovery by centrifugation, samples were re-suspended in 300 µl of FC media, and 
transferred to 5 ml, round bottom tubes (BD Becton-Dickinson, Oxford, UK) for 
immediate analysis by FC. 10,000 events were acquired on a FACScalibur 
cytometer (Becton Dickinson Immunocytometry Systems, Oxford, UK) using 
CellQuest Pro software version 4.0.2, which also was used to analyse the data by 
gating live cells on a plot of forward scatter (FSC-H, which represents cell size) 
against side scatter (SSC-H, which represents cell granularity). A plot of 
fluorescence (FL1-H) against cell counts was used to quantify the number of live 
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cells positive for the protein of interest by manually setting the marker to incorporate 
< 1 % of the isotype and negative control cells. The geometric mean was then used 
to determine the positivity of the cells, with an arbitrary value of 5 being classified as 
positive. This value was set because the geometric mean of the negative control and 
the isotype control was between 2 and 4. 
 
The same procedure was followed for HDLEC, except that cells initially were 
resuspended in FC media (Optimem 1 Reduced Serum Media with 0.1% BSA; 
Invitrogen, Paisley, UK) to a final concentration of 3 x 105 cells/ml. HDLEC were 
either stimulated with IFNγ (100 ng/ml, Peprotech, London, UK) or TNFα (10 ng/ml, 
R&D Systems, Abingdo, UK), or left in media alone, for 24 hours prior to FC. 
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Table 4 Antibodies used for flow cytometry and adhesion function blocking 
experiments. 
 
Antigen Supplier Species 
Raised In 
Final 
Concentration 
(FC) 
Final 
Concentration 
(Adhesion 
Function 
Blocking) 
LYVE-1 R&D Systems goat 10 µg/ml 5 µg/ml 
ICAM-1  R&D Systems mouse 5 µg/ml 10 µg/ml 
VCAM-1  R&D Systems mouse 10 µg/ml 30 µg/ml 
E-selectin R&D Systems mouse 10 ug/ml 10 µg/ml 
CD 44 Sigma-Aldrich rabbit 10 µg/ml NA 
α4 Integrin R&D Systems mouse 10 µg/ml 5 µg/ml 
αvβ6 Integrin, 
Clone 53a2 
Dr John Marshall 
(Barts Cancer 
Institue) 
rat 10 µg/ml 10 µg/ml 
α5 Integrin, Clone 
P1D6 
Millipore mouse 10 µg/ml 10 µg/ml 
α9β1 Millipore mouse 5 µg/ml 5 µg/ml 
CLEVER-1 Dr Sirpa Jalkenen 
(Institute of 
Molecular Medicine, 
Finland) 
mouse 10 µg/ml 20 µg/ml 
 
 
 
3.14 Tissue Microarray (TMA) 
 
For IHC validation, in-house tissue microarrays (TMA) were constructed of 0.6 mm 
representative cores of the 18 primary PDAC Croatian cases spotted in triplicate with 
a manual arrayer (Beecher Scientific). Normal donor pancreas was used for 
orientation. The 40 cases of primary PDAC from BTL had been included previously 
on a TMA of 80 cases of primary PDAC (kind gift from Mr Hemant Kocher). The 
matched metastatic LNs were analysed as whole sections due to the limited amount 
of malignant infiltrate in some of the cases. 
  
84 
 
3.15 Immunohistochemistry (IHC) 
 
Three candidate proteins were selected for IHC validation on 4 µm sections using 
the Discovery XT system according to the manufacturer’s protocols (Ventana 
Medical Systems Inc., Illkirch, France) using commercially available antibodies at the 
following dilutions: S100P (R&D systems, Abingdon, UK) 1:100; 14-3-3 sigma 
(Abcam, Cambridge, UK) 1:50 and moesin (Abcam, Cambridge, UK) 1:200. All 
sections were scored by two independent observers, with any discrepancies being 
resolved by consultation. Sections were evaluated for both intensity (0 = no stain; 1 = 
background; 2 = mild; 3 = moderate; 4 = severe) and percentage of epithelial cells 
that stained positive (0 = 0-5 %; 1 = 6-25 %; 2 = 26-50 %; 3 = 51-75 %; 4 = > 75 %). 
Total scores were derived from a sum of the intensity and percentage of 
immunoreactive cells (187). A total score of > 2 was considered positive.  
 
4 m sections of FFPE mouse tissue (orthotopic pancreatic tumours and peri-
pancreatic LN) were stained with anti-mouse LYVE-1 (Abcam, Cambridge, UK) at a 
1:100 dilution in order to visualise lymphatics, and anti-human cytokeratin-8 
(Epitomics, California, USA) in order to visualise pancreatic cancer cells.  
 
3.16 Functional Assays 
 
3.16.1 Proliferation Assays 
 
2.5 x 104 cells/well were plated into 24-well plates (Becton-Dickinson, Oxford, UK), 
and left to adhere overnight in a humidified atmosphere (5% CO2 at 37
oC). Cells 
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remained in this humidified atmosphere for the duration of the experiment, and were 
removed only for quantitation. At this time, cells were overlayed with 500 µl of 1% 
trypsin EDTA. Following a 3 minute incubation in a humidified atmosphere (5% CO2 
at 37oC), the plate was tapped sharply to dislodge any adherent cells. 500 µl of 
DMEM supplemented with 10% FCS then was added to each well in order to 
inactivate the trypsin. The cell suspensions from each well then were transferred to 
1.5 ml Eppendorf tubes. Cells were counted using a haemocytometer every 24 hours 
for a period of five days.  
 
3.16.2 siRNA Transfection 
 
2 × 105 S5L cells were plated into six-well plates (Becton-Dickinson, Oxford, UK) and 
incubated overnight in a humidified atmosphere (5% CO2 at 37
oC). A standard 
Interferin (Polyplus) protocol was then followed according to the manufacturer’s 
instructions. Briefly, S100P or non-targeting siRNA (both from Dharmacon, Chicago, 
USA) were diluted to a final concentration of 50 nM in serum-free media (Sigma, 
Poole, UK) with Interferin (Polypus, Strasbourg, France) and incubated with the cells 
for 24 hours in a humidified atmosphere (5% CO2 at 37
oC). The cells were incubated 
in DMEM media supplemented with 10% FCS thereafter for a further 48 hours in a 
humidified atmosphere (5% CO2 at 37
oC), at which time cells were harvested for 
Western Blot analysis. 
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3.16.3 Invasion Assays 
 
Invasion assays were done using Biocoat Matrigel Invasion Chambers with 8 µm 
pores (Becton-Dickinson, Oxford, UK). 2.5 x 104 cells in 500 µl serum-free DMEM 
were added to the upper chamber, and 700 µl DMEM supplemented with 10% FCS 
was added to the lower chamber; cultures were incubated for 48 h in a humidified 
atmosphere (5% CO2 at 37
oC). Cells that had moved through the pores were fixed in 
100% methanol and stained with 1% Giemsa blue (Sigma, Poole, UK). The number 
of invaded cells was counted by averaging five random fields (x20 objective, Zeiss 
Axiophot microscope, Hertfordshire, UK).  
 
3.16.4 Cancer cell – HDLEC Adhesion Assays 
 
Adhesion assays were performed using 96-well plates (Becton-Dickinson, Oxford, 
UK). Initially, 50 µl of FN (Becton-Dickinson, Oxford, UK) at a 0.5 µg/ml 
concentration was added to each well and left to set for one hour at 37oC. 1.5 x 104 
HDLEC were then seeded into each well and left to settle overnight in a humidified 
atmosphere (5% CO2 at 37
oC). The following day, HDLEC were either stimulated 
with IFNγ (100 ng/ml, Peprotech, London, UK) or TNFα (10 ng/ml, R&D Systems, 
Abingdo, UK), or left in media alone, for 24 hours. The next day, V3L or S5L cells 
were labelled with the red fluorescent dye DiIC12 (Becton-Dickinson, Oxford, UK) at a 
final concentration of 10 µg/ml for one hour at 37oC. Medium containing the relevant 
cytokines was removed from HDLEC; HDLEC were washed with PBS and 1 x 104 
fluorescent cancer cells in a 50 µl volume of Optimem I Reduced Serum Media 
(Invitrogen, Paisely, UK) then were added to each well. Co-cultures were incubated 
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for 45 minutes in a humidified atmosphere (5% CO2 at 37
oC), after which, each well 
was washed thrice with PBS to remove any non-adherent cancer cells. Fluorescence 
was quantified using the Fluostar Optima (BMG Labtech, Ortenberg, Germany) in 
relation to a standard curve to determine the absolute number of adherent cancer 
cells.  
 
For function blocking experiments, HDLEC were incubated with 50 µl of the 
appropriate blocking antibodies (Table 4) for 1 hour in a humidified atmosphere (5% 
CO2 at 37
oC), with any unbound antibody thereafter being washed off with PBS, prior 
to the addition of fluorescently-labelled cancer cells. 
 
3.16.5 Hyaluronic Acid (HA) Binding Assays 
 
These assays were performed in 96-well plates (Becton-Dickinson, Oxford, UK). 50 
µl of fluorescein hyaluronic acid (Sigma, Poole, UK) at a 1 mg/ml concentration was 
added to each well, and left to set for one hour at 37oC. 1 x 104 V3L or S5L cells 
suspended in 50 µl of Optimem I Reduced Serum Media (Invitrogen, Paisley, UK) 
were then added per well, and left to incubate at 37oC for one hour. Wells were 
washed three times with PBS to remove any non-adherent HA. The amount of 
remaining HA in each well was quantified using the Fluostar Optima (BMG LabTech, 
Ortenberg, Germany) in relation to a standard curve.  
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3.16.6 Fibronectin (FN) Binding Assays 
 
These assays were performed in 96-well plates (Becton-Dickinson, Oxford, UK). 50 
µl of FN (BD Biosciences, Oxford, UK) at a 20 µg/ml concentration was added to 
each well, and left to set overnight at 4oC. The next day, V3L or S5L cells (1 x 104 
per 50 µl of Optimem I Reduced Serum Media (Invitrogen, Paisley, UK)), which had 
been labelled with the red fluorescent dye DiIC12 (BD Biosciences, Oxford, UK) 
earlier that day, then were added to each well, and left to incubate in a humidified 
atmosphere (5% CO2 at 37
oC) for 45 minutes. Wells were washed three times with 
PBS to remove any non-adherent cells. The number of adherent cells was then 
quantified on the Fluostar Optima (BMG LabTech, Ortenberg, Germany) in relation 
to a standard curve.  
 
3.16.7 Permeability and Translymphatic Endothelial Migration (TLEM) Assays  
 
These assays were performed in 24-well Migration Chambers with 8 µm pores 
(Becton-Dickinson, Oxford, UK). Initially, 100 µl of FN at a 0.5 µg/ml concentration 
(Becton-Dickinson, Oxford, UK) was added to the upper chamber of each well and 
left to set at 4oC overnight. At D0, 2.5 x 105 HDLEC were seeded onto the FN, and 
left overnight in a humidified atmosphere (5% CO2 at 37
oC) to form a confluent 
monolayer. At D1, 5 x 105 V3L or S5L cells were seeded onto this monolayer in 500 
µl of Optimem I Reduced Serum Media (Invitrogen, Paisley, UK) containing 2 million 
MW FITC-Dextran (Sigma, Poole, UK) at a 1 mg/ml concentration (Figure 6). 700 µl 
of Optimem I Reduced Serum Media (without FITC-Dextran) was then added to the 
lower chamber, in order to establish a diffusion gradient. Permeability through the 
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HDLEC monolayer was quantified by measuring the amount of FITC-Dextran that 
permeated into the lower chamber at 1, 4, 8, 12 and 24 hours post-seeding in 
relation to a standard curve on the Fluostar Optima (BMG Labtech, Ortenberg, 
Germany) (Figure 7). For example, at one hour post-seeding, the inserts were 
moved into new wells containg 700 µl of Optimem I Reduced Serum Media (without 
FITC-Dextran), which were used for the next time-point. Then 50 µl of media from 
each of the inital wells was transferred to a 96-well plate containing a standard curve 
of FITC-Dextran (serial 1:2 dilutions of 1 mg/ml stock concentration) from which the 
FITC-Dextran concentration of each test sample was extrapolated. Standards and 
test samples were measured in triplicate.  
 
At D2, the inserts containing the co-cultures (Figure 8) were moved into a new 24-
well plate (Becton-Dickinson, Oxford, UK). Upper chambers were replenished with 
500 µl Optimem I Reduced Serum Media, whilst 700 µl of DMEM containing 10% 
FCS was added to the bottom chamber as an attractant. The number of cells which 
had migrated into the lower chamber was quantified 72 hours later using the Coulter 
Counter (Beckman Coulter, Inc., High Wycombe, UK). 
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Figure 6 Permeability assay schema. 5 x 105 cancer cells (blue) were seeded onto a 
HDLEC monolayer (mauve) in 500 µl of Optimem I Reduced Serum Media 
containing 1 mg/ml of FITC-Dextran (2 million MW; green). This insert, which 
contained both cell types, was then inserted into a 24-well plate; each well contained 
700 µl Optimem I Reduced Serum Media without FITC-Dextran (fawn). The red 
arrow represents the diffusion gradient. The amount of FITC-Dextran that permeated 
through the HDLEC monolayer over time was used as a measure of permeability. 
 
  
Media containing FITC-Dextran 
Cancer cells 
HDLEC monolayer 
91 
 
 
 
 
 
 
 
Figure 7 Measuring permeability. At each time-point, inserts were moved to new 
wells containing 700 µl Optimem I Reduced Serum Media (red arrow). Then 50 µl of 
media from each used well was transferred (in triplicate) to a 96-well plate (blue 
arrow). The amount of FITC-Dextran that had permeated through the HDLEC 
monolayer into the bottom well at each time-point was quantified in relation to a 
standard curve (green) using a fluorescent plate-reader. 
 
 
1 Hour 
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8 Hours 
12 Hours 
V3L S5L 
50 µl of each sample removed 
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Figure 8 Translymphatic endothelial migration assay schema. Inserts containing 
cancer cells (blue) and HDLEC (mauve), which had been used to measure 
permeability over 24 hours, were moved into new 24-well plates. The top wells were 
replenished with 500 µl Optimem I Reduced Serum Media (Serum-free media; fawn), 
whilst 700 µl of DMEM (grey) which had been supplemented with 10% FCS was 
added to the lower wells. The latter served as a chemoattractant. The migration of 
cancer cells through the HDLEC monolayer then was quantified over 48 hours. 
 
 
  
Cancer cells 
Serum-free media 
HDLEC monolayer 
Serum-containing media 
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3.16.8 Luciferase Assay 
 
Quantification of luciferase expression of V3L and S5L cells in vitro was done using 
the Luciferase Assay System (Promega, Southampton, UK). Briefly, 5 x 105 cells 
were lysed in 1 x lysis buffer. The sample was centrifuged at 12,000 x g for 15 
seconds at room temperature, after which the supernatant was transferred to a new 
1.5 ml Eppendorf tube. Serial 1:10 dilutions were performed on these stock samples. 
These samples then were quantified using a VICTOR 1420 Multilabel Counter 
(Perkin Elmer, Massachusetts, USA). 
 
3.16.9 Soft Agar Assays 
 
A total of 200 cells in a single-cell suspension were mixed, on ice, in 5 ml of DMEM 
medium with 0.3% agarose (Sigma, Poole UK). After 20 minutes, 1 ml of DMEM 
containing 10% FCS was added.  Cultures were incubated in a humidified 
atmosphere (5% CO2 at 37
oC) for 18 days, at which point the wells were 
photographed on a Stemi SV11 microscope (Zeiss, Hertfordshire, UK). The total 
number of colonies was counted, and the total area of the colonies was determined 
using ImageJ software. Briefly, the microscopy images initially were converted into 
grey-scale format using Adobe Photoshop CS4 software; these grey-scale images 
were then opened in ImageJ. Colonies were highlighted using the ‘wand’ tool, and 
the total area then was quantified using the ‘measure’ tool. 
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3.17 Mouse Models 
 
Mice were anaesthetised using inhalation anaesthesia (Isoflurane with Oxygen and 
Nitrous Oxide) for both induction and maintenance.  
 
For the orthotopic pancreatic mouse model (n = 10 per group), a 2 cm incision was 
made in the abdominal wall, parallel to the ribcage. After exteriorisation of the 
pancreas and spleen, 40 l of cell suspension (containing 6.5 x 105 V3L or S5L cells 
suspended in PBS) was injected into the tail of the pancreas using an insulin syringe, 
and a 29 gauge x ½ inch needle (Southern Syringe Services, Leicester, UK). The 
injection site was dabbed gently with a cotton swab (Southern Syringe Services, 
Leicester, UK) immediately following injection to ensure that no leakage occurred. 
Skin and muscle were sutured using Vicryl 4.0 (Southern Syringe Services, 
Leicester, UK). Immediately after surgery, mice were transferred to a ‘recovery 
cage’, which contained food and water, and which was heated externally using a 
heater. As only inhalation anaesthesia was used for induction and maintenance, 
recovery usually occurred within 30 minutes post-operatively. Mice were monitored 
daily thereafter, initially to ensure that the sutures had healed adequately, and 
thereafter to ensure that they were not showing signs of ill health. Mice were imaged 
weekly from week 1 post-operation using the IVIS imaging system to monitor both 
the growth of the primary tumour and the potential development of metastases (see 
below). The experiment was terminated at 10 weeks post-injection.  
 
In order to assess site-specific growth, mice (n = 7 per group) were subjected to the 
above-mentioned procedure, with the following modifications: 
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5 x 105 V3L or S5L cells were injected in a 40 µl volume into the spleen in order to 
seed to the liver; and 1 x 105 V3L or S5L cells were injected in a 10 µl volume using 
a 30 gauge x 5 mm custom syringe (Hamilton Syringes) into the right axillary lymph 
node, following a 1 cm incision into the overlying skin. The former experiment was 
terminated at 6 weeks, the latter at 10 weeks, post-injection.  
 
Lastly, 5 x 105 V3L or S5L cells in a 200 µl volume were injected directly into the tail 
vein in order to assess experimental metastasis. No anaesthesia was given for this 
procedure. Mice were pre-warmed using warm air in order to dilate the blood 
vessels. This experiment was terminated at 4 weeks post-injection.  
 
3.18 Bioluminescence Imaging in vivo 
 
Mice received an intraperitoneal injection of 150 µl of D-luciferin (Caliper Life 
Sciences, Cheshire, UK) diluted with distilled water to a final concentration of 15 
mg/ml. Thereafter, they were anaesthetised using inhalation anaesthesia (Isoflurane 
with Oxygen and Nitrous Oxide) for the duration of the imaging procedure. Images 
were taken using the IVIS-100 (Xenogen, Caliper Life Sciences, Cheshire, UK) at 10 
minutes post-injection. Regions of interest (ROI) were calculated for each mouse. 
ROI calculates the signal intensity for a standardised area for each mouse, and is a 
quantitative measure of bioluminescence, and thus tumour growth. The ROI for each 
mouse were plotted weekly until each experiment was terminated. In addition, 
average ROIs for each experimental group (i.e. V3L and S5L) were calculated for the 
duration of each experiment. 
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3.19 Processing of Mouse Tissues 
 
Harvested tissues (tumours, normal pancreas, duodenum, liver, lungs, any tissue 
suspicious for metastasis, and lymph nodes) were either formalin-fixed and paraffin-
embedded, or snap-frozen in liquid nitrogen. Frozen tissue was stored in 2 ml 
cryovials at -80oC. All tumours were weighed prior to processing. 
 
3.20 Ingenuity Pathway Analysis (IPA) 
 
Proteomics data were analysed using IPA (version 4.0), a web-based application 
(http://www.ingenuity.com/) that identifies biologically relevant pathways from gene 
and/or protein expression data. This software is based on the IKPB (Knowledge 
Base database), one of the largest curated bioinformatics databases containing 
millions of computable relationships between genes, proteins, drugs and diseases. 
IPA builds biological networks and explores signalling pathways based on entered 
experimental data and known published associations. Furthermore, scores are 
generated for each network, quantifying the likelihood of associations not being due 
to chance alone (e.g., a score of 2 gives a 99% confidence, with higher scores 
signifying greater confidence). Based on these scores, IPA prioritises networks, 
identifies associated proteins, and assigns the most significant biological functions to 
each network. The global functional analysis feature calculates this significance 
using a right-tailed Fisher’s exact test, with a p-value ≤ 0.05 being considered 
significant.  
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3.21 Statistics and Target Selection  
 
3.21.1 Normalisation of MudPIT data 
 
Proteins initially were filtered to exclude those that appeared only in MudPIT 
experiment 1 or experiment 2. The remaining proteins, common to both experiments, 
then were filtered according to spectral count. Data were normalised to correct for 
the differences in spectral counts between samples as follows: 
 
Spectral count of individual protein x ((Total LN spectral count  Total PDAC spectral 
count) + 0.01) 
 
A corrective factor of 0.01 was used to eliminate any zeroes for g-test calculations. 
As two experiments were performed, a mean spectral count was calculated for 
PDAC and LN samples, respectively. All proteins with a mean spectral count 
between 0 and 5 in both samples were excluded from downstream analysis due to 
the limited sensitivity of the mass spectrometer, particularly when dealing with a low 
number of replicate samples.  
 
3.21.2 G-test Analysis of MudPIT data  
 
For the remaining proteins a g-test was performed. The g-test (likelihood ratio; 
goodness-of-fit) has been shown to be superior for samples with less than three 
measurements (90). It calculates the x2-distribution with one degree of freedom. A g-
value of ≥ 3.8 is considered significant. 
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The original equation used for the calculation of the g-value is as follows: 
 
g = 2fobs1 ln(fobs1/fexp1) + 2fobs2 ln (fobs2/fexp2) 
 
Where fobs1 = observed value in sample 1 
  fobs2 = observed value in sample 2 
  fexp1 = expected frequencies in sample 1 
  fexp2= expected frequencies in sample 2 
 
The null hypothesis is that there is no differential expression between the 2 samples. 
Therefore 
fobs1 = fobs2 = (fobs1 + fobs2)/2 
 
This also is equal to the mean of the observed counts between all samples (meanT). 
Therefore the equation becomes 
 
g = 2 fobs1 ln(fobs1/meanT) + 2 fobs2 ln (fobs2/meanT) 
 
Which becomes 
 
g = 2 [(fobs1 ln(fobs1/meanT) + fobs2 ln(fobs2/meanT)] 
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3.21.3 IHC Validation 
 
For IHC validation, the average score for each matched case was calculated, and a 
Mann-Whitney test was performed to determine differential expression between 
primary PDAC and metastatic LN samples. A p-value ≤ 0.05 was considered 
significant.  
 
3.21.4 Experiments conducted in vitro   
 
All the in vitro experiments were repeated three times in triplicate. A paired Student’s 
t-test was then performed, with a p-value of ≤ 0.05 being considered significant. 
Error bars show standard error of the mean (SEM). 
 
3.21.5 Experiments conducted in vivo   
 
A Mann-Whitney test was performed on all data, with a p-value of ≤ 0.05 being 
considered significant. Error bars show standard error of the mean (SEM). 
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4.  RESULTS (Part I):  PROTEOMICS 
 
4.1.   LCM  and MudPIT Analysis 
 
In order to differentiate the malignant epithelia from the surrounding connective 
tissue, sections were stained with haematoxylin before LCM. Seven matched cases 
(10,000 - 15,000 cells/case) were dissected in total, with four and three cases 
subsequently being pooled. This resulted in four pooled samples – two PDACs and 
two matched LN metastases – each comprising 10 µg of protein (40,000 - 45,000 
cells) that were used for downstream Multidimensional Protein Identification 
Technology (MudPIT) analysis. Representative sections of a malignant pancreatic 
duct before and after LCM are shown in Figure 9, together with the subsequent 
workflow for analysis.  
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Figure 9 Laser Capture Microdissection (LCM). Representative images (100x 
magnification) show a malignant pancreatic duct before (A) and after (B) LCM. The 
workflow for LCM is shown in (C).  
 
 
In total, 1504 proteins were identified across both experiments. Table 5 displays the 
total number of proteins identified, as well as the total spectral counts, for each 
sample. Spectral counts reflect the number of peptides identified in silico and the 
number of times those matched peptides were observed. Spectral count has been 
shown to be a semi-quantitative measure of abundance across samples, with a 
linear correlation to relative abundance over a two order of magnitude linear dynamic 
range (89). This correlation is seen in our samples – the higher the number of total 
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spectral counts, the higher the number of identified proteins. On average, a lower 
number of proteins were seen in primary PDACs as opposed to LN metastases. 
However, this did not affect the statistical analysis, as samples were normalised 
before being tested for differential expression. Normalisation corrects for the 
differences in total spectral count seen between samples, and ensures a ‘level 
playing field’ before differential expression is calculated. The False Discovery Rate 
(FDR), which represents the number of false positives or the number of peptides that 
were incorrectly identified, was < 1.5% for all samples.  
 
 
 
 
Table 5 MudPIT results. The total number of proteins, as well as the total spectral 
counts, identified in PDAC samples and matched LN metastases. The false 
discovery rate (FDR) for all samples was <1.5%.   
 
 
 
 
 
 
  
 PDAC 1 PDAC 2 LN 1 LN 2 
Total no. of proteins 598 858 858 1119 
Total spectral counts 4794 7723 8066 11049 
Total unique peptides 2577 4213 4068 5696 
Mean spectral count 8.017 9.001 9.401 9.874 
Mean unique peptides 4.309 4.910 4.741 5.090 
No. of reverse hits 4 8 6 8 
% FDR 1.329 0.924 1.389 0.710 
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The relationship between the proteins found across both experiments is illustrated in 
the Venn diagram in Figure 10. Of the 1504 proteins found, 650 were found in only 
one of the two MudPIT experiments and were thus excluded from further analysis. 
The remaining 854 proteins were commonly expressed in both experiments 
(Appendix I); these represent the proteome of primary PDAC and LN metastases. 
Following filtering on the basis of spectral count, a statistical g-test was performed – 
this resulted in a list of 115 significantly differentially expressed proteins (g-value ≥ 
3.8) (Table 6). 
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Table 6 List of 115 significantly differentially expressed proteins. The 854 proteins 
common to all four samples were subjected to a g-test to determine which proteins 
were significantly differentially expressed (g ≥ 3.8). Of these, S100P (high g-value), 
14-3-3 sigma (intermediate g-value) and moesin (low g-value; all three proteins are 
highlighted in red), were selected for validation using immunohistochemistry (IHC). 
The IHC served to validate the statistical approach used, as well as to validate the 
up-regulation of the candidate proteins.  
Identified Proteins Accession No. MW G-Value 
TUBA4A Tubulin alpha-4A chain IPI00007750 50 kDa 49.76 
TPM4 Isoform 2 of Tropomyosin alpha-4 chain IPI00216975 33 kDa 34.52 
HNRNPH1 Heterogeneous nuclear 
ribonucleoprotein H IPI00013881 49 kDa 33.13 
YWHAH 14-3-3 protein eta IPI00216319 28 kDa 31.75 
KRT7 Keratin, type II cytoskeletal 7 IPI00306959 51 kDa 27.77 
CSE1L Isoform 1 of Exportin-2 IPI00022744 110 kDa 27.59 
IQGAP2 Isoform 1 of Ras GTPase-activating-
like protein IQGAP2 IPI00299048 181 kDa 25.12 
COL12A1 Isoform 4 of Collagen alpha-1(XII) 
chain IPI00302944 325 kDa 24.28 
H2AFY2 Core histone macro-H2A.2 IPI00220994 40 kDa 22.05 
S100P Protein S100-P IPI00017526 10 kDa 20.66 
ENO2 Gamma-enolase IPI00216171 47 kDa 20.66 
LCP1 Plastin-2 IPI00010471 70 kDa 18.80 
TUBB2A Tubulin beta-2A chain IPI00013475 50 kDa 18.72 
KRT20 Keratin, type I cytoskeletal 20 IPI00021298 48 kDa 17.58 
TPM1 tropomyosin 1 alpha chain isoform 7 IPI00216134 29 kDa 16.56 
RPL8 60S ribosomal protein L8 IPI00012772 28 kDa 16.51 
S100A10 Protein S100-A10 IPI00183695 11 kDa 16.51 
CCT5 T-complex protein 1 subunit epsilon IPI00010720 60 kDa 16.51 
HNRNPA1 Isoform A1-B of Heterogeneous 
nuclear ribonucleoprotein A1 IPI00215965 39 kDa 16.27 
TNC Isoform 1 of Tenascin IPI00031008 241 kDa 16.20 
YWHAZ 14-3-3 protein zeta/delta IPI00021263 28 kDa 15.79 
DSP Isoform DPI of Desmoplakin IPI00013933 332 kDa 14.25 
FLNB Isoform 1 of Filamin-B IPI00289334 278 kDa 14.25 
SPTBN1 Isoform Long of Spectrin beta chain, 
brain 1 IPI00005614 275 kDa 14.22 
CTSG Cathepsin G IPI00028064 29 kDa 14.21 
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TRIM28 Isoform 1 of Transcription 
intermediary factor 1-beta IPI00438229 89 kDa 13.49 
MARCKS Myristoylated alanine-rich C-kinase 
substrate IPI00219301 32 kDa 13.49 
PKM2 Isoform M1 of Pyruvate kinase 
isozymes M1/M2 IPI00220644 58 kDa 12.52 
YWHAQ 14-3-3 protein theta IPI00018146 28 kDa 12.21 
HBA1;HBA2 Hemoglobin subunit alpha IPI00410714 15 kDa 12.03 
LGALS4 Galectin-4 IPI00009750 36 kDa 11.16 
SFN Isoform 1 of 14-3-3 protein sigma IPI00013890 28 kDa 11.12 
FGB Fibrinogen beta chain IPI00298497 56 kDa 10.84 
IQGAP1 Ras GTPase-activating-like protein 
IQGAP1 IPI00009342 189 kDa 10.58 
YWHAG 14-3-3 protein gamma IPI00220642 28 kDa 10.48 
DMBT1 Isoform 1 of Deleted in malignant 
brain tumors 1 protein IPI00099110 261 kDa 10.37 
ERH Enhancer of rudimentary homolog IPI00029631 12 kDa 10.18 
CRYZ Quinone oxidoreductase IPI00000792 35 kDa 9.76 
UQCRC2 Cytochrome b-c1 complex subunit 2, 
mitochondrial IPI00305383 48 kDa 9.76 
HSD17B4 Peroxisomal multifunctional enzyme 
type 2 IPI00019912 80 kDa 9.76 
S100A8 Protein S100-A8 IPI00007047 11 kDa 9.72 
WDR1 Isoform 2 of WD repeat-containing 
protein 1 IPI00216256 58 kDa 9.69 
PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61 kDa 9.07 
KRT14 Keratin, type I cytoskeletal 14 IPI00384444 52 kDa 8.78 
RPS4X 40S ribosomal protein S4, X isoform IPI00217030 30 kDa 8.76 
PRKDC Isoform 1 of DNA-dependent protein 
kinase catalytic subunit IPI00296337 469 kDa 8.70 
SFPQ Isoform Long of Splicing factor, proline- 
and glutamine-rich IPI00010740 76 kDa 8.34 
CTNNB1 Isoform 1 of Catenin beta-1 IPI00017292 85 kDa 8.29 
HADHA Trifunctional enzyme subunit alpha, 
mitochondrial IPI00031522 83 kDa 8.10 
RPL15 60S ribosomal protein L15 IPI00470528 24 kDa 7.92 
KRT18 Keratin, type I cytoskeletal 18 IPI00554788 48 kDa 7.90 
HNRNPF Heterogeneous nuclear 
ribonucleoprotein F IPI00003881 46 kDa 7.84 
TAGLN2 Transgelin-2 IPI00550363 22 kDa 7.82 
UGDH UDP-glucose 6-dehydrogenase IPI00031420 55 kDa 7.62 
LRPPRC Leucine-rich PPR motif-containing 
protein, mitochondrial IPI00783271 158 kDa 7.54 
HBB Hemoglobin subunit beta IPI00654755 16 kDa 7.29 
MPO Isoform H17 of Myeloperoxidase IPI00007244 84 kDa 7.02 
DEFA1;LOC728358 Neutrophil defensin 1 IPI00005721 10 kDa 6.93 
MVP Major vault protein IPI00000105 99 kDa 6.83 
ITPR3 Inositol 1,4,5-trisphosphate receptor 
type 3 IPI00291607 304 kDa 6.82 
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PDCD6 Programmed cell death protein 6 IPI00025277 22 kDa 6.82 
AKR1B10 Aldo-keto reductase family 1 
member B10 IPI00105407 36 kDa 6.82 
HNRNPM Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein M IPI00171903 78 kDa 6.61 
YWHAB Isoform Long of 14-3-3 protein 
beta/alpha IPI00216318 28 kDa 6.61 
TLN1 Talin-1 IPI00298994 270 kDa 6.59 
C22orf28 UPF0027 protein C22orf28 IPI00550689 55 kDa 6.54 
EVPL Envoplakin IPI00023711 232 kDa 6.54 
PDXDC1 Isoform 1 of Pyridoxal-dependent 
decarboxylase domain-containing protein 1 IPI00384689 87 kDa 6.54 
RPL4 60S ribosomal protein L4 IPI00003918 48 kDa 6.54 
ARPC1B Actin-related protein 2/3 complex 
subunit 1B IPI00005160 41 kDa 6.50 
PSMA1 Isoform Short of Proteasome subunit 
alpha type-1 IPI00016832 30 kDa 6.50 
HSPA1B;HSPA1A Heat shock 70 kDa protein 
1 IPI00304925 70 kDa 6.28 
PFKL Isoform 1 of 6-phosphofructokinase, 
liver type IPI00332371 85 kDa 6.24 
CPT1A Isoform 1 of Carnitine O-
palmitoyltransferase 1, liver isoform IPI00032038 88 kDa 5.96 
LIMA1 Isoform Beta of LIM domain and actin-
binding protein 1 IPI00008918 85 kDa 5.96 
TUFM Tu translation elongation factor, 
mitochondrial precursor IPI00027107 50 kDa 5.84 
THBS1 Thrombospondin-1 IPI00296099 129 kDa 5.80 
KTN1 Isoform 1 of Kinectin IPI00328753 156 kDa 5.75 
RAB14 Ras-related protein Rab-14 IPI00291928 24 kDa 5.73 
OGDH 2-oxoglutarate dehydrogenase E1 
component, mitochondrial IPI00098902 116 kDa 5.72 
EIF4A3 Eukaryotic initiation factor 4A-III IPI00009328 47 kDa 5.65 
APEX1 DNA-(apurinic or apyrimidinic site) 
lyase IPI00215911 36 kDa 5.52 
PARP1 Poly [ADP-ribose] polymerase 1 IPI00449049 113 kDa 5.52 
PLS1 Plastin-1 IPI00032304 70 kDa 5.52 
RPS15A 40S ribosomal protein S15a IPI00221091 15 kDa 5.52 
CYCS Cytochrome c IPI00465315 12 kDa 5.51 
TMSB4X Thymosin beta-4 IPI00220828 5 kDa 5.51 
CTNNA1 Isoform 1 of Catenin alpha-1 IPI00215948 100 kDa 5.08 
RPL5 60S ribosomal protein L5 IPI00000494 34 kDa 5.05 
DYNC1H1 Cytoplasmic dynein 1 heavy chain 
1 IPI00456969 532 kDa 4.89 
HNRNPL Heterogeneous nuclear 
ribonucleoprotein L IPI00027834 64 kDa 4.77 
GOT1 Aspartate aminotransferase, 
cytoplasmic IPI00219029 46 kDa 4.77 
LMNB1 Lamin-B1 IPI00217975 66 kDa 4.76 
LMNA Isoform A of Lamin-A/C IPI00021405 74 kDa 4.71 
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FBN1 Fibrillin-1 IPI00328113 312 kDa 4.65 
NONO Non-POU domain-containing octamer-
binding protein IPI00304596 54 kDa 4.61 
CCT4 T-complex protein 1 subunit delta IPI00302927 58 kDa 4.53 
VDAC1 Voltage-dependent anion-selective 
channel protein 1 IPI00216308 31 kDa 4.53 
EFHD2 EF-hand domain-containing protein D2 IPI00060181 27 kDa 4.53 
EHD1 EH domain-containing protein 1 IPI00017184 61 kDa 4.53 
AIFM1 Isoform 1 of Apoptosis-inducing factor 
1, mitochondrial IPI00000690 67 kDa 4.53 
PCBP2 poly(rC) binding protein 2 isoform b IPI00012066 38 kDa 4.35 
ALDOA Fructose-bisphosphate aldolase A IPI00465439 39 kDa 4.33 
PCBP1 Poly(rC)-binding protein 1 IPI00016610 37 kDa 4.28 
ANXA4 annexin IV IPI00793199 36 kDa 4.24 
HMGA1 Isoform HMG-I of High mobility group 
protein HMG-I/HMG-Y IPI00179700 12 kDa 4.23 
HIST1H1E Histone H1.4 IPI00217467 22 kDa 4.20 
SRI Sorcin IPI00027175 22 kDa 4.14 
FUBP1 Isoform 1 of Far upstream element-
binding protein 1 IPI00375441 68 kDa 4.02 
VIM Vimentin IPI00418471 54 kDa 4.01 
KPNB1 Importin subunit beta-1 IPI00001639 97 kDa 3.93 
SFRS1 Isoform ASF-1 of Splicing factor, 
arginine/serine-rich 1 IPI00215884 28 kDa 3.86 
PA2G4 Proliferation-associated protein 2G4 IPI00299000 44 kDa 3.86 
HSPB1 Heat shock protein beta-1 IPI00025512 23 kDa 3.82 
MSN Moesin IPI00219365 68 kDa 3.76 
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Figure 10 Relationship between the proteins found using MudPIT. Of the 1504 
proteins found in total, 854 proteins were seen in all four samples analysed. Of these 
854 proteins, 115 proteins were found to be significantly differentially expressed 
following a statistical g-test (g-value ≥ 3.8). 
 
 
Quantification of the subcellular compartmental distribution (Figure 11) showed that 
most of the classified proteins were cytoplasmic (57.6%) and nuclear (18.3%). Cell 
membrane constituted 8.9% of the proteome. 8.5% of the proteome was found to be 
extracellular, whilst the remaining proteins (6.7%) could not be classified or were 
unknown. 
109 
 
 
Figure 11 Subcellular compartmentalisation of 854 proteome. The majority of the 
854 proteins were cytoplasmic (57.6%) and nuclear (18.3%), with cell membrane 
(CM) proteins being less well represented. Some proteins in the proteome (8.5%) 
originated from the extracellular space (ECS). The remaining 6.7% of the 854 
proteome could not be classified or were unknown, and thus, are depicted as ‘other’. 
 
 
IPA analysis demonstrated that the top five biological functions within the 854 
discovered proteins were: cellular growth and proliferation (165 proteins); cell death 
(132 proteins); cellular movement (90 proteins); cell-to-cell signalling (69 proteins) 
and protein synthesis (44 proteins) (Figure 12). Qualitative analysis of this proteome 
highlighted a number of proteins involved in these top five biological functions: 
integrins α2, α3, αV, β1, and β4 (growth and proliferation, cellular movement and 
signalling); eight of the 21 known S100 proteins, namely S100A4, S100 A6, S100A8, 
S100A9, S100A10, S100A11, S100A16 and S100P (growth and proliferation, cellular 
movement and signalling); IQGAP1 and IQGAP2 (cellular movement and signalling); 
cathepsins B, G and Z (cellular movement); and lastly, α –, β – and δ – catenin 
(signalling). In addition, six out of seven members of the 14-3-3 family of regulatory 
proteins (14-3-3- β/α, γ, δ/δ, ε, ζ, and σ), which have the capacity to bind various 
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signalling molecules also appeared in the proteome; moreover, all of these were 
significantly differentially expressed between PDAC and LN metastasis.  
 
Comparison of our 854 proteins with previously reported proteomic data on the 
pancreas (tissues, pancreatic juice, serum and urine) using the Pancreatic 
Expression Database (http://www.pancreasexpression.org), showed a 29% overlap; 
the proteins common to all studies, including ours, are listed in Appendix II. 
 
 
 
 
Figure 12 Top five biological functions associated with the 854 proteome. Ingenuity 
Pathway Analysis (IPA) ranked cell growth and proliferation as the top biological 
function associated with the 854 identified proteins. This was followed by cell death, 
cellular movement, cell-to-cell signalling and protein synthesis. 
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4.2  Validation of MudPIT Data using IHC 
 
Three proteins with high, intermediate and low g-values, respectively were chosen 
for further validation by IHC in a larger series of 55 matched cases of primary PDAC 
and LN metastases The IHC served both to validate the statistical approach used to 
analyse the MudPIT data, as well as to confirm the up-regulation of the candidate 
proteins in LN metastases. Proteomic analysis showed that S100P (g-value = 20.66) 
and 14-3-3 sigma (g-value = 11.12) were significantly up-regulated in metastatic LN 
specimens (Table 6 – highlighted in red). Although moesin had an equivocal g-value 
of 3.76, we chose to investigate it further as it had previously been shown to be up-
regulated in association with LN metastasis. 
 
S100P was successfully analysed in 52/55 cases; whilst 14-3-3 sigma and moesin 
were successfully analysed in 51/55 cases. Some cases had to be omitted from the 
final analysis due to technical loss of tissue cores. Both S100P (p = 0.05) and 14-3-3 
sigma (p < 0.001) were confirmed to be significantly up-regulated in LN metastatic 
epithelia by IHC (Figures 13 and 14). All of the 52 cases analysed showed high 
levels of S100P expression in both the primary PDAC and LN metastases, with 
S100P localising to both the cytoplasm and nucleus (Figure 13A-D). In contrast, 14-
3-3 sigma expression was restricted to the cytoplasm of malignant epithelia (Figure 
14A-D). Only six primary PDACs did not express 14-3-3 sigma, and of those, four 
showed up-regulation in matched LN metastases, whilst two metastatic LN were 
negative for 14-3-3 sigma expression.  
112 
 
 
 
 
 
 
Figure 13 IHC validation of S100P differential expression (n = 52). Representative 
images of primary PDAC (A and C) and matched LN metastases (B and D; 100x 
magnification) show that S100P was strongly expressed in both primary PDACs and 
LN metastases, localising to the nucleus and cytoplasm. In addition, a graphical 
representation of the IHC scores (median with inter-quartile range) is shown in E; 
thus, S100P was confirmed to be up-regulated in LN metastases (p = 0.05).  
A B 
C D 
E 
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Figure 14 IHC validation of 14-3-3 sigma differential expression (n = 51). 
Representative images of primary PDAC (A and C) and matched LN metastases (B 
and D; 100x magnification) show that 14-3-3 sigma was expressed exclusively in the 
cytoplasm of malignant epithelia. LN metastases showed an increase in 14-3-3 
sigma expression relative to primary PDAC (p < 0.001), in keeping with MudPIT 
data. Quantification of differential expression is shown in E (IHC scores: median with 
inter-quartile range).  
A B 
C D 
E 
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Moesin (Figure 15) was variably expressed by the epithelial components of both 
primary PDAC and metastatic LN. Only 15/51 matched cases expressed moesin; 
with four cases showing higher expression in matched LN metastases. Thus, moesin 
was not found to be significant differentially expressed (p = 0.88). In addition, moesin 
was expressed by various stromal elements in both primary PDAC and LN 
metastases. Of note, the LN parenchyma stained strongly positive for moesin. 
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Figure 15 IHC validation of moesin expression (n = 51). Representative images of 
primary PDAC (A and C) and matched LN metastases (B and D; 100x magnification) 
show that moesin was not expressed in the malignant epithelia of most of the cases 
analysed; moreover it was expressed by stromal elements in both primary PDACs 
and LN metastases. As can be seen in B, the LN parenchyma was highly 
immunoreactive. A graphical representation of the IHC scores (median with inter-
quartile range) is shown in E; moesin was not found to be significantly differentially 
expressed.  
A B 
C D 
E 
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5. DISCUSSION (Part I): PROTEOMICS 
 
Using the Liquid Tissue MS Protein Prep Kit, we were able to analyse the proteomes 
of primary PDAC and matched LN metastases from FFPE tissues. As these samples 
were obtained from patients who qualified for surgical resection, we consider these 
proteins to be particularly relevant for therapeutic target discovery. Pre-fractionation 
of our samples during MudPIT greatly increased the number of proteins identified, 
yielding 1504 proteins from only 10 µg of tissue per sample; thus, the obtained 
proteome is, to our knowledge, the first and certainly the largest of its kind within the 
field. The full proteome will be made publically accessible through the Pancreatic 
Expression Database (188). 
 
 It has been shown that increasing the number of sample replicates in MudPIT 
analysis increases the number of commonly identified proteins by 30% per replicate 
(i.e. two replicates result in a 60% overlap, whilst three replicates result in a 90% 
overlap) (89,189). This is in keeping with our results, where 854 proteins (57%) were 
common to both experiments. Interestingly however, whilst these previously reported 
experiments were conducted on replicates of homogenous tissue (e.g. normal 
mouse liver), our samples were from seven different donors, with individual 
heterogenous tumours. Despite this heterogeneity, only 115 of the 854 proteins 
(13.5%) were significantly differentially expressed, suggesting that LN metastases 
largely resemble their tumours of origin, which is in keeping with published 
transcriptomic data (69).  
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A caveat to this interpretation however, is that whilst MudPIT increases protein yield, 
it remains an evolving technology which only ‘scratches the surface’ of the complex 
mammalian proteome. Thus, considering that the technique itself is approximately 
75% reproducible (89); in light of the fact that duplicates were analysed which select 
for a 60% overlap (89); and bearing in mind that the G-test quantitates larger fold-
changes better than smaller changes in differential protein expression (90), one has 
to wonder if these data reflect the limitations of current day proteomics, rather than 
biological diversity of the samples analysed. Had we not been limited by the scarcity 
of tissue samples, time and/or by cost, it would have been interesting to test if adding 
a third sample replicate, or adding more patient samples to the LCM pool would have 
altered the results. Furthermore, considering that homeostasis often is maintained by 
incremental or qualitative changes (e.g. phosporylation) to protein expression, it is 
also plausible that by sampling the most abundant proteins with the greatest fold-
changes in expression between the two anatomical sites, one actually misses those 
proteins that are potentially responsible for the dynamic, pathophysiological changes 
occurring during carcinogenesis and metastasis. However, in order to overcome this, 
one would need either to increase the amount of starting material used in the 
analysis, which was not possible in this study, or select for these qualitative changes 
during peptide separation, which would have decreased substantially the number of 
proteins observed overall. Thus, whilst questions remain as to how much variability 
is needed for lymphatic metastasis to occur, the 854 protein proteome of PDAC and 
matched LN metastases is a valuable, initial step towards understanding the 
proteomic changes underlying metastatic PDAC. 
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The IHC served both to validate the statistical approach used to analyse the MudPIT 
data, as well as to confirm the up-regulation of the candidate proteins in LN 
metastases. Even though moesin had an equivocal g-value, we wished to investigate 
its expression using IHC as it previously had been identified as a marker of lymphatic 
metastasis in PDAC (72). As only 29% of matched primary PDAC and LN metastatic 
epithelia in our study showed moesin expression, our data do not support the 
previous findings. Thus, the IHC findings were in agreement with the MudPIT data 
for this protein. Interestingly, Cui et al. did find that 15 of the 42 (35.7%) moesin 
positive primary PDACs analysed in their study expressed moesin in various stromal 
cells as well as in the ductal epithelia (72). We found moesin expression to be 
predominantly stromal, both in primary PDAC and LN metastases. This is perhaps of 
more practical significance, as it precludes its choice as an epithelial-specific 
therapeutic target.  
 
We chose to validate one member of the 14-3-3 protein family, as six of these seven 
evolutionarily-related proteins were found to be significantly differentially expressed 
between primary PDAC and LN metastases. These proteins can bind more than 100 
different proteins, and can potentially affect many processes within the cell, including 
signal transduction, apoptosis, cell cycle regulation and cytoskeletal organisation 
(190). The precise mechanisms of action of the 14-3-3 protein family are still poorly 
understood. Broadly speaking however, they can regulate enzyme activity; act as 
localisation anchors, localising various proteins to specific compartments within the 
cell; and are scaffolds or adaptor molecules, facilitating protein-protein interactions 
(190).  
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14-3-3 sigma, or stratifin, has been shown previously to be absent in the normal 
pancreas, but up-regulated in PanINs and primary PDAC (93,191–193). We have 
now confirmed that 14-3-3 sigma expression is up-regulated in LN metastases 
relative to primary PDAC. Interestingly, 14-3-3 sigma is expressed solely by 
epithelial cells and almost exclusively forms homodimers (other members of the 
family can form heterodimers) (194), and is therefore more amenable to specific 
targeting. Furthermore, in normal cells, 14-3-3 sigma is up-regulated by TP53 and 
BRCA1, halting the cell cycle in response to DNA damage (194). This raises 
interesting questions as to why 14-3-3 sigma expression is increased in primary 
PDAC, in which TP53 mutations are commonly found. In addition, the observed up-
regulation of 14-3-3 sigma in LN metastatic lesions is also seemingly 
counterintuitive. There are two possible explanations for this. 14-3-3 sigma has been 
observed in the cerebrospinal fluid (CSF) of patients who have undergone traumatic 
brain injury or transient cerebral ischaemia (195). Although it was not found to have 
any functional effects in the CSF of these patients, it was noted as a marker of tissue 
damage. Thus, it could serve the same role in PDAC. A more intriguiging 
explanation, however, comes from studies of co-cultures human keratinocytes and 
fibroblasts (196–198). Not only is  14-3-3 sigma a marker of differentiation in skin 
epithelia, but differentiated keratinocytes also can secrete 14-3-3 sigma, which then 
is taken up by surrounding fibroblasts (196). This secreted form of the protein has 
been shown to increase matrix metalloproteinase-1 (MMP-1) and MMP-3 expression 
in the stromal compartment (196,197). The role of the MMPs in cancer metastasis is 
well-established, and it would be interesting to explore this potential cross-talk 
mechanism in the context of PDAC. This could be done in various ways. One could 
screen a number of pancreatic cancer cell lines, with varying metastatic capabilities, 
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for 14-3-3 sigma secretion. Having established that these cells do indeed secrete 
this protein, one could then modify the above-mentioned co-cultures to include 
pancreatic cancer cells in combination with pancreatic stellate cells, in order to 
determine if 14-3-3 sigma secretion by the cancer cells stimulates MMP secretion by 
the stellate cells in vitro. In addition, primary PDAC samples could be stained, using 
IHC, for 14-3-3 sigma and MMP-1 and MMP-3, in order to determine the relevance 
of this hypothesis in human tissues. 
 
As described in 1.2.3 (pg 43-44), S100P, a 10.4 kDa calcium-binding protein, already 
has been associated with PDAC (91–97). We have shown previously that S100P is 
absent in normal pancreatic ductal epithelia, progressively increased in PanIN 
lesions, expressed in > 90% of primary PDACs, and that it increases invasion by 
mediating changes in the actin cytoskeleton and up-regulating cathepsin D in vitro 
(91,92,94). S100P also has been shown to be expressed at higher levels in PDAC 
as compared to chronic pancreatitis (93). Furthemore, S100P has been shown to  
bind to the receptor for advanced glycation end-products (RAGE), increasing 
pancreatic cancer growth, survival and invasion both in vitro and in vivo; a 
mechanism of action which is potentially targetable using cromolyn, or analogues 
thereof (95–97). Through this study, we have shown that S100P is up-regulated in 
LN metastases with a high g-value using MudPIT analysis, and a marginally 
significant p-value (p = 0.05) using IHC. This discrepancy could be due to two 
technical factors. Firstly, both primary PDAC and LN metastases stained strongly 
positive for S100P, resulting in a minimal quantitative difference. Secondly, despite 
the high g-value, the observed spectral counts obtained for S100P with MudPIT were 
low; this most likely reflects the limited sensitivity of mass spectrometry at present. It 
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could also indicate that S100P is masked by a more abundant protein during 
MudPIT, or that some inherent physicochemical property of the protein causes it to 
be lost during fractionation, resulting in it being underrepresented. However, the 
spatio-temporal expression pattern of S100P, as well as its well-established role in 
PDAC growth and invasion, makes it a viable therapeutic target.  
 
Interestingly, S100P recently has been shown to directly interact with IQGAP1 (199), 
one of the significantly differentially expressed proteins found in this study (Table 6). 
IQGAP1, a member of the IQGAP family, is a multidomain protein that can interact 
with a number of partners, affecting intracellular signal transduction and cellular 
movement by modulating the actin cytoskeleton and microtubule dynamics 
(199,200). Heil et al (199) showed that calcium-bound S100P, through its interaction 
with IQGAP1, down-regulates MEK signalling downstream of the EGF receptor. 
Importantly, this interaction does not affect IQGAP1’s ability to bind Cdc42 and 
Rac1. Thus, S100P potentially can affect cell movement and cellular proliferation in 
different ways. Furthermore, it has been shown that S100P can activate ezrin (201), 
increasing transendothelial migration of non-small cell lung cancer cells in vitro 
(202). Both these mechanisms could also, therefore, potentially affect lymphatic 
invasion in PDAC. 
 
Thus, we have shown in this study that comparative proteomic analysis of FFPE 
tissue is a valid approach for the investigation of pancreatic malignancy. In addition 
to establishing the first proteome of primary PDAC and matched LN metastases, we 
have identified S100P and 14-3-3 sigma as two proteins that may represent viable 
epithelial-specific targets for the treatment of both primary and metastatic disease.  
122 
 
6. RESULTS (Part II): THE ROLE OF S100P IN LYMPHATIC 
METASTASIS IN PDAC 
 
 6.1 Analysis of S100P in Lymphatic Metastasis in PDAC in vitro 
 
As described in 1.2.3 (pg 43-44), S100P has been a long-standing focus of interest 
in our laboratory. We have shown that S100P is absent in normal pancreatic ductal 
epithelia, progressively increased in PanIN lesions, expressed in > 90 % of primary 
PDACs, and that it increases invasion by mediating changes in the actin 
cytoskeleton and up-regulating cathepsin D in vitro (91,92,94). Recently, we have 
shown S100P to be a potential candidate gene involved in the haematological 
dissemination of PDAC, increasing transendothelial migration both in vitro and in 
vivo (Sayka Barry, PhD Thesis, 2009). Furthermore, the secretion of S100P by 
pancreatic cancer cells has been reported to stimulate primary tumour growth, 
survival and metastasis by interacting with RAGE (95). Evidence is thus 
accumulating that S100P contributes to metastasis in PDAC, but the role of this 
protein in lymphatic metastasis in PDAC is still unknown. Having validated the 
relative increase in S100P expression in LN metastases, we chose to further 
investigate its potential role in lymphatic invasion in vitro and in vivo. 
 
6.1.1  Creation and Characterisation of V3L and S5L Cell Lines 
 
We aimed to create an orthotopic pancreatic mouse model to evaluate the effects of 
S100P on primary tumour growth, as well as its potential role in metastasis. As 
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S100P is not expressed endogenously in mice (203), the transgenic KRASG12D 
and/or the KRASG12D/TP53 mouse models, would not be relevant to the investigation 
of S100P without further engineering. In order to allow for the imaging of tumours 
and/or metastases in real-time in vivo, the V3 and S5 cell lines (94) were further 
engineered to express luciferase using a lentivirus (204). This was performed with 
the help of Dr David Gould, Bone and Joint Research Unit, William Harvey Institute. 
Following transduction, characterisation of the V3 Luciferase+ (V3L) and S5 
Luciferase+ (S5L) cell lines was performed in order to ensure that the luciferase 
transfection had not resulted in functional alteration, i.e. proliferation, invasion and 
anchorage-independent growth. 
 
6.1.1.1 Confirmation of S100P over-expression 
 
S100P expression was evaluated in V3L and S5L cells at both the transcript (Figure 
16) and protein levels (Figure 17). S5L cells were found to express significantly 
higher levels of both S100P mRNA (p = 0.04) and protein (p = 0.03). However, I was 
only able to show protein expression using a V5 antibody, and not using an antibody 
to S100P. In order to confirm that the observed protein was, in fact, S100P, a 
transient silencing experiment was performed. The Western blots and siRNA 
knockdown experiments also were performed by Kate Lines, a fellow PhD student in 
the laboratory, after I had optimised the protocols, in order to ensure that the data 
were reproducible. 
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Figure 16 qPCR for S100P in vitro. Extracted mRNA from V3L and S5L cell lines 
was analysed for S100P transcript; S5L cells express significantly higher levels of 
S100P mRNA than V3L cells (p = 0.04).  
  
* 
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Figure 17 Confirmation of S100P protein expression. Representative Western blots 
(A performed by me; B performed by Kate Lines) showing the expression of V5-
tagged S100P in V3L and S5L cells, as well as in the S5L cell line following 
knockdown with either non-targeting control siRNA (NT siRNA) or siRNA to S100P. 
Densitometry (C) confirmed that S100P protein is significantly over-expression in 
S5L cells (p = 0.03). The silencing experiments were performed in order to confirm 
the specificity of the V5-antibody in detecting S100P protein, as well as to show that 
the Western blot could be reproduced by someone else in the lab. HSC-70 and actin 
were used as loading controls.  
 
  
S100P (17kDa)  
Actin (42 kDa) HSC 70 (70 kDa) 
A B 
C 
V
3
L
 
 S
5
L
 
  
S100P (17kDa)  
N
T
 s
iR
N
A
 
S
1
0
0
P
 s
iR
N
A
 
126 
 
6.1.1.2 Functional Characterisation 
 
In order to confirm that the luciferase transduction was successful, and that it did not 
alter the behaviour of the V3L and S5L cell lines in vitro, a series of functional 
characterisation experiments were performed. 
 
Quantification of luciferase expression in vitro showed that the V3L and S5L cell 
lines expressed equivalent amounts of luciferase (Figure 18), i.e 50 V3L cells 
expressed the same amount of luciferase as 50 S5L cells; the same result was seen 
when 5 x 105 cells were used. Thus, any differences in bioluminescence imaging 
seen in vivo would represent a true difference in growth or metastasis, and not 
reflect a difference in luciferase transduction between the two cell lines.  
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Figure 18 Quantification of luciferase expression in vitro. Luciferase quantification 
was performed on serial 1:10 dilutions of 5 x 105 V3L and S5L cells following 
lentiviral transduction. No differences were seen between the two cell lines. 
 
 
In the V3 and S5 cell lines, no difference in proliferation between the two cell lines 
had been seen up to 96 hours in vitro (94). The same result was obtained using the 
V3L and S5L cell lines (Figure 19).  
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Figure 19 Proliferation assays. At Day 0, 2.5 x 104 V3L and S5L cells were seeded 
into 24-well plates. Daily counts were performed using a haemocytometer. The 
experiment lasted five days in total. No differences were seen between the two cell 
lines, in keeping with data obtained using the V3 and S5 cell lines. 
 
 
It had previously been shown that the S5 cell line was significantly more invasive 
than the V3 cell line in Matrigel assays in vitro (94). Thus, these assays were 
repeated using the luciferase-expressing cell lines. As can be seen in Figure 20, the 
S5L cells were significantly more invasive than V3L cells (p = 0.0002), in keeping 
with previous data.  
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Figure 20 S100P increases invasion in vitro. Invasion assays were performed on 
V3L and S5L cells in Matrigel-coated transwell chambers. A significantly higher 
number of S5L cells had invaded through the Matrigel barrier after 48 hours (p = 
0.0002). (HPF = high power field; x20 objective) 
 
 
 
 
Soft agar assays were performed to assess the tumourigenicity of both these cell 
lines (Figure 21). No significant differences, neither in the total number, nor in the 
average area of colonies formed, were observed, indicating that S100P does not 
affect anchorage-independent growth. 
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Figure 21 Soft agar assays. 200 V3L or S5L cells in a single suspension were mixed 
in 0.3% agarose and left to grow for 18 days (A = V3L; B = S5L; both images taken 
at 40x magnification). The average number of colonies (C), as well as the average 
area of the colonies formed (D), was then quantified using ImageJ software. No 
differences were seen between the two cell lines. 
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6.1.2  Interaction of the V3L and S5L Cell Lines with Human Dermal Lymphatic 
Endothelial Cells  
 
Human Dermal Lymphatic Endothelial Cells (HDLEC), which were purchased at 
passage three and used until passage seven, were used as a proxy for pancreatic 
lymphatics in vitro. Co-cultures, containing V3L or S5L cells in combination with 
HDLEC, were established to investigate cancer cell adhesion to HDLEC; 
permeability through a HDLEC monolayer; and translymphatic endothelial cell 
migration. 
 
6.1.2.1 Confirmation of the Lymphatic Lineage of HDLEC 
 
HDLEC were fluorescently stained for the lymphatic-specific markers LYVE-1 and 
podoplanin (Figure 22) to verify that these cells were truly lymphatic, and not blood 
vascular, endothelial cells. All experiments were conducted between passage three 
and seven, as cells became senescent thereafter.  
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Figure 22 Verification of the lymphatic lineage of human dermal lymphatic 
endothelial cells (HDLEC). In order to ensure that a pure population of lymphatic 
cells was used in all experiments, cells were immunofluorescently stained for the 
lymphatic markers LYVE-1 (B) and podoplanin (C). A merged image is shown in (D). 
(All images at 63x magnification under oil immersion) 
 
6.1.2.2 Activating HDLEC  
 
For the functional assays, HDLEC were stimulated with either IFN (100 ng/ml) or 
TNF (10 ng/ml) for 24 hours prior to the addition of V3L or S5L cells. These 
concentrations were chosen based on previously published data (151).  ICAM-1, 
VCAM-1 and E-selectin were used as markers of activation status following 
A B 
C D 
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determination of basal levels of expression on resting HDLEC by flow cytometry 
(Figure 23), as these three markers previously had been shown to increase 
following TNF stimulation of HDLEC (151). At rest, HDLEC did not express VCAM-
1 or E-selectin, but did express ICAM-1. Following stimulation with IFNγ, ICAM-1 
expression was maintained at levels equivalent to that at rest (p = 0.36), and cells 
did not express VCAM-1 or E-selectin. TNFα stimulation significantly increased 
ICAM-1 (p = 0.04) and E-selectin (p = 0.04) expression. Whilst VCAM-1 expression 
did increase following treatment with TNFα, the increase was not statistically 
significant (p = 0.07). Representative histograms (for ICAM-1) of the flow cytometry 
experiments, including statistical quantification of the number of positive cells, are 
shown in Figure 24. The geometric mean was used as a measure of mean 
fluorescent intensity (MFI) and indicates expression levels, and has been shown on 
all subsequent graphs. 
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Figure 23 Cell surface expression of ICAM-1, VCAM-1 and E-selectin on HDLEC. 
As can be seen in A, resting HDLEC express ICAM-1. IFNγ stimulation (100 ng/ml) 
maintained ICAM-1 expression at equivalent levels to those seen at rest (p = 0.36) 
whilst TNFα stimulation (10 ng/ml) significantly up-regulated ICAM-1 expression (p = 
0.04). In contrast, VCAM-1 and E-selectin are not expressed on resting HDLEC (B), 
nor are they expressed following IFNγ stimulation. Although VCAM-1 expression did 
increase upon TNFα stimulation, this increase was not statistically significant (p = 
0.07). TNFα stimulation did significantly increase the cell surface expression of E-
selectin (p = 0.04). 
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Figure 24 Representative histograms of the flow cytometry experiments. Histograms 
are shown for a negative control (A), IgG control (B) and ICAM-1 cell surface 
expression at rest (C) and following IFNγ (100 ng/ml; D) and TNFα (10 ng/ml; E) 
stimulation. The geometric mean was used as a measure of mean fluorescent 
intensity (MFI) which is shown on all subsequent graphs.  
A B 
C D 
E 
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Flow cytometry was performed to assess the cell surface expression of LYVE-1 
(Figure 25), both to confirm the lymphatic lineage by a method other than ICC, and 
as it previously had been shown that TNFα stimulation ablates LYVE-1 expression 
on HDLEC (104,151). We were able to reproduce these findings. LYVE-1 was found 
to be significantly expressed on resting HDLEC (p = 0.01), relative to the negative 
and IgG controls. Cytokine stimulation with both IFNγ (p = 0.02), and TNFα (p = 
0.007), significantly decreased LYVE-1 surface expression relative to levels 
observed on resting HDLEC. 
 
 
 
 
Figure 25 Cell surface expression of LYVE-1 on HDLEC. Resting HDLEC express 
significant levels of LYVE-1 (p = 0.01). This confirms that these endothelial cells are 
lymphatic in lineage. LYVE-1 expression significantly decreased following IFNγ 
stimulation (100 ng/ml; p = 0.02) and TNFα stimulation (10 ng/ml; p = 0.007). (MFI = 
mean fluorescent intensity) 
 
* 
*** 
* 
137 
 
Having reproduced the data reported by Johnson et al. (104,151), flow cytometry 
was performed on resting and cytokine-stimulated HDLEC to assess the cell surface 
expression of CLEVER-1 and the fibronectin-binding integrins α4β1, α5β1 and α9β1, 
both at rest and following cytokine stimulation (Figures 26 - 28).   
 
CLEVER-1 (Figure 26) was expressed on resting HDLEC (geometric mean = 8.9), 
and this expression was significantly higher than the IgG control (p = 0.0009). Of 
note, CLEVER-1 expression was constant i.e. the levels seen on resting HDLEC 
were similar to levels seen on activated HDLEC (geometric mean following IFNγ 
stimulation = 8.5 (p = 0.75), and TNFα stimulation = 10.3 (p = 0.07)).  
 
 
 
 
Figure 26 Cell surface expression of CLEVER-1 on HDLEC. Resting HDLEC 
express CLEVER-1 at the cell surface at significantly higher levels than the IgG 
control (p = 0.0009). Following cytokine stimulation with both IFNγ (100 ng/ml) and 
TNFα (10 ng/ml), CLEVER-1 expression is maintained at levels similar to that seen 
on resting HDLEC. (MFI = mean fluorescent intensity) 
*** 
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HDLEC expressed high levels of α5β1 integrin at rest, relative to the IgG control (p = 
0.0003) (Figure 27). Interestingly, expression of this integrin decreased significantly 
following IFNγ treatment (p = 0.04), but increased significantly following TNFα (p = 
0.02) stimulation, compared to levels seen at rest. In contrast, HDLEC were found to 
express low levels of α4β1 and α9β1 at rest (geometric means: α4β1 = 6.7 and α9β1 
= 9.3) (Figure 28). As was the case for α5β1 integrin, IFNγ stimulation decreased the 
cell surface expression of these integrins (geometric means: α4β1 = 4.8 and α9β1 = 
5.3) whilst TNFα stimulation increased their expression (geometric means: α4β1 = 
10.5 and α9β1 = 15.0). None of these changes reached statistical significance 
however. 
 
  
 
 
Figure 27 Cell surface expression of α5β1 integrin on HDLEC. Resting HDLEC 
express α5β1 at the cell surface, relative to IgG control (p = 0.0003). Following IFNγ 
(100 ng/ml) stimulation, expression significantly decreased (p = 0.04) as compared 
to levels seen at rest. However, following TNFα (10 ng/ml), α5β1 expression 
significantly increased (p = 0.02). (MFI = mean fluorescent intensity) 
*** * 
* 
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Figure 28 Cell surface expression of α4β1 and α9β1 integrins on HDLEC. Resting 
HDLEC express low levels of α4β1 and α9β1. Following cytokine stimulation with 
IFNγ (100 ng/ml), cell surface expression of both these integrins decreases to levels 
seen on negative and IgG controls. Although both α4β1 and α9β1 increased 
following TNFα stimulation (10 ng/ml) expression, these increases did not reach 
statistical significance. (MFI = mean fluorescent intensity) 
 
6.1.2.3 S100P Increases Adhesion to Activated HDLEC  
 
The adhesion of V3L and S5L cells to resting and activated HDLEC was tested to 
determine if S100P affects adhesion (Figure 29). At rest, no differences were seen 
between the adhesive behaviour of the two cell lines. Following IFN stimulation, S5L 
cells were significantly better able to adhere to HDLEC than V3L cells (p = 0.01). 
Interestingly, stimulation with TNFα significantly decreased the adhesion of V3L cells 
as compared with basal V3L adhesion to resting HDLEC (p = 0.03), but did not alter 
the number of adherent S5L cells in comparison to that seen at rest. Thus, this 
decrease in V3L adhesion resulted in a significant difference between V3L and S5L 
cell adhesion following TNFα stimulation (p = 0.02). These results indicate that 
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cancer cell adhesion to HDLEC is not activation dependent, but also show that V3L 
cells are less able to bind to activated HDLEC than S5L cells. 
 
 
 
 
 
 
Figure 29 Adhesion of V3L and S5L cells to HDLEC. The ability of V3L and S5L 
cells to adhere to HDLEC was tested at rest and following HDLEC activation. No 
differences were seen between the two cell lines in adhesion to resting lymphatics. 
However, S5L cells were significantly better able to bind to IFN- (100 ng/ml) 
activated HDLEC than V3L cells (p = 0.01). Although S5L adhesion to TNF- (10 
ng/ml) stimulated HDLEC was equivalent to that seen at rest, V3L adhesion following 
TNF- stimulation was significantly decreased (p = 0.03). Thus, S5L cells appear to 
adhere better to TNF- activated HDLEC than V3L cells (p = 0.02).  
 
 
In order to assess whether or not these differences in adhesion were due to the 
effects of S100P, the experiments were repeated using recombinant S100P (100 
nM), which was added to the media surrounding both HDLEC and V3L cells (Figure 
* * 
* 
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30). Surprisingly, the presence of recombinant S100P in the assay significantly 
decreased the adhesion of V3L cells to resting HDLEC (p = 0.03). No change in 
adhesion was seen when HDLEC were stimulated with IFNγ. However, V3L 
adhesion to HDLEC which had been stimulated with TNFα for 24 hours significantly 
increased in the presence of recombinant S100P (p = 0.008). 
 
 
 
 
 
Figure 30 The effects of recombinant S100P on V3L adhesion to HDLEC. In order to 
assess if the observed differences in adhesion to activated HDLEC between the V3L 
and S5L cell lines were mediated by S100P, recombinant S100P (100 nM) was 
added to the media surrounding both HDLEC and V3L cells, and adhesion was 
quantified after 45 minutes. The presence of recombinant S100P significantly 
decreased adhesion to resting HDLEC (p = 0.03). No change in adhesion was seen 
when HDLEC were stimulated with IFNγ (100 ng/ml) for 24 hours. However, the 
presence of recombinant S100P significantly increased the adhesion of V3L cells to 
HDLEC which had been stimulated with TNFα (10 ng/ml) for 24 hours (p = 0.008). 
* 
** 
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6.1.2.4 V3L and S5L Cells Adhere to HDLEC via Different Receptors 
 
6.1.2.4.1 Function Blocking Assays 
 
In order to determine which receptors might be involved in and/or mediate the 
observed differences in adhesion of V3L and S5L cells to HDLEC, function blocking 
experiments were performed using antibodies to ICAM-1, VCAM-1, E-selectin, 
LYVE-1, β1 integrin, α4 integrin, α9β1 integrin, α5β1 and CLEVER-1 (Figures 32 – 
37; summarised in Table 7 below).  A function blocking antibody to the epithelial-
specific β6 integrin was used as a negative control, since HDLEC, V3L and S5L cells 
do not express this integrin (Figure 31). β6 blockade did not alter the binding of 
cancer cells to resting HDLEC, or of S5L cells to IFNγ-stimulated and TNFα-
stimulated HDLEC. Whilst β6 blockade did appear to have an effect on the binding of 
V3L cells to activated HDLEC, this did not reach statistical significance (p = 0.07 
following IFNγ-stimulation and p = 0.08 following TNFα-stimulation).     
 
V3L adhesion to resting HDLEC is mediated by multiple receptors, including LYVE-1 
(p = 0.02), CLEVER-1 (0.04), α4 integrin (p = 0.03), α9β1 (p = 0.02), and β1 integrin 
(p = 0.03) (Figures 32 and 33). However, only CLEVER-1 and α5 integrin appear to 
be involved in V3L adhesion to activated HDLEC. Surprisingly, CLEVER-1 and α5 
integrin blockade significantly increased V3L adhesion to IFNγ-stimulated HDLEC 
(CLEVER-1: p = 0.003; α5 integrin: p = 0.008) and TNFα-stimulated HDLEC 
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(CLEVER-1: p = 0.03; α5 integrin: p = 0.003). α5 integrin does not appear to be 
involved in V3L adhesion to resting HDLEC. 
 
 
 
 
 
 
 
 
 
Figure 31 V3L and S5L cells do not express β6 integrin at the cell surface. Flow 
cytometry for β6 integrin was negative on both the V3L and S5L cell lines. Thus, β6 
function blocking antibody was used as a control in the integrin function blocking 
experiments. 
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Figure 32 LYVE-1 and CLEVER-1 mediate V3L adhesion to HDLEC. Functional 
blocking antibodies to LYVE-1 and CLEVER-1 were used to evaluate if these 
molecules are involved in V3L adhesion to resting and activated HDLEC. As can be 
seen in A, LYVE-1 blockade significantly decreased adhesion to resting HDLEC (p = 
0.02), but not to activated HDLEC. Conversely, CLEVER-1 blockade (B) significantly 
decreased V3L adhesion to resting HDLEC (p = 0.04), but significantly increased 
V3L adhesion to IFNγ–stimulated (p = 0.003) and TNFα–stimulated (p = 0.03) 
HDLEC. 
  
* 
A B 
* 
** 
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Figure 33 The β1 integrins (α4β1, α5β1 and α9β1) appear to mediate V3L adhesion 
to resting HDLEC. Function blocking antibodies to the integrin subunits β1 (A, p = 
0.03), α4 (B, p = 0.03), and to the integrin α9β1 (C, p = 0.02), significantly decreased 
adhesion to resting HDLEC. None of these integrins appear to mediate V3L 
adhesion to activated HDLEC. In contrast, functional blockade of α5 (D) significantly 
increased V3L adhesion to IFNγ–stimulated (p = 0.008) and TNFα–stimulated (p = 
0.003) HDLEC, but did not appear to be involved in V3L adhesion to resting HDLEC. 
Functional blockade of the integrin β6 (E, negative control) did not affect adhesion to 
resting HDLEC but did appear to have some effect on V3L binding to activated 
HDLEC. This did not reach statistical significance however. 
* 
* 
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Blocking LYVE-1 significantly decreased S5L adhesion to resting HDLEC (p = 
0.004), as well as to HDLEC stimulated with IFNγ (p = 0.03) (Figure 34). In contrast 
to V3L cells, CLEVER-1 did not appear to play a role in S5L adhesion to both resting 
and activated HDLEC. None of the β1 integrins were found to mediate S5L adhesion 
to resting HDLEC (Figure 35). Rather, these integrins appear to be recruited 
following HDLEC activation. Whilst β1 blockade significantly decreased adhesion 
after IFNγ (p = 0.001) and TNFα (p = 0.02) stimulation, α4 (p = 0.01) and α9β1 (p = 
0.01) were found to mediate adhesion to IFNγ-stimulated HDLEC. However, neither 
of these integrins appear to mediate adhesion to TNFα-stimulated HDLEC. 
Functional blockade of the integrin α5 did not affect S5L adhesion to resting and/or 
activated HDLEC. 
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Figure 34 LYVE-1, but not CLEVER-1, appears to mediate S5L adhesion to HDLEC. 
Function blocking antibodies to LYVE-1 (A) and CLEVER-1 (B) were used to 
determine if these molecules mediate S5L adhesion to resting and activated HDLEC. 
As can be seen in A, S5L adhesion to resting (p = 0.004) and IFNγ–stimulated 
HDLEC (p = 0.03) significantly decreased following LYVE-1 functional blockade; S5L 
adhesion to TNFα-stimulated HDLEC was unaffected. Functional blockade of 
CLEVER-1 did not affect S5L adhesion to resting or activated HDLEC (B). 
** 
* 
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Figure 35 The β1 integrins (α4β1 and α9β1) appear to mediate S5L adhesion to 
activated, but not resting, HDLEC. A function blocking antibody to the integrin 
subunit β1 significantly decreased S5L adhesion to IFNγ–stimulated (A, p = 0.001) 
and TNFα–stimulated (A, p = 0.02) HDLEC. Functional blockade of the integrin 
subunit α4 significantly decreased S5L adhesion to IFNγ–stimulated HDLEC (B, p = 
0.01), as did a function blocking antibody to the integrin α9β1 (C, p = 0.01). However, 
neither of these integrins appear to affect S5L adhesion to TNFα–stimulated HDLEC. 
Functional blockade of the integrins α5 (D), and β6 (E, negative control) did not 
affect S5L adhesion to resting and/or activated HDLEC. 
** 
* 
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ICAM-1, VCAM-1 and E-selectin were not found to mediate cancer cell adhesion to 
HDLEC, neither at rest, nor following activation (Figures 36 and 37). 
 
 
 
 
Figure 36 ICAM-1, VCAM-1 and E-Selectin do not appear to mediate V3L adhesion 
to HDLEC. Function blocking antibodies to ICAM-1, VCAM-1 and E-Selectin were 
used to evaluate if these molecules mediated V3L adhesion to resting and activated 
HDLEC. As VCAM-1 and E-selectin are not expressed on the surface of resting 
HDLEC (shown in Figure 22), these molecules were only functionally blocked on 
activated HDLEC. None of these molecules appear to mediate adhesion to resting 
and/or activated HDLEC. 
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Figure 37 ICAM-1, VCAM-1 and E-Selectin do not appear to mediate S5L adhesion 
to HDLEC. Function blocking antibodies to ICAM-1, VCAM-1 and E-Selectin were 
used to evaluate if these molecules mediated S5L adhesion to resting and activated 
HDLEC. As VCAM-1 and E-selectin are not expressed on the surface of resting 
HDLEC (shown in Figure 22), these molecules were only functionally blocked on 
activated HDLEC. None of these molecules appear to mediate adhesion to resting 
and/or activated HDLEC. 
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Table 7 Summary of the adhesion molecules involved in V3L and S5L adhesion to 
resting and activated HDLEC. Experiments utilising function blocking antibodies to 
the tabulated adhesion molecules showed that V3L adhesion to resting HDLEC is 
mediated by LYVE-1, CLEVER-1, and the β1 integrins (α4β1, α5β1 and α9β1). Only 
CLEVER-1 and α5β1 integrin were found to mediate V3L adhesion to activated 
HDLEC, and functional blockade of both these molecules was found to increase V3L 
adhesion to activated HDLEC. In contrast, only LYVE-1 was found to mediate S5L 
adhesion to resting HDLEC. In addition, LYVE-1, together with the integrins α4β1 
and α9β1, were found to mediate S5L adhesion to IFNγ-stimulated HDLEC. A 
function blocking antibody to the integrin subunit β1 did significantly decrease S5L 
adhesion to TNF-stimulated HDLEC; however no other integrin subunit was found to 
mediate this adhesion. 
 
 
 
  
 V3L + 
HDLEC 
V3L + IFNγ 
+ HDLEC 
V3L + 
TNFα +  
HDLEC 
S5L + 
HDLEC 
S5L + IFNγ 
+ HDLEC 
S5L + 
TNFα + 
HDLEC 
ICAM-1 - - - - - - 
VCAM-1 NA - - NA - - 
E-Selectin NA - - NA - - 
LYVE-1 ↓ - - ↓↓ ↓ - 
CLEVER-1 ↓ ↑↑ ↑↑ - - - 
β1 ↓ - - - ↓↓ ↓ 
α4 ↓ - - - ↓ - 
α9β1 ↓ - - - ↓ - 
α5 - ↑↑ ↑↑ - - - 
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6.1.2.4.2 V3L and S5L Adhesion Receptor Profiles 
 
Having identified which HDLEC adhesion receptors mediate the adhesion of cancer 
cells to lymphatic endothelium, V3L and S5L cells were examined for any adhesion 
receptors that could bind directly to these receptors, namely VCAM-1 (which binds 
the integrins α4β1 and α9β1) and CD44 (which can bind LYVE-1), using flow 
cytometry. In addition, as both LYVE-1 and the β1 integrins can bind ECM as 
previously described (101,104,127,131,140–144), cancer cells were analysed for the 
cell surface expression receptors that are known to bind to HA (CD44 and ICAM-1). 
A previous screen of the Panc-1 parental cell line, from which the V3L and S5L cells 
were derived, had shown that these cells express the FN-binding integrins, αvβ3, 
αvβ5, αvβ8 and α5. We had hoped to analyse the V3L and S5L cells for these 
integrins, but no antibodies for the three αv integrins were available at the time at 
which these experiments were performed. The flow cytometry results are shown in 
Figure 38. Both V3L and S5L cells expressed equivalent levels of the hyaluronon-
binding receptors ICAM-1 and CD44. Neither cell line expressed VCAM-1. Thus, the 
V3L and S5L cells appear to express adhesion molecules that bind preferentially to 
ECM components, rather than receptors that can directly interact with cognate 
receptors on HDLEC. 
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Figure 38 Cancer cell flow cytometry. V3L and S5L cells were analysed for the cell 
surface expression of adhesion molecules that could directly bind to the adhesion 
molecules expressed by HDLEC, namely VCAM-1 and CD44. Cells were also tested 
for adhesion receptors that could bind the ECM protein, hyaluronic acid (HA) i.e 
CD44 and ICAM-1. Both V3L and S5L cells expressed CD44 (which can bind LYVE-
1 directly) and ICAM-1 which can bind HA at equivalent levels. Neither of the cell 
lines expressed VCAM-1 (which can directly bind to the integrins α4β1 and α9β1). 
 
6.1.2.4.3 Hyaluronic Acid and Fibronectin Binding Assays 
 
As no obvious changes in the adhesion receptor profiles tested were seen between 
V3L and S5L cells, we wondered if the differences in adhesion might be due to 
differences in the ability of these cells to bind to the ECM components, HA and FN. 
Thus, binding assays were performed. No differences were seen between the two 
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cell lines in their ability to bind HA (Figure 39). However, a significantly higher 
number of S5L cells were able to bind FN (Figure 40; p = 0.03).  
 
 
 
 
Figure 39 V3L and S5L cells show equivalent binding to hyaluronic acid. 1x104 V3L 
or S5L cells were plated onto FITC-labelled hyaluronic acid (HA; 1 mg/ml). One hour 
later, the HA was washed off and the amount of bound HA was quantified in relation 
to a standard curve using a fluorescent plate reader. No differences were seen 
between the two cell lines in their capacity to bind HA. 
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Figure 40 S5L cells bind FN better than V3L cells. 1 x 104 V3L or S5L cells were 
plated onto fibronectin (20 µg/ml; FN). After 45 minutes, any non-adherent cells were 
washed off and the number of bound cells was quantified in relation to a standard 
curve using a fluorescent plate reader. A significantly higher number of S5L cells 
were able to bind FN than V3L cells (p = 0.03). 
 
 
 
6.1.2.5 S100P Increases Permeability and Migration through a HDLEC Monolayer 
 
In order to assess the effect of S100P on translymphatic endothelial migration 
(TLEM), we first had to establish a confluent HDLEC monolayer in vitro. A series of 
optimisation experiments were performed to determine the number of HDLEC that 
had to be plated to allow for a confluent monolayer to form overnight. Structurally, 
the monolayer was visualised by H&E staining following fixation. Functionally, 
monolayer integrity was assessed through the quantification of permeability to FITC-
Dextran (2 million MW). Initially, 1 x 105 and 2 x 105 cells were seeded onto 
membranes coated with fibronectin (0.5 µg/ml). The following day, the permeability 
of these cell layers was tested. Although the permeability decreased as the number 
* 
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of HDLEC increased (Figure 41), histological assessment showed that membranes 
were not completely covered by HDLEC. Thus, the number of cells initially seeded 
was increased to 2.5 x 105. As can be seen in Figure 42, this resulted in an 
adequate HDLEC monolayer, both structurally and functionally.  
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Figure 41 Pilot FITC-Dextran evaluation of HDLEC monolayer. Either 1 x 105 (A - C) 
or       2 x 105 HDLEC (D - F) were seeded onto fibronectin (0.5 µg/ml) and left to 
settle overnight. The integrity of the monolayer was then assessed by measuring 
permeability to FITC-Dextran (2 million MW) at 20 minutes (G). Membranes onto 
which the HDLEC has been seeded were fixed in methanol, and stained with H&E; 
representative images of these membranes are shown (A and D at 50x 
magnification; B and E at 100x magnification; C and F at 200x magnification). 
Neither concentration of cells resulted in a complete monolayer, though permeability 
to FITC-Dextran decreased as the number of seeded HDLEC increased. (n = 1 in 
duplicate). 
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Figure 42 Optimal HDLEC monolayer. 2.5 x 105 HDLEC were seeded onto 
fibronectin (0.5 µg/ml) and left to settle overnight. A (50x magnification) shows a 
representative membrane, with images taken at five different points in order to 
construct a composite image. As can be seen, the entire transwell membrane is 
covered with HDLEC; fibronectin (FN) is also visible between HDLEC. The centre of 
the membrane is shown at 100x magnification in B. Functionally (C), this monolayer 
was significantly less permeable to FITC-Dextran (2 million MW) than monolayers 
comprising 1 x 105 HDLEC were (p =0.04). (n = 1 in triplicate). 
HDLEC 
FN 
A 
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Having established a confluent monolayer, permeability and TLEM assays were 
performed. Co-cultures containing S5L cells caused monolayers to become 
significantly more permeable to FITC-Dextran at one (p = 0.02), four (p = 0.002) and 
eight (p = 0.007) hours (Figure 43), as compared to co-cultures containing an equal 
number of V3L cells. As a fixed concentration of FITC-Dextran was used, this trend 
continued up to 24 hours, but was not significant after eight hours. No cells had 
migrated through the monolayer at 24 hours.  
 
 
 
Figure 43 S100P increases permeability through a HDLEC monolayer. 5 x 105 V3L 
or S5L cells were plated onto HDLEC monolayers in 500 µl of Opti-MEM Reduced 
Serum Medium I containing 1 mg/ml of FITC-dextran (2 million MW). The 
permeability of the monolayer was assessed by quantifying the amount of FITC-
Dextran in the bottom well over 24 hours. The permeability of S5L wells was 
significantly higher at one (p = 0.02), four (p = 0.002) and eight hours (p = 0.007), 
than wells containing an equal number of V3L cells. No cells had migrated through 
the monolayers at 24 hours (the wells were analysed at this time for cells using a 
Coulter counter).  
* ** 
** 
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The migration of cancer cells through the monolayer over the next 48 hours was 
quantified (i.e. an end-point measurement was taken at 72 hours after seeding of 
cancer cells onto the monolayer). A significantly higher number of S5L cells had 
migrated through the HDLEC monolayer at 72 hours (Figure 44; p = 0.006). 
 
 
 
Figure 44 S100P increases translymphatic endothelial migration (TLEM). The 
increase in permeability seen in the first 24 hours after seeding was followed by an 
increase in cancer cell migration over the next 48 hours. Thus, at 72 hours, the 
number of migrated S5L cells was significantly higher than the number of migrated 
V3L cells (p = 0.006). 
 
 
  
** 
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6.2  Analysis of the Roles of S100P in vivo 
 
As mentioned previously, because mice do not express endogenous S100P (203), 
the transgenic KRASG12D and/or the KRASG12D/TP53 mouse models would not be 
relevant for preclinical therapeutic evaluation of S100P targeting therapies without 
further engineering. Thus, together with Dr Wasfi Alrawashdeh, a clinical research 
fellow in our laboratory, a CD1 nude mouse orthotopic model of pancreatic cancer 
was created using the V3L and S5L cells. Using bioluminescence, we aimed to 
investigate the potential roles of S100P in primary pancreatic tumour growth and the 
potential occurrence of spontaneous metastasis (lymphatic and haematological). We 
hoped that this model would be useful for the future evaluation of novel therapies. 
 
6.2.1 Pilot Study  
 
A pilot study was performed in order to determine if the parental V3 and S5 cells 
would grow orthotopically in the pancreas; if any metastases would spontaneously 
develop; and if the pancreas and/or metastases could be adequately imaged and 
quantified using bioluminescence. 
 
Three groups (n = 5 animals per group) of mice were used. The first two groups had 
either 2 x 106 V3 or S5 cells injected orthotopically into the pancreas. Mice were 
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killed at various time-points, with organs being harvested for histological examination 
(Figure 45). The experiment was terminated at four months post-injection. All 10 
animals grew pancreatic tumours (tumour sizes ranged from 1 x 1 mm2 to 15 x 23 
mm2), but no metastases (lymphatic or haematological) were seen in either group. 
 
 
 
 
Figure 45 A representative orthotopic S5 tumour. 2 x 106 V5 or S5 cells were 
orthotopically injected into the pancreas of CD1 nude mice. A macroscopic tumour 
(A) excised at four months post-injection, together with the corresponding H&E 
section (B; 100x magnification), is shown above. Arrows highlight areas of central 
necrosis. Orthotopic implantation of both V3 and S5 cells resulted in primary tumour 
growth. 
 
  
A B 
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The third, or imaging, group had S5 cells injected subcutaneously and orthotopically 
into the pancreas. The rationale behind this double injection was that we hoped to 
use the size of the subcutaneous tumours as an indirect guide as to when to image 
the orthotopic pancreatic tumours. A smaller number of cells, 6.5 x 105 cells, were 
injected in this group due to a technical error (i.e. cells were incorrectly counted prior 
to suspension in PBS for injection). Despite this error, however, four of the five 
animals grew tumours (sizes ranged from 4 x 5 mm2 to 7 x 8 mm2 for subcutaneous 
tumours, and from 10 x 14 mm2 to 12 x 25 mm2 for orthotopic pancreatic tumours). In 
addition, lymphatic metastases were seen in the peri-pancreatic LNs (Figure 46). In 
fact, lymphatic invasion of the pancreatic lymphatic vasculature was seen as early as 
six weeks post-injection. No haematological metastases were seen in any of the 
mice, as evidenced by histological examination of livers and lungs which were 
resected from these animals post-mortem. 
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Figure 46 S5 cells metastasise to peri-pancreatic lymph nodes (LN). An imaging 
group (n = 5), in which 6.5 x 105 S5 cells had been injected, developed LN 
metastases. Representative images of a peri-tumoural lymphatic vessel (100x 
magnification) stained for the anti-human epithelial marker, cytokeratin-8 (A), and the 
murine lymphatic marker LYVE-1 (B) showed that S5 cells had invaded these 
vessels. Furthemore, cytokeratin-8 positive S5 cells were seen in peri-pancreatic LN 
(C; 100x magnification. D shows a peri-pancreatic LN stained for LYVE-1 (100x 
magnification). 
 
Lastly, in order to confirm that the orthotopic pancreatic tumours could be imaged                                            
using bioluminescence, tumours were imaged using a luciferase-expressing Vaccinia 
A B 
C D 
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virus (kind gift from Dr Yaohe Wang). The virus was injected intravenously by Dr 
Crispin Hiley (clinical research fellow working with Dr Wang), followed by an intra-
peritoneal injection of D-luciferin (15 mg/ml). Thereafter, animals were imaged using 
the IVIS system. We were able to image orthotopic tumours reproducibly, while they 
were as small as 2 mm3 (Figure 47). 
 
 
 
 
Figure 47 Bioluminescence imaging of S5 orthotopic pancreatic tumours. A 
luciferase-expressing Vaccinia virus was injected into the tail veins of S5 imaging 
mice, followed by the intra-peritoneal administration of D-luciferin (15 mg/ml). This 
mouse was killed after imaging; at this point, the tumour was excised and measured. 
The tumour shown above measured 2 mm3. 
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6.2.2 Orthotopic Pancreatic Mouse Model using Luciferase-Transduced Cells 
 
After the pilot study, the V3L and S5L cell lines were created and characterised as 
described in 6.1.1 (pages 119-126). The orthotopic pancreatic injections were 
repeated using 6.5 x 105 V3L and S5L cells (n = 10 per group) in order to evaluate 
the effects of S100P over-expression on primary pancreatic tumour growth, as well 
as to determine if the lymphatic invasion seen in the pilot study was reproducible. 
Mice were imaged from one week post-injection on a weekly basis for real-time 
assessment of primary tumour growth and the occurrence of spontaneous 
metastasis. 
 
6.2.2.1 S100P Accelerates Primary Pancreatic Tumour Growth 
 
From as early as week one post-injection, larger pancreatic tumours were seen in 
S5L animals as compared with V3L animals using bioluminescence (Figure 48). 
One S5L mouse had to be killed at operation due to peri-operative trauma, resulting 
in only nine S5L animals being used in the experiment. The experiment was 
terminated at nine weeks post-injection for two reasons: firstly, the earliest evidence 
of lymphatic invasion was seen at six weeks post-injection in the pilot study; and 
secondly, a significant difference in bioluminescence imaging between V3L and S5L 
tumour growth was seen by eight weeks (Figure 49; p = 0.002). Upon killing, 
tumours were harvested and weighed (Figure 50). S5L tumours weighed 
significantly more than V3L tumours (p = 0.01). One S5L mouse became ill, and had 
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to be killed at an earlier time-point, and thus was excluded from the analysis. A 
tumour was present in this mouse, but it measured 1 mm3 and could not be weighed.  
 
 
 
 
Figure 48 Bioluminescence imaging of orthotopic pancreatic tumours at week 1 
post-injection. The orthotopic pancreas mouse model was repeated using 6.5 x 105 
V3L and S5L cells following in vitro characterisation, in order to confirm the results of 
the pilot study. V3L animals (n = 10) are shown in the upper panel, with S5L animals 
(n = 9; one mouse had to be killed at operation due to peri-operative trauma) shown 
in the lower panel. Orthotopic tumours are already present in both groups, with larger 
tumours being seen in the S5L group (quantification shown in Figure 48). 
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Figure 49 S5L orthotopic pancreatic tumours grow at a faster rate than V3L 
orthotopic pancreatic tumours. Regions of interest (ROI) were quantified weekly for 
each animal, and the average bioluminescence was plotted for each group. ROI 
calculates the signal intensity for a standardised area for each mouse, and is a 
quantitative measure of bioluminescence, and thus tumour growth. The S5L group (n 
= 9) showed a significantly higher rate of tumour growth than the V3L group (n=10; p 
= 0.002), as calculated by a linear regression of the weekly plots of average 
bioluminescence for each group. 
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Figure 50 S5L orthotopic pancreatic tumours are larger than time-matched V3L 
orthotopic pancreatic tumours. V3L and S5L orthotopic pancreatic tumours were 
allowed to grow for nine weeks, after which tumours were harvested and weighed. 
S5L tumours (n = 8) were significantly larger than V3L tumours (n = 10; p = 0.01). 
One S5L animal had to be excluded from the analysis as it became ill, and had to be 
killed at an earlier time-point. A 1 mm3 tumour could be seen at necropsy which 
could not be weighed. 
 
 
 
Harvested tumours were analysed for S100P mRNA expression (Figure 51). S5L 
tumours expressed approximately three times more S100P transcript than V3L 
tumours (p = 0.01). 
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Figure 51 S5L orthotopic pancreatic tumours express higher levels of S100P 
transcript. qPCR was performed on RNA extracted from fresh frozen V3L and S5L 
orthotopic pancreatic tumours for S100P expression. On average, S5L tumours 
expressed 3x more S100P transcript than V3L tumours (p = 0.01).  
 
 
However, in this experiment, lymphatic invasion was seen in both V3L and S5L 
primary tumours (Figure 52), both peri- and intra- tumourally. A 24-point Chalkley 
graticule was used to evaluate tumours for lymphatic vessel density (LVD) and the 
percentage of cancer-filled lymphatics. No significant differences were seen between 
the V3L and S5L tumours. Furthermore, no invaded LNs were found in either 
experimental group. 
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Figure 52 Quantification of peri-tumoural and intra-tumoural lymphatic invasion. 
Cancer cells were noted inside peri-tumoural (A and B) and intra-tumoural (C and D) 
lymphatic vessels in both V3L (A and C) and S5L (B and D) animals. Representative 
sections (100x magnification) from time-matched orthotopic pancreatic tumours were 
stained for LYVE-1; tumours were then assessed for the percentage area of cancer-
filled lymphatics (E) and for lymphatic vessel density (LVD) (F) using a 24-piece 
Chalkley graticule. No differences were found between the two groups, both in terms 
of percentage area of cancer-filled lymphatics (p = 0.07) and LVD (p = 0.08). 
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We attempted to confirm these findings by repeating the orthotopic pancreatic 
injections (n = 7 per group). We also had planned on lengthening the duration of the 
experiment, in order to determine if a larger primary tumour size would select for 
spontaneous metastasis. Unfortunately, due to an outbreak of infection in both V3L 
and S5L cages, the experiment was compromised and had to be terminated at ten 
weeks post-injection. Data from this experiment were thus inconclusive. 
 
6.2.3 The Effects of S100P on Site-Specific Growth in vivo  
 
A previous experiment conducted in our laboratory had shown that S5 cells (18/18 
mice) grew better subcutaneously than V3 cells (3/18 mice) in nu/nu mice. This, in 
conjunction with the data from the CD1 nude orthotopic pancreatic mouse model 
described above, led us to explore if S100P could affect site-specific tumour growth. 
Thus, we created three experimental metastasis mouse models to determine if the 
expression of S100P by cancer cells accelerated tumour growth in the liver (n = 7 
per group), lungs (n = 7 per group) or right axillary LN (n = 7 per group). 
 
6.2.3.1 Tail Vein Injections 
 
5 x 105 V3L or S5L cells were injected directly into the tail vein of CD1 nude mice (n 
= 7 per group). Mice were imaged weekly using bioluminescence. The experiment 
was terminated at four weeks post-injection, at which time the lungs, pancreas, 
spleen, liver, duodenum and pancreatic LN were harvested from each mouse for 
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histological examination. No evidence of tumour growth was seen in either group 
(Figure 53). 
 
 
 
 
 
 
 
 
Figure 53 Tail vein injections of V3L and S5L cells. 5 x 105 V3L or S5L cells were 
injected into the tail veins of CD1 nude mice (n = 7 per group). Mice were imaged 
weekly using bioluminescence (A), and the experiment was terminated at four weeks 
post-injection. Representative H&E sections through the lungs of a V3L (B) and S5L 
(C) animal at 100x magnification are shown. No tumours grew in either group. 
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6.2.3.2 Intrasplenic Injections 
 
5 x 105 V3L or S5L cells were injected into the spleen, in order to seed cells to the 
liver. Mice were imaged weekly using bioluminescence. The experiment was 
terminated at six weeks post-injection, at which time the lungs, pancreas, spleen, 
liver, duodenum, small bowel and large bowel and pancreatic LN were harvested 
from each mouse for histological examination. No evidence of tumour growth was 
seen in either group (Figure 54 and 55). 
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Figure 54 Intrasplenic injections of V3L and S5L cells. 5 x 105 V3L or S5L cells were 
injected orthotopically into the spleens of CD1 nude mice (n = 7 per group) in order 
to induce liver metastasis experimentally. Animals were imaged weekly using 
bioluminescence until 6 weeks post-injection, at which time the experiment was 
terminated. Neither group grew tumours in the liver (representative H&E images of 
the liver of a V3L animal (A) and S5L animal (B) are shown at 50x magnification. 
Furthermore, no positive peri-pancreatic lymph nodes (LN) were seen in any of the 
14 animals (representative H&E images of peri-pancreatic LN from a V3L (C) and 
S5L (D) animal are shown at 50x magnification). Only one S5L animal grew an 
orthotopic pancreatic tumour (E) as well as a splenic tumour (F); representative H&E 
images shown at 50x magnification. 
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Figure 55 Bioluminescence imaging of mice after orthotopic intrasplenic injections. 
Although differences in bioluminescence were seen between the two groups, these 
were not statistically significant. 
 
 
6.2.3.3 Intranodal Injections 
 
1 x 105 V3L or S5L cells were injected directly into the right axillary lymph node of 
CD1 nude mice (n = 7 per group). Mice were imaged weekly using bioluminescence. 
The experiment was terminated at ten weeks post-injected, at which time axillary, 
inguinal and pancreatic lymph nodes were harvested, together with pancreas, 
spleen, liver and duodenum for histological examination. No evidence of tumour 
growth was seen in either group (Figure 56). 
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Figure 56 Intranodal injections of V3L and S5L cells. 1 x 105 V3L or S5L cells were 
injected into the right axillary lymph nodes of CD1 nude mice (n = 7 per group). Mice 
were imaged weekly using bioluminescence (A), and the experiment was terminated 
at nine weeks post-injection. B and C show representative H&E sections through the 
right axillary LN of a V3L (B) and S5L (C) animal at 50x magnification. No tumours 
grew in either group. 
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7.  DISCUSSION (Part II): THE ROLE OF S100P IN LYMPHATIC 
METASTASIS IN PDAC 
 
As discussed earlier, S100P, a 10.4 kDa calcium-binding protein, previously has 
been found to contribute to the progression of PDAC, in a number of studies (91–
97), many of which were performed in our laboratory (91,92,94). Thus, we decided to 
investigate the potential roles of S100P in lymphatic invasion further, both in vitro 
and in vivo. 
 
We were able to show that the luciferase transduction did not alter the expression of 
S100P in the V3L and S5L cell lines, neither at a mRNA nor at a protein level. 
Furthermore, the functional behaviour of these two cell lines in vitro did not change 
i.e. V3L and S5L cell lines mirrored the parental V3 and S5 cell lines in terms of 
proliferation and invasion (94). We also were able to show that both cell lines 
expressed equivalent levels of luciferase, and were able to grow in soft agar, a 
surrogate for tumourigenic capacity. Thus, we concluded that these cell lines 
probably could be used to develop a CD1 nude orthotopic mouse model of PDAC. 
 
The co-culture experiments performed using cancer cells in conjunction with HDLEC 
yielded some intriguing results. These experiments aimed to evaluate if cancer cell 
adhesion to HDLEC governs migration into lymphatic vessels, or if TLEM can 
proceed even in the face of weak binding between cancer cells and HDLEC. In 1981, 
GL Nicolson published a paper entitled ‘Metastatic tumour cell attachment and 
invasion assay utilizing vascular endothelial cell monolayers’, which describes his 
analysis of the ‘intravasation’ step of the metastatic cascade (179). These 
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experiments were performed using co-cultures of endothelial cells and melanoma 
cell lines with varying metastatic capacities. Nicolson found that intravasation was 
initiated by tumour cell attachment to a blood vascular endothelial cell monolayer. 
Indeed, tumour cell lines that were more metastatic attached better to these 
monolayers than less metastatic cell lines. Furthermore, tumour cells preferentially 
attached at or near endothelial intercellular junctions, and this attachment facilitated 
endothelial cell retraction (Figure 57). Retraction was defined as the ‘breaking of 
intercellular junctions between endothelial cells, a retraction of the endothelial cell 
edges, and subsequent cell rounding with exposure of the basal lamina’. Once cells 
had retracted, a haptotactic gradient was established; as cancer cells bound slowly 
and weakly to endothelial cells, but bound quickly and strongly to basal lamina, cells 
preferentially moved towards the basal lamina underlying the endothelial cell 
monolayer. Invasive cells were then able to degrade and migrate through the basal 
lamina beneath the endothelial cell monolayer. 
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Figure 57 Endothelial retraction allows for the transmigration of tumour cells. A 
tumour cell attaches to the abluminal surface of blood endothelium, near the 
intercellular junctions (A). This causes the endothelial cells to retract (B). The tumour 
cell then migrates through the retracted endothelium, due to a haptotactic gradient 
between the endothelial cells (to which tumour cells can bind weakly) and the basal 
lamina (to which tumour cells can bind strongly) (C). Once the tumour cell has 
migrated through the monolayer, the endothelial intercellular junction reforms (D). 
The tumour cell can then migrate through the basal lamina. (179)). 
 
 
A variety of endothelial cells were used in Nicolson’s study: bovine aortic endothelial 
cells; HUVECs and murine lung and brain capillary endothelial cells. Thus, the 
experiments comprehensively represented all branches of the blood vascular tree 
(i.e. in terms of vessel size) (179). Interestingly, none of the melanoma cells were 
able to adhere to aortic endothelia, whilst most cells (melanoma, sarcoma, and 
platelets) were able to bind to murine capillary endothelia and HUVECs. This 
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suggests that adhesion to endothelium probably is more important in smaller 
vessels. Notably, fibroblasts were unable to bind to capillary endothelia (179). This is 
interesting in light of the more recent emergence of the concept of fibroblast-led 
cancer cell invasion (205). Fibroblast-led invasion has been shown to occur during 
collective cell invasion; fibroblasts at the leading edge of tumours create ‘tracks’ in 
ECM along which epithelial cancer cells invade. It would be interesting to adapt the 
3D co-cultures used in these experiments to include endothelial cells, to determine if 
or how this fibroblast-led invasion changes during intravasation. Nicolson’s 
experiments also were conducted in the absence of flow, or under static conditions. 
Whilst this is not truly representative of the blood vasculature, it is relevant to 
lymphatics where propulsion of lymph occurs at a relatively slow rate. 
 
The concept of ‘retraction’, as applied to blood vascular endothelium, has been 
developed substantially over the last three decades (206–208). Endothelial 
permeability has been shown to be controlled by a variety of chemical and 
mechanical stimuli, originating both in the blood (e.g. thrombin from activated 
platelets and pulsatile blood flow) and in the tissues surrounding blood vessels (e.g. 
histamine released from mast cells and TNFα secreted by activated leukocytes) 
(208). Furthermore, confluent blood vascular endothelial cells (BVEC) behave 
differently from sparse BVEC (206). When confluent, BVEC exhibit an epitheliod 
phenotype with apical-basal polarity. Cell-to-cell contact inhibits growth and motility, 
and protects the cells from apoptosis. Under sparse conditions, like angiogenesis, 
however, BVEC become fibroblastic and motile, and begin to proliferate. Blood 
vessel integrity is maintained by the stability of intercellular junctions, and by 
changes in the actomyosin cytoskeleton within endothelial cells. Many adhesion 
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molecules have been shown to play a role in mediating junctional stability, and their 
involvement is usually governed largely by the nature of the stimulus. However, VE-
cadherin as emerged as being central to maintaining blood vessel integrity (206). 
Indeed, VE-cadherin knockout mice are embryonically lethal due to vascular 
insufficiency (209). Furthermore, this member of the calcium-dependent cadherin 
family of proteins has been found to serve as an interface between the ECM and the 
intracellular compartment. In quiescent BVEC, VE-cadherin couples with VEGFR-2, 
preventing endocytosis of VEGFR-2, securing the endothelial cell barrier (210). In 
the presence of VEGF however, VE-cadherin is internalised, destabalising 
intercellular junctions (211–213). In addition, VE-cadherin has been shown to 
stimulate the Rho GTPases Rac and Cdc42, which aids in the assembly and 
maturation of endothelial cell junctions (214,215). In the context of metastasis, it has 
been shown that adhesion of breast MDA MB231 cancer cells to the HUVECs alters 
VE-cadherin intercellular localisation and permeability (216). Furthermore, it has 
been shown that the pancreatic cancer cell lines MiaPACA2 and Panc1 increase 
permeability through a HUVEC monolayer via two mechanisms: first, by 
redistributing VE-cadherin and PECAM, destabalising intercellular junctions; and 
second by mediating changes in the actin cytoskeleton (217). Whilst these 
phenomena are well-established for BVEC, their relevance to the lymphatic 
vasculature has yet to be explored. 
 
Indeed, only one study to date has evaluated ‘retraction’ in the context of the 
lymphatic vasculature. This study, in essence, recreated Nicolson’s original 
experiment: M21 melanoma cells were seeded onto bovine lymphatic endothelial 
cells (obtained from the thoracic duct) under static conditions; cultures were fixed, 
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stained and analysed using scanning electron microscopy. The M21 melanoma cells 
were found to induce a retraction of the LEC monolayer, resulting in TLEM (218). A 
flaw of this study is that only LEC obtained from collecting lymphatics, and not 
capillary lymphatics, were used. It is these lymphatic capillaries which serve as a 
point of entry during metastasis. Furthermore, only one melanoma cell line was 
used; the authors could have included cell lines with different metastatic potentials, 
as Nicolson did (179). However, it must be remembered that this study, however 
flawed, for the first time, established the relevance of endothelial cell retraction to the 
lymphatic vasculature and that this phenomenon occurs in the presence of added 
cancer cells. 
 
We sought to evaluate the effects of S100P over-expression in pancreatic cancer on 
the interaction of tumour cells with the lymphatic endothelium. To that end, the V3L 
and S5L cells were tested for their ability to migrate through a HDLEC monolayer. 
Our data suggest that, at least in the context of S100P over-expression, cancer cell 
adhesion to resting lymphatic endothelium is not essential for TLEM. This conclusion 
can be drawn from two results: firstly, V3L cells adhered just as well to resting 
HDLEC as S5L cells; and secondly, a significantly higher number of S5L cells 
migrated through a resting HDLEC monolayer at 72 hours. This suggests that the 
observed difference in TLEM is not mediated by cell-to-cell contact. Rather, it 
suggests that a greater haptotactic gradient for migration exists when S100P is over-
expressed. The FN binding assays showed a statistically significant difference 
between V3L and S5L binding. Thus, theorectically, as V3L and S5L cells bind 
equally as well to HDLEC, but S5L cells bind better to FN, a greater haptotactic 
gradient exists for S5L TLEM than V3L TLEM. However, as the observed difference 
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in FN binding between the two cell lines was small (12.5%), the biological relevance 
of this remains doubtful. There is a possibility that the concentration of FN used in 
these assays was suboptimal for adhesion. Thus, had I had more time, I would have 
liked to have repeated the assay using a range of FN concentrations. An alternative 
to this co-culture model is one in which V3L and S5L adhesion to mouse tissue 
explants containing the throrac duct, and/or smaller lymphatic capillaries (if possible), 
is tested. Finally, the invasion assays showed S5L invasion through Matrigel to be 
significantly higher than V3L invasion in vitro. This supports the argument that 
S100P over-expression increases degradation of, and thus invasion through, the 
basal lamina underlying the intima following TLEM.  
 
We aimed to assess ‘retraction’ functionally using the permeability assays. Our data 
show that permeability through a resting HDLEC monolayer from one to eight hours 
in culture was significantly higher for S5L cells than V3L cells. As the assays were 
conducted on resting HDLEC, we assume that there was no difference in the 
adhesion of V3L and S5L cells to the lymphatic monolayer. Thus, this increase in 
permeability was not mediated by cell-to-cell contact. As this change began at one 
hour post-seeding, it suggests that retraction of the lymphatic endothelium, rather 
than apoptosis (which usually occurs within six to eight hours), is responsible for this 
increased permeability; however this requires further investigation. This could have 
been confirmed by treating HDLEC with recombinant S100P, V3L conditioned media 
(CM), S5L CM, and a negative control, after which cells could have been fixed and 
stained for phalloidin to allow for the quantification of intercellular ‘gaps’. 
Alternatively, the potential retraction of HDLEC could have been imaged in real-time 
using time-lapse microscopy. In order to confirm that these effects were due to 
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S100P, the experiment would also have to include conditioned media harvested from 
cells in which S100P had been silenced using siRNA.  
 
Finally, both the permeability and the TLEM assays would need to be repeated using 
additional pancreatic cancer cell lines which express high levels of endogenous 
S100P, such as the BXPC3 cell line. This would serve to validate the increase in 
permeability and TLEM seen with the S5L cell line, in which S100P had been 
induced. Furthermore, transient knockdown of S100P, both in the S5L and BXPC3 
cell lines using siRNA, would need to be performed in order to confirm that the 
observed increase in permeability and TLEM was indeed due to S100P. 
Unfortunately, by the time I had arrived at this point in my investigations, there simply 
was no time available to conduct these experiments. 
 
As the data from these functional studies had not highlighted cell-to-cell contact as 
being central to the interaction between V3L or S5L cells and HDLEC, we wanted to 
investigate the paracrine effects of cancer cell supernatant on HDLEC. It has been 
reported previously that S100P is secreted by pancreatic cancer cells, and interacts 
with RAGE on these cells, creating an autocrine loop that promotes growth, survival 
and invasion both in vitro and in vivo (95,96). Thus, we questioned if a similar 
paracrine mechanism exists between the S5L cells and HDLEC.  
 
Unfortunately, our attempts to quantify S100P protein expression in the supernatants 
of V3L and S5L cells by Western blotting were inconclusive. The detection of the 
product from the S100P construct in cell lysates required much optimisation since 
most commercially available S100P antibodies (from various companies, both mono- 
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and poly- clonal, and directed at both the N- and C-terminals) were unable to detect 
S100P in the S5L cell line. We were only able to detect intracellular S100P using a 
V5-antibody, which recognised the tagged C-terminus of our construct. This antibody 
failed to detect S100P in conditioned media from the S5L cell line. Thus, although 
this suggests that S100P might not be secreted by S5L cells, we cannot confidently 
exclude the possibility that this represents a technical shortcoming. Furthermore, 
there are no commercial ELISA kits which adequately detect S100P in cell 
supernatants available at present. Had I had more time, I would liked to have tried to  
develop an ELISA assay in-house, using the V5-antibody and a few different S100P 
antibodies, in order to analyse V3L and S5L supernatants for the presence of this 
protein. In addition, HDLEC were negative for RAGE using flow cytometry. Again, 
this experiment needs to be repeated using a different RAGE antibody to exclude 
technical error. However, it seems unlikely that secreted S100P, at least in the S5L 
cell line, stimulates HDLEC via RAGE. 
 
In order to assess the potential functional effects of secreted S100P on cancer cell 
adhesion to HDLEC, recombinant S100P was added to the media surrounding both 
cancer cells and HDLEC for the duration of the assay. Interestingly, recombinant 
S100P significantly decreased V3L adhesion to resting HDLEC. A possible 
explanation for this could be that S100P binds calcium, which is essential for integrin 
activation. This hypothesis could be confirmed by repeating the assay using calcium-
depleted media, or by adding a calcium-binding molecule like EDTA. Alternatively, it 
suggests that secreted S100P does not activate HDLEC in the same manner as 
IFNγ and TNFα. Had I had more time, I could have confirmed this by repeating the 
187 
 
flow cytometry experiments following pre-treatment of HDLEC with recombinant 
S100P.  
 
Conversely, the addition of recombinant S100P significantly increased V3L adhesion 
to TNFα activated HDLEC, resulting in levels comparable to those seen with S5L 
cells. This effect was not seen following IFNγ stimulation of HDLEC. These data 
could support the premise that recombinant S100P decreases integrin activation, as 
the flow cytometry results showed that TNFα upregulated integrin expression, 
perhaps to a level that adequately compensates for the calcium-binding effects of 
recombinant S100P. Alternatively, it is known that S100P over-expression in our cell 
line results in the translocation of S100P to the nucleus (94). Furthermore, as 
mentioned previously, S100P can bind to RAGE receptors on pancreatic cancer 
cells, activating NF-KB signalling (190,199), which, in turn, can increase TNFα 
production (219). Thus, S100P over-expression could result in an increase in TNFα 
production by pancreatic cancer cells, which then would activate the lymphatic 
endothelium. This hypothesis would need to be confirmed by quantifying TNFα levels 
in V3L and S5L supernatant. Should this prove true, then the observed increase in 
S5L adhesion to activated HDLEC becomes important, as it may confer a metastatic 
advantage in the context of cancer inflammation. 
 
Not only can differences in adhesion facilitate different rates of cancer cell invasion, 
but the molecules facilitating adhesion have long been recognised as a defining 
factor in the type of cancer cell movement underlying invasion (147). Thus, we 
sought to define what mediated V3L and S5L attachment to HDLEC.  Our results 
highlight the complexity of these interactions.  
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Whilst we were able to show that V3L cells adhere to resting lymphatic endothelium 
via LYVE-1, CLEVER-1 and the integrin subunits α4, α9 and β1, we have yet to 
define what mediates V3L attachment to activated lymphatic endothelium. 
Interestingly, function blocking antibodies to CLEVER-1 and the integrin subunit α5 
significantly increased V3L adhesion to activated HDLEC. Whilst this may seem 
counter-intuitive, the same trend has been observed with CLEVER-1 blockade in 
relation to dendritic cell cell adhesion to lymphatic endothelium (154). Perhaps of 
even greater significance however, is that whilst CLEVER-1 blockade increased 
dendritic cell adhesion to lymphatics, it decreased dendritic cell TLEM (154). A 
similar mechanism might, therefore, exist for V3L TLEM and should be investigated 
further. The observed increase in adhesion to activated HDLEC seen with α5β1 
blockade also warrants further investigation. This could be done by repeating the 
TLEM assay, using the same function blocking antibodies which were used in the 
adhesion assays. 
 
S5L cells adhered to HDLEC in a different fashion. S5L adhesion to resting 
endothelium was mediated by LYVE-1. This receptor also mediated attachment to 
IFNγ-stimulated HDLEC. CLEVER-1 and α5β1 blockade had no effect on S5L 
adhesion to HDLEC, resting or activated. In contrast to V3L cells, β1 integrin-
dependent adhesion occurred only when HDLEC were activated. Specifically, α4β1 
and α9β1 integrin mediated S5L adhesion to IFNγ-stimulated HDLEC. This raises an 
interesting question regarding the type of cell movement adopted by S5L cells in the 
context of inflammation. Collective cell migration is known to be β1-dependent (147), 
and our results indicate that S5L preferentially use β1-integrins to adhere to IFNγ-
stimulated HDLEC. Furthermore, a previous gene expression profiling experiment of 
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the parental V3 and S5 cell lines showed a significant increase in E-cadherin in the 
S5 cells (Sayka Barry, PhD Thesis, 2009); again suggesting an increase in epithelial 
cohesion. However, further investigation is required to resolve this. 
 
None of the molecules analysed appear to mediate S5L adhesion to TNFα– 
stimulated HDLEC. This suggests that other molecules which have not been 
decribed in the literature may be present on HDLEC, and mediate functional 
interactions between lymphatic endothelium and cancer cells. Furthermore, the fact 
that blocking one adhesion molecule at a time resulted only in a small, yet 
significant, decrease in cancer cell adhesion to HDLEC suggests that adhesion 
potentially is mediated by a number of receptors acting in concert together. It would 
be interesting to repeat the function blocking experiments using combinations of 
different antibodies, to see if cancer cell adhesion to HDLEC can be totally ablated. 
Unfortunately, I was unable to perform these experiments due to a shortage of time. 
 
The lack of cognate adhesion receptors on V3L and S5L cells seen using flow 
cytometry suggests that it is possible that the ECM plays an important role in cancer 
cell adhesion to HDLEC (Figure 58). Whilst we were able to show that V3L and S5L 
cells express equivalent levels of the HA binding molecules CD44 and ICAM-1, we 
have yet to determine which FN-binding integrin(s) are expressed by these cells. 
Regardless, it is possible that FN and HA potentially act as a bridge between cancer 
cells and lymphatic endothelial cells. The importance of HA in facilitating cancer cell 
adhesion to blood endothelium, as well as its importance in haematological 
metastasis, has been described previously (220–222). In 1995, Zhang et al. showed, 
using a melanoma cell line expressing high levels of HA (HA-H) and a melanoma cell 
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line expressing low levels of HA (HA-L), that the HA-H cells formed a greater number 
of metastatic nodules in the lungs of C57BL/6 mice than HA-L cells, following tail 
vein injection (220). Furthermore, the survival of mice into which HA-H cells had 
been injected was significantly decreased. Interestingly, this paper also assessed the 
ability of these two cell lines to bind to CD44 positive, SV40-transformed lymphoid 
endothelial cells (SVEC4-10). HA-H cells were better able to adhere to SVEC4-10 
cells, and this adhesion was significantly decreased in the presence of hyaluronidase 
and/or function blocking antibodies to CD44 (220). HA has been shown 
subsequently to facilitate adhesion and transendothelial migration in both prostate 
and colon carcinoma in vitro (221,222). Had I had more time, I would have liked to 
have repeated the HA binding assays incorporating hyaluronidase, to assess the 
importance of HA in mediating V3L and S5L adhesion to HDLEC.  
 
As lymphatics are responsible for clearing debris and ECM, it may be beneficial for 
cancer cells to tether themselves to these matrix components in order to gain entry 
into lymphatics. Furthermore, due to the presence of button-hole junctions, 
lymphatics theoretically are easier to enter than blood vessels. It is possible that 
instead of having to ‘unzip’ the VE-cadherin in lymphatics, cancer cells can use the 
ECM to increase traction on the lymphatic vasculature, causing a ‘bulging’ of these 
button-holes, and allowing cancer cells to gain entry. This is however speculative, 
and requires further elucidation. I would have like to have tried to image this in vitro, 
had time permitted. This could have been done by establishing co-cultures of 
HDLEC with V3L or S5L cells; each cell type could have been fluorescently labelled 
with cell trackers, and the cells could have been placed in fluorescently-labelled 
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ECM (either HA or FN). Using confocal microscopy, I then would have tried to image 
these potential ‘bridges’.  
 
               
 
 
Figure 58 Schematic diagram depicting the potential mechanism through which the 
extracellular matrix (ECM) facilitates binding between cancer cells and lymphatic 
endothelium, allowing for translymphatic endothelial migration (TLEM). V3L and S5L 
cells express the hyaluronic acid binding molecules CD44 and ICAM-1, as well as 
fibronectin binding integrins. These allow cancer cells to bind to the ECM. The ECM, 
in turn, acts as a ‘bridge’, allowing cancer cells to bind to the lymphatic endothelium. 
In addition, the traction forces generated by this binding open up gaps in between 
lymphatic endothelial cells, allowing for paracellular transmigration. (Adapted from 
Nourshargh et al. (223)) 
 
Fibronectin binding 
integrin 
CD44 
ICAM-1 
ECM 
Lymphatic endothelium 
192 
 
Thus, whilst these in vitro experiments provide valuable clues as to the roles of 
S100P in lymphatic invasion, further investigation is required to determine the 
precise mechanisms through which it operates. 
 
It has been shown previously, in an orthotopic mouse model, that cromolyn 
decreases the growth and invasion of S100P-expressing tumours (96). Thus, we 
wanted to develop a CD1 nude orthotopic mouse model in our laboratory in which 
these drugs (i.e. cromolyn and its analogues), as well as any other novel therapies to 
S100P, could be investigated preclinically. Furthermore, we hoped to use this model 
to confirm the effects of S100P over-expression on primary pancreatic tumour 
growth, and/or the occurrence of spontaneous metastases. 
 
We were able to confirm, in the pilot study, that establishing a S100P over-
expressing orthotopic mouse model was feasible: there was no peri- or post- 
operative morbidity or mortality associated with the surgical procedure; and the 
animals showed no signs of illness up to four months post-injection, at which point 
tumour growth was substantial. We were able to confirm that both V3 and S5 cells 
grow orthotopically in the pancreas of CD1 nude mice. Furthermore, data from the 
imaging group suggested that using a smaller number of injected cells could be 
beneficial as it resulted in lymphatic invasion. Thus, 6.5 x 105 cells were used in 
subsequent experiments. In addition, as caliper tumour measurements were found to 
be user-dependent and thus variable, we decided that tumour weight would be a 
more objective measure of tumour growth upon killing. Lastly, we concluded that 
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bioluminescence imaging adequately measured primary pancreatic tumour growth in 
real time. 
 
The findings of the pilot, and subsequent two repeats, of the orthotopic injections 
highlight the difficulties associated with animal models. Firstly, whilst we observed 
LN metastases in the pilot study, we were unable to reproduce these data in the 
subsequent experiment. One possible explanation for this is that the parental V3 and 
S5 cell lines were used in the pilot study, whilst the V3L and S5L cell lines were used 
in the second experiment. Thus, although the in vitro data did not show any 
functional alterations in the V3L and S5L cell lines, it is possible that the luciferase 
transduction did alter the behaviour of these cell lines in vivo.  This could have been 
confirmed by repeating the orthotopic injections using the parental V3 and S5 cell 
lines, however, this would preclude bioluminescent imaging, and thus, was not 
performed. Secondly, it is possible that a larger number of cells was injected during 
the pilot study than was thought, as an error with cell counting occurred prior to 
orthotopic injection. Thus, it is possible that larger tumours occurred earlier in the 
pilot study than in the repeat experiment, and that these larger tumours were more 
prone to direct invasion of the surrounding LN, as well as true lymphovascular 
invasion (observed on H&E sections). We were unable to confirm this, as tumours 
were not weighed in the pilot study. In addition, caliper measurements were taken 
only in two dimensions, and thus were sub-optimal for calculated conversions. 
Thirdly, in the pilot experiment, cells were injected at two sites i.e. subcutaneously 
and into the pancreas. There is emerging evidence that soluble factors released from 
primary subcutaneous tumours may result in the formation of a premetastatic niche, 
which increases haematological dissemination (224). Hiratsuka et al. showed, in 
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C57BL/6 mice bearing subcutaneous Lewis Lung Carcinoma (LLC) and B16 
melanoma tumours, that S100A8 and S100A9 are up-regulated in the lung 
premetastatic niche. These soluble factors increased the extravasation of cancer 
cells following tail vein injection, and thus increased the number of lung metastases. 
In addition, the observed increase in lung metastases significantly decreased in the 
presence of neutralising antibodies to S100A8 and S100A9. Furthermore, 
pretreatment of normal controls with serum from tumour-bearing mice resulted in the 
upregulation of S100A8 and S100A9 in the lungs, and an increase in lung 
metastases following tail vein injection (224). Thus, it is possible that the presence of 
subcutaneous tumours in the pilot experiment contributed to development of 
metastasis. And finally, the third experiment, which was meant to resolve these 
discrepancies, had to be terminated early due to an infection contracted post-
operatively. This highlights the complexities of animal experiments, and emphasises 
the importance of ensuring that neoplasms are kept free of mouse pathogens in 
order to obtain interpretable data (225).  
 
Despite this, we were able to show reproducibly that S100P accelerates primary 
tumour growth, in keeping with data obtained in the previous study by Arumugam et 
al. (95). Furthermore, we were able to adequately monitor this growth from as early 
as one week post-injection using bioluminescence. Thus, this model can be used in 
the future to evaluate the effects of novel therapies against S100P on primary 
tumour growth. 
 
We were also able to demonstrate the presence of both V3L and S5L cells in peri- 
and intra-tumoural lymphatic vessels in our model. This confirms that both the V3L 
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and S5L cell lines are able to intravasate into lymphatics. The in vitro TLEM data 
suggest that the S5L cells would invade at a faster rate. Thus, as no positive peri-
pancreatic LN were found at ten weeks, the data from the repeat experiment suggest 
that lymphovascular invasion occurs within ten weeks post-injection. It would be 
interesting to define when the first evidence of lymphovascular invasion arises, as 
well as to test if this occurs at an earlier time-point when S100P is over-expressed as 
compared to the control cells that show no endoegenous S100P. This could be done 
by repeating the orthotopic experiment using the V3L and S5L cell lines, and killing 
at least five mice weekly, looking for histological evidence of lymphovascular 
invasion.  
 
As no evidence of spontaneous metastases was seen in this model, we decided to 
experimentally induce metastasis in CD1 nude mice in order to assess if the V3L and 
S5L are able to survive in vessels, extravasate and colonise distant tissues. Our data 
suggest that neither of these cell lines can survive in blood vessels (tail vein 
injections); extravasate from blood vessels (tail vein injections and splenic 
injections); or establish growth at specific sites i.e. liver, lungs and lymph nodes. 
However, it is possible that the strain of mouse used affected the results obtained. 
Thus, as all of these experiments were conducted in the CD1 nude mouse, they 
could be repeated in a different immunodeficient mouse strain in order to evaluate if 
this affected the occurrence of metastasis or not.  
 
Thus, although the data from the in vivo studies clearly show a role for S100P in 
accelerating primary pancreatic tumour growth, and although there is evidence that 
S100P is involved in the process of communication between carcinoma cells and the 
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lymphatic endothelium, these data do not support a causative role for S100P in 
inducing lymphatic and/or haematological metastasis. 
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8.  CONCLUDING REMARKS 
 
Although lymphatic invasion is known to be an early and important step in the 
dissemination of PDAC, few studies have analysed the molecular mechanisms 
underlying this process (66,67,69–72). Only one previous study had examined this 
process at a protein level, by analysing primary pancreatic tumours using MALDI-
TOF and correlating the data obtained to clinicopathological parameters (72). For 
that reason, we sought to analyse the molecular mechanisms underlying lymphatic 
invasion in PDAC using a shotgun proteomics approach. This is the first study to 
analyse the metastatic LN from patients with resectable PDAC; to compare protein 
expression from primary PDAC epithelia to protein expression in LN metastatic 
epithelia; and to use LCM FFPE tissue samples for the proteomic investigation of 
metastatic PDAC.  
 
From our analysis, we were able to validate that two candidate molecules, S100P 
and 14-3-3 sigma, were up-regulated significantly in LN metastases relative to 
primary PDAC. As the study was performed on tissue which had been fixed at a 
specific point in disease progression however, it is important to note that these 
findings could be co-incidental, and do not imply a causative role for either of these 
proteins in PDAC pathogenesis. Further investigation would be required in order to 
prove a causal association. Regardless, both of these molecules represent viable 
therapeutic targets. These data have been published (226), and will be made 
available to the general public through the Pancreatic Expression Database (188). 
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Due to its well-established role in PanIN progression and PDAC in human tissue 
samples (91,93), and based on previously published data supporting a causative role 
for S100P in PDAC invasion both in vitro and in vivo (92,94–97), we went on to 
investigate the roles of S100P in lymphatic invasion in PDAC.  
 
This is the first study to attempt to co-culture pancreatic cancer cell lines with 
HDLEC, and to use these co-cultures to investigate the interactions of pancreatic 
cancer cells with lymphatic endothelial cells. Furthermore, it is the first study to look 
specifically at the effects of S100P over-expression on the adhesion of pancreatic 
cancer cells to HDLEC; on permeability through a HDLEC monolayer; and on TLEM. 
We feel that the data arising from these studies are promising in some regards, 
though disappointing in others. Using the V3L and S5L cell lines, we were able to 
show that S100P over-expression alters the molecules involved in adhesion to 
resting and activated HDLEC, and increases permeability and TLEM through a 
HDLEC monolayer. Further work, however, is required both to confirm that these 
data are of a general significance (e.g. by repeating the experiments using addition 
pancreatic cancer cell lines which express high levels of endogenous S100P), and to 
prove that these functional changes are mediated by S100P specifically (e.g. using 
siRNA knockdown). So far, however, the data seem to suggest a causative role for 
S100P in lymphovascular invasion.  
 
This conclusion was challenged by our in vivo data. Whilst we were able to show that 
S100P over-expression accelerates primary pancreatic tumour growth, we were not 
able to demonstrate that S100P over-expression causes spontaneous lymphatic 
and/or haematological metastasis. Furthermore, although lymphovascular invasion 
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was noted in primary tumours, this was seen in both V3L and S5L orthotopic 
tumours to the same extent. In addition, the experimental metastasis and site-
specific growth experiments did not result in growth in the lungs, liver and/or LN. 
Thus, we conclude that S100P alone does not cause lymphatic invasion in the CD1 
nude mouse. It is possible that the strain of mouse used affected the outcome, and 
thus, these experiments would need to be confirmed in a different immunodeficient 
mouse strain, before concluding that they are a true representation of the impact of 
S100P expression on in vivo behaviour. 
 
Finally, we were able to develop a CD1 nude orthotopic mouse model that can be 
used for the preclinical evaluation of novel therapies targeting S100P in our 
laboratory. Specifically, this model can be used to assess the effects of such 
therapies on primary tumour growth and this, in itself, might well be a useful system 
to exploit in seeking novel anti-PDAC therapeutic approaches. 
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Appendix I 
 
Appendix I tabulates the 854 proteome of PDAC and matched LN metastases in 
alphabetical order (MW = molecular weight). 
 
Identified Proteins 
Accession 
No. MW 
- 22 kDa protein IPI00219910 22 kDa 
A1BG Alpha-1B-glycoprotein IPI00022895 54 kDa 
A2M Alpha-2-macroglobulin IPI00478003 163 kDa 
AARS Alanyl-tRNA synthetase, cytoplasmic IPI00027442 107 kDa 
ABCF1 Isoform 1 of ATP-binding cassette sub-family F member 1 IPI00873899 96 kDa 
ABHD11 Isoform 4 of Abhydrolase domain-containing protein 11 IPI00171152 34 kDa 
ABHD14B Isoform 1 of Abhydrolase domain-containing protein 14B IPI00063827 22 kDa 
ABLIM1 Isoform 1 of Actin-binding LIM protein 1 IPI00329495 88 kDa 
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial IPI00001539 42 kDa 
ACADVL cDNA FLJ56425, highly similar to Very-long-chain specific acyl-
CoAdehydrogenase, mitochondrial IPI00028031 75 kDa 
ACAT1 Acetyl-CoA acetyltransferase, mitochondrial IPI00030363 45 kDa 
ACBD3 Golgi resident protein GCP60 IPI00009315 61 kDa 
ACO2 Aconitate hydratase, mitochondrial IPI00017855 85 kDa 
ACOT2 Isoform 1 of Acyl-coenzyme A thioesterase 2, mitochondrial IPI00220906 53 kDa 
ACP1 Isoform 2 of Low molecular weight phosphotyrosine protein 
phosphatase IPI00218847 18 kDa 
ACTB Actin, cytoplasmic 1 IPI00021439 42 kDa 
ACTN1 Alpha-actinin-1 IPI00013508 103 kDa 
ACTN4 Alpha-actinin-4 IPI00013808 105 kDa 
ACTR2 Actin-related protein 2 IPI00005159 45 kDa 
ACTR3 Actin-related protein 3 IPI00028091 47 kDa 
ADAM10 ADAM 10 IPI00013897 84 kDa 
ADD1 Isoform 1 of Alpha-adducin IPI00019901 81 kDa 
AEBP1 Isoform 1 of Adipocyte enhancer-binding protein 1 IPI00745313 131 kDa 
AFG3L2 AFG3-like protein 2 IPI00001091 89 kDa 
AGR2 AGR2 IPI00007427 22 kDa 
AGRN Agrin IPI00374563 215 kDa 
AHCY Adenosylhomocysteinase IPI00012007 48 kDa 
AHNAK Neuroblast differentiation-associated protein AHNAK IPI00021812 629 kDa 
AHNAK2 Isoform 1 of Protein AHNAK2 IPI00856045 617 kDa 
AIFM1 Isoform 1 of Apoptosis-inducing factor 1, mitochondrial IPI00000690 67 kDa 
AK2 Isoform 3 of Adenylate kinase isoenzyme 2, mitochondrial IPI00172460 22 kDa 
AK3 GTP:AMP phosphotransferase mitochondrial IPI00465256 26 kDa 
219 
 
AKR1A1 Alcohol dehydrogenase [NADP+] IPI00220271 37 kDa 
AKR1B1 Aldose reductase IPI00413641 36 kDa 
AKR1B10 Aldo-keto reductase family 1 member B10 IPI00105407 36 kDa 
AKR1C1 Aldo-keto reductase family 1 member C1 IPI00029733 37 kDa 
AKR7A2 Aflatoxin B1 aldehyde reductase member 2 IPI00305978 40 kDa 
AKR7A3 Aflatoxin B1 aldehyde reductase member 3 IPI00293721 37 kDa 
ALB Isoform 1 of Serum albumin IPI00745872 69 kDa 
ALDH18A1 Isoform Long of Delta-1-pyrroline-5-carboxylate synthetase IPI00008982 87 kDa 
ALDH1A1 Retinal dehydrogenase 1 IPI00218914 55 kDa 
ALDH2 Aldehyde dehydrogenase, mitochondrial IPI00006663 56 kDa 
ALDH7A1 aldehyde dehydrogenase 7 family, member A1 IPI00221234 58 kDa 
ALDH9A1 aldehyde dehydrogenase 9A1 IPI00479877 56 kDa 
ALDOA Fructose-bisphosphate aldolase A IPI00465439 39 kDa 
ALDOC Fructose-bisphosphate aldolase C IPI00418262 39 kDa 
ANP32B Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family 
member B IPI00007423 29 kDa 
ANXA1 Annexin A1 IPI00218918 39 kDa 
ANXA10 Annexin A10 IPI00296528 37 kDa 
ANXA2 Annexin A2 IPI00455315 39 kDa 
ANXA3 Annexin A3 IPI00024095 36 kDa 
ANXA4 annexin IV IPI00793199 36 kDa 
ANXA5 Annexin A5 IPI00329801 36 kDa 
ANXA6 annexin VI isoform 2 IPI00002459 75 kDa 
AP1M2 Isoform 1 of AP-1 complex subunit mu-2 IPI00002552 48 kDa 
AP2A1 Isoform B of AP-2 complex subunit alpha-1 IPI00256684 105 kDa 
AP2B1 Isoform 1 of AP-2 complex subunit beta-1 IPI00784156 105 kDa 
APEH Acylamino-acid-releasing enzyme IPI00337741 81 kDa 
APEX1 DNA-(apurinic or apyrimidinic site) lyase IPI00215911 36 kDa 
APOA1 Apolipoprotein A-I IPI00021841 31 kDa 
APRT Adenine phosphoribosyltransferase IPI00218693 20 kDa 
ARCN1 Putative uncharacterized protein DKFZp686M09245 IPI00298520 62 kDa 
ARF1 ADP-ribosylation factor 1 IPI00215914 21 kDa 
ARF4 ADP-ribosylation factor 4 IPI00215918 21 kDa 
ARHGAP1 cDNA FLJ60782, highly similar to Rho-GTPase-activating protein 1 IPI00020567 53 kDa 
ARPC1B Actin-related protein 2/3 complex subunit 1B IPI00005160 41 kDa 
ARPC2 Actin-related protein 2/3 complex subunit 2 IPI00005161 34 kDa 
ARPC3 Actin-related protein 2/3 complex subunit 3 IPI00005162 21 kDa 
ARPC5 Isoform 1 of Actin-related protein 2/3 complex subunit 5 IPI00550234 16 kDa 
ASL Argininosuccinate lyase IPI00220267 52 kDa 
ASS1 Argininosuccinate synthase IPI00020632 51 kDa 
ATIC Bifunctional purine biosynthesis protein PURH IPI00289499 65 kDa 
ATL3 Isoform 1 of Atlastin-3 IPI00550523 61 kDa 
ATP1A1 Isoform Long of Sodium/potassium-transporting ATPase subunit 
alpha-1 IPI00006482 113 kDa 
ATP1B1 Isoform 1 of Sodium/potassium-transporting ATPase subunit beta-1 IPI00747849 35 kDa 
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ATP2A2 Isoform SERCA2A of Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 IPI00177817 110 kDa 
ATP5A1 ATP synthase subunit alpha, mitochondrial IPI00440493 60 kDa 
ATP5B ATP synthase subunit beta, mitochondrial IPI00303476 57 kDa 
ATP5F1 ATP synthase subunit b, mitochondrial IPI00029133 29 kDa 
ATP5H Isoform 1 of ATP synthase subunit d, mitochondrial IPI00220487 18 kDa 
ATP5O ATP synthase subunit O, mitochondrial IPI00007611 23 kDa 
ATP6V1A V-type proton ATPase catalytic subunit A IPI00007682 68 kDa 
ATP6V1B2 V-type proton ATPase subunit B, brain isoform IPI00007812 57 kDa 
B2M Beta-2-microglobulin IPI00004656 14 kDa 
BAIAP2L1 Brain-specific angiogenesis inhibitor 1-associated protein 2-like 
protein 1 IPI00179326 57 kDa 
BCAP31 B-cell receptor-associated protein 31 IPI00218200 28 kDa 
BCAS1 Isoform 1 of Breast carcinoma-amplified sequence 1 IPI00025311 62 kDa 
BGN Biglycan IPI00010790 42 kDa 
BLVRA Biliverdin reductase A IPI00294158 33 kDa 
BPNT1 Isoform 1 of 3'(2'),5'-bisphosphate nucleotidase 1 IPI00410214 33 kDa 
BUB3 Mitotic checkpoint protein BUB3 IPI00013468 37 kDa 
C17orf28 Isoform 3 of UPF0663 transmembrane protein C17orf28 IPI00247634 63 kDa 
C19orf21 Uncharacterized protein C19orf21 IPI00217121 75 kDa 
C21orf33 Isoform Long of ES1 protein homolog, mitochondrial IPI00024913 28 kDa 
C22orf28 UPF0027 protein C22orf28 IPI00550689 55 kDa 
C3 Complement C3 (Fragment) IPI00783987 187 kDa 
C4A Complement C4-A IPI00032258 193 kDa 
CA2 Carbonic anhydrase 2 IPI00218414 29 kDa 
CALD1 Isoform 4 of Caldesmon IPI00218696 63 kDa 
CALM3;CALM1;CALM2 Calmodulin IPI00075248 17 kDa 
CALR Calreticulin IPI00020599 48 kDa 
CAND1 Isoform 1 of Cullin-associated NEDD8-dissociated protein 1 IPI00100160 136 kDa 
CANX cDNA FLJ55574, highly similar to Calnexin IPI00020984 72 kDa 
CAP1 Isoform 1 of Adenylyl cyclase-associated protein 1 IPI00008274 52 kDa 
CAPG Macrophage-capping protein IPI00027341 39 kDa 
CAPN1 Calpain-1 catalytic subunit IPI00011285 82 kDa 
CAPN2 Calpain-2 catalytic subunit IPI00289758 80 kDa 
CAPNS1 Calpain small subunit 1 IPI00025084 28 kDa 
CAPZA1 F-actin-capping protein subunit alpha-1 IPI00005969 33 kDa 
CAT Catalase IPI00465436 60 kDa 
CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 30 kDa 
CCDC109A Isoform 1 of Coiled-coil domain-containing protein 109A IPI00171573 40 kDa 
CCDC6 Coiled-coil domain-containing protein 6 IPI00000634 66 kDa 
CCT2 T-complex protein 1 subunit beta IPI00297779 57 kDa 
CCT3 chaperonin containing TCP1, subunit 3 isoform b IPI00290770 60 kDa 
CCT4 T-complex protein 1 subunit delta IPI00302927 58 kDa 
CCT5 T-complex protein 1 subunit epsilon IPI00010720 60 kDa 
CCT6A T-complex protein 1 subunit zeta IPI00027626 58 kDa 
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CCT7 T-complex protein 1 subunit eta IPI00018465 59 kDa 
CCT8 59 kDa protein IPI00302925 59 kDa 
CD44 Isoform 12 of CD44 antigen IPI00297160 39 kDa 
CD63 CD63 antigen IPI00215998 26 kDa 
CDH1 Cadherin 1, type 1, E-cadherin (Epithelial), isoform CRA_c IPI00000513 91 kDa 
CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5 IPI00027486 77 kDa 
CFL1 Cofilin-1 IPI00012011 19 kDa 
CGN cingulin IPI00844508 137 kDa 
CHD4 Isoform 1 of Chromodomain-helicase-DNA-binding protein 4 IPI00000846 218 kDa 
CHMP4B Charged multivesicular body protein 4b IPI00025974 25 kDa 
CKAP4 Isoform 1 of Cytoskeleton-associated protein 4 IPI00141318 66 kDa 
CLIC1 Chloride intracellular channel protein 1 IPI00010896 27 kDa 
CLIC3 Chloride intracellular channel protein 3 IPI00000692 27 kDa 
CLPTM1 Isoform 2 of Cleft lip and palate transmembrane protein 1 IPI00107357 78 kDa 
CLTC Isoform 1 of Clathrin heavy chain 1 IPI00024067 192 kDa 
CMPK1 cytidine monophosphate (UMP-CMP) kinase 1, cytosolic isoform a IPI00219953 26 kDa 
CNDP2 Cytosolic non-specific dipeptidase IPI00177728 53 kDa 
CNN1 Calponin-1 IPI00021264 33 kDa 
CNN3 Calponin-3 IPI00216682 36 kDa 
CNP Isoform CNPI of 2',3'-cyclic-nucleotide 3'-phosphodiesterase IPI00220993 45 kDa 
COL12A1 Isoform 4 of Collagen alpha-1(XII) chain IPI00302944 325 kDa 
COL14A1 Isoform 1 of Collagen alpha-1(XIV) chain IPI00176193 194 kDa 
COL18A1 Isoform 2 of Collagen alpha-1(XVIII) chain IPI00022822 154 kDa 
COL1A1 Collagen alpha-1(I) chain IPI00297646 139 kDa 
COL1A2 Collagen alpha-2(I) chain IPI00304962 129 kDa 
COL3A1 Isoform 1 of Collagen alpha-1(III) chain IPI00021033 139 kDa 
COL4A1 Putative uncharacterized protein COL4A1 IPI00743696 161 kDa 
COL4A2 Collagen alpha-2(IV) chain IPI00306322 168 kDa 
COL6A1 Collagen alpha-1(VI) chain IPI00291136 109 kDa 
COL6A2 Isoform 2C2 of Collagen alpha-2(VI) chain IPI00304840 109 kDa 
COL6A3 Isoform 1 of Collagen alpha-3(VI) chain IPI00022200 344 kDa 
COPA Isoform 1 of Coatomer subunit alpha IPI00295857 138 kDa 
COPB1 Coatomer subunit beta IPI00295851 107 kDa 
COPB2 Coatomer subunit beta' IPI00220219 102 kDa 
COPE epsilon subunit of coatomer protein complex isoform c IPI00399319 29 kDa 
COPG Coatomer subunit gamma IPI00783982 98 kDa 
CORO7 Coronin-7 IPI00027996 101 kDa 
COTL1 Coactosin-like protein IPI00017704 16 kDa 
COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial IPI00006579 20 kDa 
COX5A Cytochrome c oxidase subunit 5A, mitochondrial IPI00025086 17 kDa 
CP Ceruloplasmin IPI00017601 122 kDa 
CPNE3 Copine-3 IPI00024403 60 kDa 
CPT1A Isoform 1 of Carnitine O-palmitoyltransferase 1, liver isoform IPI00032038 88 kDa 
CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial IPI00012912 74 kDa 
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CRYZ Quinone oxidoreductase IPI00000792 35 kDa 
CS Citrate synthase, mitochondrial IPI00025366 52 kDa 
CSDE1 Isoform Long of Cold shock domain-containing protein E1 IPI00470891 89 kDa 
CSE1L Isoform 1 of Exportin-2 IPI00022744 110 kDa 
CSRP1 Cysteine and glycine-rich protein 1 IPI00442073 21 kDa 
CSTB Cystatin-B IPI00021828 11 kDa 
CTNNA1 Isoform 1 of Catenin alpha-1 IPI00215948 100 kDa 
CTNNB1 Isoform 1 of Catenin beta-1 IPI00017292 85 kDa 
CTNND1 Isoform 1AB of Catenin delta-1 IPI00182469 107 kDa 
CTSD Cathepsin D IPI00011229 45 kDa 
CTSG Cathepsin G IPI00028064 29 kDa 
CTSZ Cathepsin Z IPI00002745 34 kDa 
CTTN Src substrate cortactin IPI00029601 62 kDa 
CYB5A Isoform 2 of Cytochrome b5 IPI00182933 11 kDa 
CYB5R1 NADH-cytochrome b5 reductase 1 IPI00470674 34 kDa 
CYB5R3 Isoform 1 of NADH-cytochrome b5 reductase 3 IPI00328415 34 kDa 
CYCS Cytochrome c IPI00465315 12 kDa 
CYFIP1 Isoform 1 of Cytoplasmic FMR1-interacting protein 1 IPI00644231 145 kDa 
CYP2S1 Isoform 2 of Cytochrome P450 2S1 IPI00164018 62 kDa 
DAK Dihydroxyacetone kinase IPI00551024 59 kDa 
DARS Aspartyl-tRNA synthetase, cytoplasmic IPI00216951 57 kDa 
DBN1 Isoform 1 of Drebrin IPI00003406 71 kDa 
DBNL Isoform 3 of Drebrin-like protein IPI00101968 49 kDa 
DCD Dermcidin IPI00027547 11 kDa 
DCN Isoform A of Decorin IPI00012119 40 kDa 
DCXR L-xylulose reductase IPI00448095 26 kDa 
DDAH1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 IPI00220342 31 kDa 
DDAH2 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 IPI00000760 30 kDa 
DDOST dolichyl-diphosphooligosaccharide-protein glycosyltransferase 
precursor IPI00297084 51 kDa 
DDRGK1 Isoform 1 of Uncharacterized protein C20orf116 IPI00028387 36 kDa 
DDX17 DEAD box polypeptide 17 isoform 1 IPI00023785 80 kDa 
DDX21 Isoform 1 of Nucleolar RNA helicase 2 IPI00015953 87 kDa 
DDX23 Probable ATP-dependent RNA helicase DDX23 IPI00006725 96 kDa 
DDX6 Probable ATP-dependent RNA helicase DDX6 IPI00030320 54 kDa 
DEFA1;LOC728358 Neutrophil defensin 1 IPI00005721 10 kDa 
DHRS4 peroxisomal short-chain alcohol dehydrogenase IPI00106913 30 kDa 
DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase 
DHX15 IPI00396435 91 kDa 
DHX9 ATP-dependent RNA helicase A IPI00844578 141 kDa 
DLD Dihydrolipoyl dehydrogenase, mitochondrial IPI00015911 54 kDa 
DLST Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial IPI00420108 49 kDa 
DMBT1 Isoform 1 of Deleted in malignant brain tumors 1 protein IPI00099110 261 kDa 
DMD Isoform 4 of Dystrophin IPI00006091 427 kDa 
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DNAJA1 DnaJ homolog subfamily A member 1 IPI00012535 45 kDa 
DNAJB1 DnaJ homolog subfamily B member 1 IPI00015947 38 kDa 
DNPEP aspartyl aminopeptidase IPI00015856 53 kDa 
DPP3 Isoform 1 of Dipeptidyl-peptidase 3 IPI00020672 83 kDa 
DPYSL2 Dihydropyrimidinase-related protein 2 IPI00257508 62 kDa 
DPYSL3 DPYSL3 protein IPI00029111 74 kDa 
DSG2 Desmoglein-2 IPI00028931 122 kDa 
DSP Isoform DPI of Desmoplakin IPI00013933 332 kDa 
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 IPI00456969 532 kDa 
DYNC1I2 Isoform 2C of Cytoplasmic dynein 1 intermediate chain 2 IPI00216348 68 kDa 
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial IPI00011416 36 kDa 
ECHS1 Enoyl-CoA hydratase, mitochondrial IPI00024993 31 kDa 
EEA1 Early endosome antigen 1 IPI00329536 162 kDa 
EEF1A1 Elongation factor 1-alpha 1 IPI00396485 50 kDa 
EEF1D Elongation factor 1-delta IPI00023048 31 kDa 
EEF1G cDNA FLJ56389, highly similar to Elongation factor 1-gamma IPI00000875 56 kDa 
EEF2 Elongation factor 2 IPI00186290 95 kDa 
EFHD2 EF-hand domain-containing protein D2 IPI00060181 27 kDa 
EFTUD2 116 kDa U5 small nuclear ribonucleoprotein component IPI00003519 109 kDa 
EHD1 EH domain-containing protein 1 IPI00017184 61 kDa 
EHD2 EH domain-containing protein 2 IPI00100980 61 kDa 
EIF2S1 Eukaryotic translation initiation factor 2 subunit 1 IPI00219678 36 kDa 
EIF2S3 Eukaryotic translation initiation factor 2 subunit 3 IPI00297982 51 kDa 
EIF3A Eukaryotic translation initiation factor 3 subunit A IPI00029012 167 kDa 
EIF3B Isoform 1 of Eukaryotic translation initiation factor 3 subunit B IPI00396370 92 kDa 
EIF3C;EIF3CL Eukaryotic translation initiation factor 3 subunit C IPI00016910 105 kDa 
EIF3D Eukaryotic translation initiation factor 3 subunit D IPI00006181 64 kDa 
EIF3EIP Eukaryotic translation initiation factor 3, subunit E interacting 
protein IPI00465233 71 kDa 
EIF3I Eukaryotic translation initiation factor 3 subunit I IPI00012795 37 kDa 
EIF4A3 Eukaryotic initiation factor 4A-III IPI00009328 47 kDa 
EIF4B cDNA FLJ54492, highly similar to Eukaryotic translation initiation factor 
4B IPI00012079 70 kDa 
EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 isoform 2 IPI00384463 167 kDa 
ELAVL1 cDNA FLJ60076, highly similar to ELAV-like protein 1 IPI00301936 39 kDa 
EMILIN1 EMILIN-1 IPI00013079 107 kDa 
EML4 Echinoderm microtubule-associated protein-like 4 IPI00001466 109 kDa 
ENO1 Isoform alpha-enolase of Alpha-enolase IPI00465248 47 kDa 
ENO2 Gamma-enolase IPI00216171 47 kDa 
EPB41L2 Band 4.1-like protein 2 IPI00015973 113 kDa 
EPHX1 Epoxide hydrolase 1 IPI00009896 53 kDa 
EPPK1 epiplakin 1 IPI00010951 556 kDa 
EPRS Bifunctional aminoacyl-tRNA synthetase IPI00013452 171 kDa 
EPS8 Epidermal growth factor receptor kinase substrate 8 IPI00290337 92 kDa 
EPS8L1 Isoform 1 of Epidermal growth factor receptor kinase substrate 8-like IPI00301250 80 kDa 
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protein 1 
EPS8L3 Isoform 1 of Epidermal growth factor receptor kinase substrate 8-like 
protein 3 IPI00181833 67 kDa 
ERH Enhancer of rudimentary homolog IPI00029631 12 kDa 
ERO1L ERO1-like protein alpha IPI00386755 54 kDa 
ESD S-formylglutathione hydrolase IPI00411706 31 kDa 
ETFA Electron transfer flavoprotein subunit alpha, mitochondrial IPI00010810 35 kDa 
ETFB Isoform 1 of Electron transfer flavoprotein subunit beta IPI00004902 28 kDa 
ETHE1 Protein ETHE1, mitochondrial IPI00003766 28 kDa 
EVPL Envoplakin IPI00023711 232 kDa 
EWSR1 Ewing sarcoma breakpoint region 1, isoform CRA_h IPI00009841 69 kDa 
EZR Ezrin IPI00746388 69 kDa 
FAM129B Niban-like protein 1 IPI00456750 83 kDa 
FARSA Phenylalanyl-tRNA synthetase alpha chain IPI00031820 58 kDa 
FARSB Phenylalanyl-tRNA synthetase beta chain IPI00300074 66 kDa 
FASN Fatty acid synthase IPI00026781 273 kDa 
FBLN1 Isoform B of Fibulin-1 IPI00218803 77 kDa 
FBN1 Fibrillin-1 IPI00328113 312 kDa 
FBP1 Fructose-1,6-bisphosphatase 1 IPI00073772 37 kDa 
FERMT2 Isoform 1 of Fermitin family homolog 2 IPI00000856 78 kDa 
FGA Isoform 1 of Fibrinogen alpha chain IPI00021885 95 kDa 
FGB Fibrinogen beta chain IPI00298497 56 kDa 
FGG Isoform Gamma-B of Fibrinogen gamma chain IPI00021891 52 kDa 
FH Isoform Mitochondrial of Fumarate hydratase, mitochondrial IPI00296053 55 kDa 
FKBP3 FK506-binding protein 3 IPI00024157 25 kDa 
FKBP4 FK506-binding protein 4 IPI00219005 52 kDa 
FLJ12529 Isoform 1 of Cleavage and polyadenylation specificity factor 
subunit 7 IPI00550821 52 kDa 
FLNA Isoform 2 of Filamin-A IPI00302592 280 kDa 
FLNB Isoform 1 of Filamin-B IPI00289334 278 kDa 
FLOT1 Flotillin-1 IPI00027438 47 kDa 
FN1 Isoform 1 of Fibronectin IPI00022418 263 kDa 
FSCN1 Fascin IPI00163187 55 kDa 
FTH1 Ferritin heavy chain IPI00554521 21 kDa 
FTL Ferritin IPI00375676 21 kDa 
FUBP1 Isoform 1 of Far upstream element-binding protein 1 IPI00375441 68 kDa 
FUBP3 Isoform 1 of Far upstream element-binding protein 3 IPI00377261 62 kDa 
FUS Isoform Short of RNA-binding protein FUS IPI00221354 53 kDa 
G3BP2 Isoform A of Ras GTPase-activating protein-binding protein 2 IPI00009057 54 kDa 
G6PD Isoform Long of Glucose-6-phosphate 1-dehydrogenase IPI00216008 64 kDa 
GALE UDP-glucose 4-epimerase IPI00553131 38 kDa 
GANAB cDNA FLJ61290, highly similar to Neutral alpha-glucosidase AB IPI00383581 113 kDa 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase IPI00219018 36 kDa 
GARS Glycyl-tRNA synthetase IPI00783097 83 kDa 
GATM Isoform Mitochondrial of Glycine amidinotransferase, mitochondrial IPI00032103 48 kDa 
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GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide exchange 
factor 1 IPI00021954 206 kDa 
GCA Grancalcin IPI00004524 24 kDa 
GDI1 Rab GDP dissociation inhibitor alpha IPI00010154 51 kDa 
GDI2 cDNA FLJ60299, highly similar to Rab GDP dissociation inhibitor beta IPI00031461 51 kDa 
GFPT1 Isoform 1 of Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1 IPI00217952 79 kDa 
GIGYF2 Isoform 2 of PERQ amino acid-rich with GYF domain-containing 
protein 2 IPI00647635 153 kDa 
GLO1 Lactoylglutathione lyase IPI00220766 21 kDa 
GLT25D1 Glycosyltransferase 25 family member 1 IPI00168262 72 kDa 
GLUD1 Glutamate dehydrogenase 1, mitochondrial IPI00016801 61 kDa 
GMDS GDP-mannose 4,6 dehydratase IPI00030207 42 kDa 
GMPS GMP synthase [glutamine-hydrolyzing] IPI00029079 77 kDa 
GNAS Isoform XLas-1 of Guanine nucleotide-binding protein G(s) subunit 
alpha isoforms XLas IPI00095891 111 kDa 
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 IPI00003348 37 kDa 
GNB2L1 Guanine nucleotide-binding protein subunit beta 2-like 1 IPI00641950 38 kDa 
GOLGA3 Isoform 1 of Golgin subfamily A member 3 IPI00305267 167 kDa 
GOLGB1 Golgin subfamily B member 1 IPI00004671 376 kDa 
GOLM1 Golgi membrane protein 1 IPI00171411 46 kDa 
GOT1 Aspartate aminotransferase, cytoplasmic IPI00219029 46 kDa 
GOT2 Aspartate aminotransferase, mitochondrial IPI00018206 47 kDa 
GPD2 Isoform 1 of Glycerol-3-phosphate dehydrogenase, mitochondrial IPI00017895 81 kDa 
GPI Glucose-6-phosphate isomerase IPI00027497 63 kDa 
GPX1 glutathione peroxidase 1 isoform 1 IPI00293975 22 kDa 
GPX2 Glutathione peroxidase 2 IPI00298176 22 kDa 
GRB2 Isoform 1 of Growth factor receptor-bound protein 2 IPI00021327 25 kDa 
GRHPR Glyoxylate reductase/hydroxypyruvate reductase IPI00037448 36 kDa 
GSN Isoform 1 of Gelsolin IPI00646773 81 kDa 
GSS Glutathione synthetase IPI00010706 52 kDa 
GSTK1 Glutathione S-transferase kappa 1 IPI00219673 25 kDa 
GSTO1 Glutathione S-transferase omega-1 IPI00019755 28 kDa 
GSTP1 Glutathione S-transferase P IPI00219757 23 kDa 
GSTT1 Glutathione S-transferase theta-1 IPI00741097 27 kDa 
GTF2I Isoform 1 of General transcription factor II-I IPI00054042 112 kDa 
H1F0 Histone H1.0 IPI00550239 21 kDa 
H2AFY H2A histone family, member Y isoform 2 IPI00059366 39 kDa 
H2AFY2 Core histone macro-H2A.2 IPI00220994 40 kDa 
HADHA Trifunctional enzyme subunit alpha, mitochondrial IPI00031522 83 kDa 
HADHB Trifunctional enzyme subunit beta, mitochondrial IPI00022793 51 kDa 
HARS Histidyl-tRNA synthetase, cytoplasmic IPI00021808 57 kDa 
HBA1;HBA2 Hemoglobin subunit alpha IPI00410714 15 kDa 
HBB Hemoglobin subunit beta IPI00654755 16 kDa 
HDAC1 Histone deacetylase 1 IPI00013774 55 kDa 
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HDGF Hepatoma-derived growth factor IPI00020956 27 kDa 
HDLBP Vigilin IPI00022228 141 kDa 
HEBP1 Heme-binding protein 1 IPI00148063 21 kDa 
HIBCH Isoform 1 of 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial IPI00419802 43 kDa 
HIST1H1B Histone H1.5 IPI00217468 23 kDa 
HIST1H1E Histone H1.4 IPI00217467 22 kDa 
HK1 Isoform 1 of Hexokinase-1 IPI00018246 102 kDa 
HLA-A HLA class I histocompatibility antigen, A-69 alpha chain IPI00760554 41 kDa 
HLA-DQA1 MHC class II antigen IPI00719648 29 kDa 
HMGA1 Isoform HMG-I of High mobility group protein HMG-I/HMG-Y IPI00179700 12 kDa 
HMGB1 High mobility group protein B1 IPI00419258 25 kDa 
HNRNPA1 Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1 IPI00215965 39 kDa 
HNRNPA2B1 43 kDa protein IPI00874030 43 kDa 
HNRNPA3 Isoform 1 of Heterogeneous nuclear ribonucleoprotein A3 IPI00419373 40 kDa 
HNRNPAB Isoform 2 of Heterogeneous nuclear ribonucleoprotein A/B IPI00334587 36 kDa 
HNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 IPI00216592 32 kDa 
HNRNPD Isoform 1 of Heterogeneous nuclear ribonucleoprotein D0 IPI00028888 38 kDa 
HNRNPF Heterogeneous nuclear ribonucleoprotein F IPI00003881 46 kDa 
HNRNPH1 Heterogeneous nuclear ribonucleoprotein H IPI00013881 49 kDa 
HNRNPH3 Isoform 1 of Heterogeneous nuclear ribonucleoprotein H3 IPI00013877 37 kDa 
HNRNPK Isoform 1 of Heterogeneous nuclear ribonucleoprotein K IPI00216049 51 kDa 
HNRNPL Heterogeneous nuclear ribonucleoprotein L IPI00027834 64 kDa 
HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M IPI00171903 78 kDa 
HNRNPR Heterogeneous nuclear ribonucleoprotein R IPI00012074 71 kDa 
HNRNPU Isoform Short of Heterogeneous nuclear ribonucleoprotein U IPI00479217 89 kDa 
HNRNPUL1 Isoform 1 of Heterogeneous nuclear ribonucleoprotein U-like 
protein 1 IPI00013070 96 kDa 
HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like protein 2 IPI00456887 85 kDa 
HP1BP3 Isoform 1 of Heterochromatin protein 1-binding protein 3 IPI00642238 61 kDa 
HSD17B10 Isoform 1 of 3-hydroxyacyl-CoA dehydrogenase type-2 IPI00017726 27 kDa 
HSD17B4 Peroxisomal multifunctional enzyme type 2 IPI00019912 80 kDa 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 
isoform 1 IPI00382470 98 kDa 
HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 83 kDa 
HSP90B1 Endoplasmin IPI00027230 92 kDa 
HSPA1B;HSPA1A Heat shock 70 kDa protein 1 IPI00304925 70 kDa 
HSPA4 Heat shock 70 kDa protein 4 IPI00002966 94 kDa 
HSPA5 HSPA5 protein IPI00003362 72 kDa 
HSPA8 Isoform 1 of Heat shock cognate 71 kDa protein IPI00003865 71 kDa 
HSPA9 Stress-70 protein, mitochondrial IPI00007765 74 kDa 
HSPB1 Heat shock protein beta-1 IPI00025512 23 kDa 
HSPD1 60 kDa heat shock protein, mitochondrial IPI00784154 61 kDa 
HSPE1 10 kDa heat shock protein, mitochondrial IPI00220362 11 kDa 
HSPG2 Basement membrane-specific heparan sulfate proteoglycan core 
protein IPI00024284 469 kDa 
227 
 
HUWE1 482 kDa protein IPI00179298 482 kDa 
HYOU1 Hypoxia up-regulated protein 1 IPI00000877 111 kDa 
IARS2 Isoleucyl-tRNA synthetase, mitochondrial IPI00017283 114 kDa 
IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic IPI00027223 47 kDa 
IDH2 Isocitrate dehydrogenase [NADP], mitochondrial IPI00011107 51 kDa 
IDH3A Isoform 1 of Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial IPI00030702 40 kDa 
IGF2BP3 Isoform 1 of Insulin-like growth factor 2 mRNA-binding protein 3 IPI00658000 64 kDa 
IGJ immunoglobulin J chain IPI00178926 18 kDa 
ILF2 Interleukin enhancer-binding factor 2 IPI00005198 43 kDa 
ILF3 Isoform 5 of Interleukin enhancer-binding factor 3 IPI00219330 75 kDa 
IMMT Isoform 1 of Mitochondrial inner membrane protein IPI00009960 84 kDa 
INF2 Isoform 2 of Inverted formin-2 IPI00876962 135 kDa 
IQGAP1 Ras GTPase-activating-like protein IQGAP1 IPI00009342 189 kDa 
IQGAP2 Isoform 1 of Ras GTPase-activating-like protein IQGAP2 IPI00299048 181 kDa 
ISG15 Interferon-induced 17 kDa protein IPI00375631 18 kDa 
ITGA2 Integrin alpha-2 IPI00013744 129 kDa 
ITGA3 Isoform Alpha-3A of Integrin alpha-3 IPI00215995 117 kDa 
ITGAV Isoform 1 of Integrin alpha-V IPI00027505 116 kDa 
ITGB1 Isoform Beta-1C of Integrin beta-1 IPI00217561 92 kDa 
ITGB4 Isoform Beta-4C of Integrin beta-4 IPI00027422 202 kDa 
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 IPI00305461 106 kDa 
ITPR3 Inositol 1,4,5-trisphosphate receptor type 3 IPI00291607 304 kDa 
IVD Isovaleryl-CoA dehydrogenase, mitochondrial IPI00645805 46 kDa 
JUP cDNA FLJ60424, highly similar to Junction plakoglobin IPI00789324 63 kDa 
JUP Junction plakoglobin IPI00554711 82 kDa 
KARS Lysyl-tRNA synthetase IPI00014238 68 kDa 
KCTD12 BTB/POZ domain-containing protein KCTD12 IPI00060715 36 kDa 
KHSRP KH-type splicing regulatory protein IPI00479786 73 kDa 
KIAA0564 Isoform 3 of Uncharacterized protein KIAA0564 IPI00158296 161 kDa 
KIAA1967 Isoform 1 of Protein KIAA1967 IPI00182757 103 kDa 
KIF13B Kinesin-like protein KIF13B IPI00021753 203 kDa 
KIF5B Kinesin-1 heavy chain IPI00012837 110 kDa 
KLC4 Isoform 1 of Kinesin light chain 4 IPI00398812 69 kDa 
KPNB1 Importin subunit beta-1 IPI00001639 97 kDa 
KRT1 Keratin, type II cytoskeletal 1 IPI00220327 66 kDa 
KRT10 Keratin, type I cytoskeletal 10 IPI00009865 60 kDa 
KRT14 Keratin, type I cytoskeletal 14 IPI00384444 52 kDa 
KRT16 Keratin, type I cytoskeletal 16 IPI00217963 51 kDa 
KRT17 Keratin, type I cytoskeletal 17 IPI00450768 48 kDa 
KRT18 Keratin, type I cytoskeletal 18 IPI00554788 48 kDa 
KRT19 Keratin, type I cytoskeletal 19 IPI00479145 44 kDa 
KRT2 Keratin, type II cytoskeletal 2 epidermal IPI00021304 66 kDa 
KRT20 Keratin, type I cytoskeletal 20 IPI00021298 48 kDa 
KRT7 keratin 7 IPI00847342 51 kDa 
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KRT7 Keratin, type II cytoskeletal 7 IPI00306959 51 kDa 
KRT8 Keratin, type II cytoskeletal 8 IPI00554648 54 kDa 
KRT9 Keratin, type I cytoskeletal 9 IPI00019359 62 kDa 
KTN1 Isoform 1 of Kinectin IPI00328753 156 kDa 
LAD1 Ladinin-1 IPI00514234 57 kDa 
LAMA5 Laminin subunit alpha-5 IPI00783665 400 kDa 
LAMB1 Laminin subunit beta-1 IPI00013976 198 kDa 
LAMB2 Laminin subunit beta-2 IPI00296922 196 kDa 
LAMB3 Laminin subunit beta-3 IPI00299404 130 kDa 
LAMC1 Laminin subunit gamma-1 IPI00298281 178 kDa 
LAMC2 Isoform Long of Laminin subunit gamma-2 IPI00015117 131 kDa 
LAP3 Isoform 1 of Cytosol aminopeptidase IPI00419237 56 kDa 
LASP1 Isoform 1 of LIM and SH3 domain protein 1 IPI00000861 30 kDa 
LCP1 Plastin-2 IPI00010471 70 kDa 
LDHA Isoform 1 of L-lactate dehydrogenase A chain IPI00217966 37 kDa 
LDHB L-lactate dehydrogenase B chain IPI00219217 37 kDa 
LETM1 LETM1 and EF-hand domain-containing protein 1, mitochondrial IPI00017592 83 kDa 
LGALS1 Galectin-1 IPI00219219 15 kDa 
LGALS3 Galectin-3 IPI00465431 26 kDa 
LGALS3BP Galectin-3-binding protein IPI00023673 65 kDa 
LGALS4 Galectin-4 IPI00009750 36 kDa 
LGALS9 Isoform Long of Galectin-9 IPI00010477 40 kDa 
LIMA1 Isoform Beta of LIM domain and actin-binding protein 1 IPI00008918 85 kDa 
LMCD1 LIM and cysteine-rich domains protein 1 IPI00303258 41 kDa 
LMNA Isoform A of Lamin-A/C IPI00021405 74 kDa 
LMNB1 Lamin-B1 IPI00217975 66 kDa 
LMNB2 Lamin-B2 IPI00009771 70 kDa 
LMO7 Isoform 3 of LIM domain only protein 7 IPI00291802 154 kDa 
LPP Lipoma-preferred partner IPI00023704 66 kDa 
LRBA Lipopolysaccharide-responsive and beige-like anchor protein IPI00002255 319 kDa 
LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial IPI00783271 158 kDa 
LTBP2 Latent-transforming growth factor beta-binding protein 2 IPI00292150 195 kDa 
LUC7L2 Isoform 1 of Putative RNA-binding protein Luc7-like 2 IPI00006932 47 kDa 
LUM Lumican IPI00020986 38 kDa 
LYPLA1 cDNA FLJ60607, highly similar to Acyl-protein thioesterase 1 IPI00007321 28 kDa 
LYZ Lysozyme C IPI00019038 17 kDa 
MACF1 Microtubule-actin cross-linking factor 1, isoform 4 IPI00432363 670 kDa 
MAGT1 magnesium transporter 1 IPI00301202 42 kDa 
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 IPI00219604 43 kDa 
MAPK1 Mitogen-activated protein kinase 1 IPI00003479 41 kDa 
MAPK3 Mitogen-activated protein kinase 3 IPI00018195 43 kDa 
MARCKS Myristoylated alanine-rich C-kinase substrate IPI00219301 32 kDa 
MAT2A S-adenosylmethionine synthetase isoform type-2 IPI00010157 44 kDa 
MAT2B Isoform 1 of Methionine adenosyltransferase 2 subunit beta IPI00002324 38 kDa 
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MATR3 Matrin-3 IPI00017297 95 kDa 
MDH1 Malate dehydrogenase, cytoplasmic IPI00291005 36 kDa 
MDH2 Malate dehydrogenase, mitochondrial IPI00291006 36 kDa 
MIF;LOC284889 Macrophage migration inhibitory factor IPI00293276 12 kDa 
MLEC Malectin IPI00029046 32 kDa 
MLPH Isoform 1 of Melanophilin IPI00012201 66 kDa 
MMAA MMAA protein IPI00217023 47 kDa 
MPO Isoform H17 of Myeloperoxidase IPI00007244 84 kDa 
MPST 3-mercaptopyruvate sulfurtransferase IPI00165360 33 kDa 
MSN Moesin IPI00219365 68 kDa 
MTCH2 Mitochondrial carrier homolog 2 IPI00003833 33 kDa 
MT-CO2 Cytochrome c oxidase subunit 2 IPI00017510 26 kDa 
MTDH Protein LYRIC IPI00328715 64 kDa 
MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic IPI00218342 102 kDa 
MUC5AC Mucin-5AC (Fragment) IPI00103397 527 kDa 
MUC5B mucin 5, subtype B, tracheobronchial IPI00855918 597 kDa 
MVP Major vault protein IPI00000105 99 kDa 
MYH10 Isoform 1 of Myosin-10 IPI00397526 229 kDa 
MYH11 Myosin-11 IPI00020501 227 kDa 
MYH14 MYH14 variant protein IPI00607818 232 kDa 
MYH9 Isoform 1 of Myosin-9 IPI00019502 227 kDa 
MYL6B;MYL6 Isoform Non-muscle of Myosin light polypeptide 6 IPI00335168 17 kDa 
MYO18A Isoform 2 of Myosin-XVIIIa IPI00334410 196 kDa 
MYO1C Myosin-Ic IPI00010418 118 kDa 
MYO1D Isoform 1 of Myosin-Id IPI00329719 116 kDa 
MYO6 Isoform 2 of Myosin-VI IPI00008455 146 kDa 
MYOF Isoform 1 of Myoferlin IPI00021048 235 kDa 
NAMPT Isoform 1 of Nicotinamide phosphoribosyltransferase IPI00018873 56 kDa 
NAP1L4 cDNA FLJ59403, highly similar to Nucleosome assembly protein 1-
like 4 IPI00017763 44 kDa 
NAPRT1 Isoform 3 of Nicotinate phosphoribosyltransferase IPI00880164 56 kDa 
NARS Asparaginyl-tRNA synthetase, cytoplasmic IPI00306960 63 kDa 
NDRG1 Protein NDRG1 IPI00022078 43 kDa 
NDUFS1 cDNA FLJ55978, highly similar to NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial IPI00604664 81 kDa 
NDUFS2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial IPI00025239 53 kDa 
NDUFV1 Isoform 1 of NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial IPI00028520 51 kDa 
NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 
isoform b IPI00807463 97 kDa 
NID2 Nidogen-2 IPI00028908 151 kDa 
NME2 Nucleoside diphosphate kinase IPI00604590 33 kDa 
NME3 Nucleoside diphosphate kinase 3 IPI00012315 19 kDa 
NNT NAD(P) transhydrogenase, mitochondrial IPI00337541 114 kDa 
NONO Non-POU domain-containing octamer-binding protein IPI00304596 54 kDa 
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NOP5/NOP58 Nucleolar protein 5 IPI00006379 60 kDa 
NP cDNA FLJ25678 fis, clone TST04067, highly similar to PURINE 
NUCLEOSIDE PHOSPHORYLASE IPI00017672 33 kDa 
NPEPPS Puromycin-sensitive aminopeptidase IPI00026216 103 kDa 
NPM1 Isoform 2 of Nucleophosmin IPI00220740 29 kDa 
NQO1 NAD(P)H dehydrogenase [quinone] 1 IPI00012069 31 kDa 
NSF Vesicle-fusing ATPase IPI00006451 83 kDa 
NSFL1C Isoform 2 of NSFL1 cofactor p47 IPI00022830 37 kDa 
NUCB1 Nucleobindin-1 IPI00295542 54 kDa 
NUDT21 Cleavage and polyadenylation specificity factor subunit 5 IPI00646917 26 kDa 
NUMA1 Isoform 2 of Nuclear mitotic apparatus protein 1 IPI00006196 237 kDa 
NUP93 Nuclear pore complex protein Nup93 IPI00397904 93 kDa 
OAS3 2'-5'-oligoadenylate synthetase 3 IPI00002405 121 kDa 
OGDH 2-oxoglutarate dehydrogenase E1 component, mitochondrial IPI00098902 116 kDa 
OGN cDNA FLJ59205, highly similar to Mimecan IPI00025465 41 kDa 
OLA1 Isoform 1 of Obg-like ATPase 1 IPI00290416 45 kDa 
OLFM4 Olfactomedin-4 IPI00022255 57 kDa 
OSBP Isoform 1 of Oxysterol-binding protein 1 IPI00024971 89 kDa 
OSTF1 Osteoclast-stimulating factor 1 IPI00414836 24 kDa 
OTUB1 cDNA FLJ56307, highly similar to Ubiquitin thioesterase protein 
OTUB1 IPI00000581 35 kDa 
P4HB Protein disulfide-isomerase IPI00010796 57 kDa 
PA2G4 Proliferation-associated protein 2G4 IPI00299000 44 kDa 
PABPC1 Isoform 1 of Polyadenylate-binding protein 1 IPI00008524 71 kDa 
PACSIN2 Isoform 1 of Protein kinase C and casein kinase substrate in 
neurons protein 2 IPI00027009 56 kDa 
PAFAH1B2 Platelet-activating factor acetylhydrolase IB subunit beta IPI00026546 26 kDa 
PAFAH1B3 Platelet-activating factor acetylhydrolase IB subunit gamma IPI00014808 26 kDa 
PARK7 Protein DJ-1 IPI00298547 20 kDa 
PARP1 Poly [ADP-ribose] polymerase 1 IPI00449049 113 kDa 
PARP4 Poly [ADP-ribose] polymerase 4 IPI00296909 193 kDa 
PCBP1 Poly(rC)-binding protein 1 IPI00016610 37 kDa 
PCBP2 poly(rC) binding protein 2 isoform b IPI00012066 38 kDa 
PCK2 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial IPI00294380 71 kDa 
PCMT1 Isoform 1 of Protein-L-isoaspartate(D-aspartate) O-
methyltransferase IPI00411680 25 kDa 
PCNP Isoform 2 of PEST proteolytic signal-containing nuclear protein IPI00060650 14 kDa 
PCYOX1 Prenylcysteine oxidase 1 IPI00384280 57 kDa 
PDCD6 Programmed cell death protein 6 IPI00025277 22 kDa 
PDCD6IP PDCD6IP protein IPI00246058 97 kDa 
PDHA1 Mitochondrial PDHA1 IPI00306301 48 kDa 
PDHB Isoform 1 of Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial IPI00003925 39 kDa 
PDIA3 Protein disulfide-isomerase A3 IPI00025252 57 kDa 
PDIA4 Protein disulfide-isomerase A4 IPI00009904 73 kDa 
PDIA6 Isoform 2 of Protein disulfide-isomerase A6 IPI00299571 54 kDa 
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PDLIM5 PDZ and LIM domain protein 5 IPI00007935 64 kDa 
PDXDC1 Isoform 1 of Pyridoxal-dependent decarboxylase domain-containing 
protein 1 IPI00384689 87 kDa 
PEA15 Astrocytic phosphoprotein PEA-15 IPI00014850 15 kDa 
PEBP1 Phosphatidylethanolamine-binding protein 1 IPI00219446 21 kDa 
PFDN2 Prefoldin subunit 2 IPI00006052 17 kDa 
PFKFB2 Isoform 2 of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 IPI00220808 54 kDa 
PFKL Isoform 1 of 6-phosphofructokinase, liver type IPI00332371 85 kDa 
PFKM cDNA FLJ44241 fis, clone THYMU3008436, highly similar to 6-
phosphofructokinase, muscle type IPI00465179 93 kDa 
PFKP 6-phosphofructokinase type C IPI00009790 86 kDa 
PFN1 Profilin-1 IPI00216691 15 kDa 
PGD 6-phosphogluconate dehydrogenase, decarboxylating IPI00219525 53 kDa 
PGK1 Phosphoglycerate kinase 1 IPI00169383 45 kDa 
PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 61 kDa 
PGM2 Phosphoglucomutase-2 IPI00550364 68 kDa 
PHB Prohibitin IPI00017334 30 kDa 
PHB2 Prohibitin-2 IPI00027252 33 kDa 
PKM2 Isoform M1 of Pyruvate kinase isozymes M1/M2 IPI00220644 58 kDa 
PKP2 plakophilin 2 isoform 2a IPI00847318 93 kDa 
PKP3 Plakophilin-3 IPI00026952 87 kDa 
PLEC1 Isoform 4 of Plectin-1 IPI00398779 516 kDa 
PLS1 Plastin-1 IPI00032304 70 kDa 
PLS3 plastin 3 IPI00216694 71 kDa 
PML Isoform PML-1 of Probable transcription factor PML IPI00022348 98 kDa 
PNN Isoform 1 of Pinin IPI00789041 82 kDa 
POF1B Isoform 1 of Protein POF1B IPI00103242 69 kDa 
POLR2B DNA-directed RNA polymerase II subunit RPB2 IPI00027808 134 kDa 
PON2 39 kDa protein IPI00844348 39 kDa 
POR NADPH--cytochrome P450 reductase IPI00470467 77 kDa 
POSTN Isoform 1 of Periostin IPI00007960 93 kDa 
PPA1 Inorganic pyrophosphatase IPI00015018 33 kDa 
PPIA Peptidyl-prolyl cis-trans isomerase A IPI00419585 18 kDa 
PPIB Peptidyl-prolyl cis-trans isomerase B IPI00646304 24 kDa 
PPL Periplakin IPI00298057 205 kDa 
PPP1CB Serine/threonine-protein phosphatase PP1-beta catalytic subunit IPI00218236 37 kDa 
PPP1R12A Isoform 1 of Protein phosphatase 1 regulatory subunit 12A IPI00183002 115 kDa 
PPP1R7 Isoform 1 of Protein phosphatase 1 regulatory subunit 7 IPI00033600 42 kDa 
PPP2CA Serine/threonine-protein phosphatase 2A catalytic subunit alpha 
isoform IPI00008380 36 kDa 
PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform IPI00554737 65 kDa 
PRDX1 Peroxiredoxin-1 IPI00000874 22 kDa 
PRDX2 Peroxiredoxin-2 IPI00027350 22 kDa 
PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial IPI00024919 28 kDa 
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PRDX4 Peroxiredoxin-4 IPI00011937 31 kDa 
PRDX5 Isoform Mitochondrial of Peroxiredoxin-5, mitochondrial IPI00024915 22 kDa 
PRDX6 Peroxiredoxin-6 IPI00220301 25 kDa 
PRELP Prolargin IPI00020987 44 kDa 
PRKAR1A cAMP-dependent protein kinase type I-alpha regulatory subunit IPI00021831 43 kDa 
PRKAR2A Protein kinase, cAMP-dependent, regulatory, type II, alpha, 
isoform CRA_b IPI00063234 43 kDa 
PRKCSH cDNA FLJ59211, highly similar to Glucosidase 2 subunit beta IPI00026154 60 kDa 
PRKDC Isoform 1 of DNA-dependent protein kinase catalytic subunit IPI00296337 469 kDa 
PRPF8 Pre-mRNA-processing-splicing factor 8 IPI00007928 274 kDa 
PRSS1 Trypsin-1 IPI00011694 27 kDa 
PSAP Isoform Sap-mu-0 of Proactivator polypeptide IPI00012503 58 kDa 
PSMA1 Isoform Short of Proteasome subunit alpha type-1 IPI00016832 30 kDa 
PSMA3 Isoform 2 of Proteasome subunit alpha type-3 IPI00171199 28 kDa 
PSMA5 Proteasome subunit alpha type-5 IPI00291922 26 kDa 
PSMA7 Isoform 1 of Proteasome subunit alpha type-7 IPI00024175 28 kDa 
PSMB1 Proteasome subunit beta type-1 IPI00025019 26 kDa 
PSMB6 Proteasome subunit beta type-6 IPI00000811 25 kDa 
PSMB8 Isoform 2 of Proteasome subunit beta type-8 IPI00215824 30 kDa 
PSMB9 Isoform LMP2.L of Proteasome subunit beta type-9 IPI00000787 23 kDa 
PSMC1 26S protease regulatory subunit 4 IPI00011126 49 kDa 
PSMC2 26S protease regulatory subunit 7 IPI00021435 49 kDa 
PSMC3 26S protease regulatory subunit 6A IPI00018398 49 kDa 
PSMC5 26S protease regulatory subunit 8 IPI00023919 46 kDa 
PSMD11 Proteasome 26S non-ATPase subunit 11 variant (Fragment) IPI00105598 48 kDa 
PSMD2 26S proteasome non-ATPase regulatory subunit 2 IPI00012268 100 kDa 
PSMD3 26S proteasome non-ATPase regulatory subunit 3 IPI00011603 61 kDa 
PSMD6 26S proteasome non-ATPase regulatory subunit 6 IPI00014151 46 kDa 
PSME1 Proteasome activator complex subunit 1 IPI00479722 29 kDa 
PSME2 Putative uncharacterized protein PSME2 IPI00384051 29 kDa 
PSPC1 Isoform 1 of Paraspeckle component 1 IPI00103525 59 kDa 
PTBP1 Isoform 1 of Polypyrimidine tract-binding protein 1 IPI00179964 57 kDa 
PTPLAD1 Protein tyrosine phosphatase-like protein PTPLAD1 IPI00008998 43 kDa 
PTPN6 Isoform 1 of Tyrosine-protein phosphatase non-receptor type 6 IPI00218604 68 kDa 
PTRF Isoform 1 of Polymerase I and transcript release factor IPI00176903 43 kDa 
PYGB Glycogen phosphorylase, brain form IPI00004358 97 kDa 
QARS Glutaminyl-tRNA synthetase IPI00026665 90 kDa 
QSOX1 Isoform 1 of Sulfhydryl oxidase 1 IPI00003590 83 kDa 
RAB10 Ras-related protein Rab-10 IPI00016513 23 kDa 
RAB11B Ras-related protein Rab-11B IPI00020436 24 kDa 
RAB14 Ras-related protein Rab-14 IPI00291928 24 kDa 
RAB1B Ras-related protein Rab-1B IPI00008964 22 kDa 
RAB2A Ras-related protein Rab-2A IPI00031169 24 kDa 
RAB5C Ras-related protein Rab-5C IPI00016339 23 kDa 
RAB7A Ras-related protein Rab-7a IPI00016342 23 kDa 
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RAC1 Isoform A of Ras-related C3 botulinum toxin substrate 1 IPI00010271 21 kDa 
RALY RNA binding protein, autoantigenic (HnRNP-associated with lethal 
yellow homolog (Mouse)), isoform CRA_a (Fragment) IPI00011268 33 kDa 
RAN GTP-binding nuclear protein Ran IPI00643041 24 kDa 
RAP1B Ras-related protein Rap-1b IPI00015148 21 kDa 
RBBP4 Histone-binding protein RBBP4 IPI00328319 48 kDa 
RBM14 Isoform 1 of RNA-binding protein 14 IPI00013174 69 kDa 
RBM25 RNA binding motif protein 25 IPI00004273 100 kDa 
RBMX Heterogeneous nuclear ribonucleoprotein G IPI00304692 42 kDa 
RBP1 retinol binding protein 1, cellular isoform a IPI00219718 22 kDa 
RCC1 regulator of chromosome condensation 1 isoform a IPI00001661 48 kDa 
RCN1 Reticulocalbin-1 IPI00015842 39 kDa 
RELA RELA protein IPI00883897 43 kDa 
RNPEP Aminopeptidase B IPI00642211 73 kDa 
RPA1 Replication protein A 70 kDa DNA-binding subunit IPI00020127 68 kDa 
RPL10 60S ribosomal protein L10 IPI00554723 25 kDa 
RPL10A 60S ribosomal protein L10a IPI00412579 25 kDa 
RPL11 Isoform 1 of 60S ribosomal protein L11 IPI00376798 20 kDa 
RPL13 60S ribosomal protein L13 IPI00465361 24 kDa 
RPL15 60S ribosomal protein L15 IPI00470528 24 kDa 
RPL18 60S ribosomal protein L18 IPI00215719 22 kDa 
RPL23A;hCG_16001 60S ribosomal protein L23a IPI00021266 18 kDa 
RPL27 60S ribosomal protein L27 IPI00219155 16 kDa 
RPL28 60S ribosomal protein L28 IPI00182533 16 kDa 
RPL3 60S ribosomal protein L3 IPI00550021 46 kDa 
RPL35A 60S ribosomal protein L35a IPI00029731 13 kDa 
RPL4 60S ribosomal protein L4 IPI00003918 48 kDa 
RPL5 60S ribosomal protein L5 IPI00000494 34 kDa 
RPL6 60S ribosomal protein L6 IPI00329389 33 kDa 
RPL8 60S ribosomal protein L8 IPI00012772 28 kDa 
RPLP0 60S acidic ribosomal protein P0 IPI00008530 34 kDa 
RPLP2 60S acidic ribosomal protein P2 IPI00008529 12 kDa 
RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa 
subunit precursor IPI00025874 73 kDa 
RPN2 Ribophorin II IPI00028635 71 kDa 
RPS12 40S ribosomal protein S12 IPI00013917 15 kDa 
RPS13 40S ribosomal protein S13 IPI00221089 17 kDa 
RPS14 40S ribosomal protein S14 IPI00026271 16 kDa 
RPS15A 40S ribosomal protein S15a IPI00221091 15 kDa 
RPS16 40S ribosomal protein S16 IPI00221092 16 kDa 
RPS18;LOC100130553 40S ribosomal protein S18 IPI00013296 18 kDa 
RPS19 40S ribosomal protein S19 IPI00215780 16 kDa 
RPS2 40S ribosomal protein S2 IPI00013485 31 kDa 
RPS20 40S ribosomal protein S20 IPI00012493 13 kDa 
RPS21 40S ribosomal protein S21 IPI00017448 9 kDa 
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RPS25 40S ribosomal protein S25 IPI00012750 14 kDa 
RPS26 Ribosomal protein 26 (RPS26) pseudogene IPI00186712 13 kDa 
RPS28 40S ribosomal protein S28 IPI00719622 8 kDa 
RPS3 40S ribosomal protein S3 IPI00011253 27 kDa 
RPS3A 40S ribosomal protein S3a IPI00419880 30 kDa 
RPS4X 40S ribosomal protein S4, X isoform IPI00217030 30 kDa 
RPS6 40S ribosomal protein S6 IPI00021840 29 kDa 
RPS8 40S ribosomal protein S8 IPI00216587 24 kDa 
RPS9 40S ribosomal protein S9 IPI00221088 23 kDa 
RPSA 33 kDa protein IPI00413108 33 kDa 
RTN4 Isoform 1 of Reticulon-4 IPI00021766 130 kDa 
RUVBL2 RuvB-like 2 IPI00009104 51 kDa 
S100A10 Protein S100-A10 IPI00183695 11 kDa 
S100A11 Protein S100-A11 IPI00013895 12 kDa 
S100A16 Protein S100-A16 IPI00062120 12 kDa 
S100A4 Protein S100-A4 IPI00032313 12 kDa 
S100A6 Protein S100-A6 IPI00027463 10 kDa 
S100A8 Protein S100-A8 IPI00007047 11 kDa 
S100A9 Protein S100-A9 IPI00027462 13 kDa 
S100P Protein S100-P IPI00017526 10 kDa 
SAMHD1 SAM domain and HD domain-containing protein 1 IPI00294739 72 kDa 
SCCPDH Probable saccharopine dehydrogenase IPI00329600 47 kDa 
SCP2 Isoform SCPx of Non-specific lipid-transfer protein IPI00026105 59 kDa 
SDCBP2 Isoform 1 of Syntenin-2 IPI00302318 32 kDa 
SEC16A Isoform 5 of Protein transport protein Sec16A IPI00031242 236 kDa 
SEC22B Vesicle-trafficking protein SEC22b IPI00006865 25 kDa 
SEC23A Protein transport protein Sec23A IPI00017375 86 kDa 
SEC31A Isoform 3 of Protein transport protein Sec31A IPI00305152 122 kDa 
SELENBP1 cDNA FLJ55757, highly similar to Selenium-binding protein 1 IPI00012303 57 kDa 
SEPT2 Septin-2 IPI00014177 41 kDa 
SEPT7 Isoform 1 of Septin-7 IPI00033025 51 kDa 
SEPT9 septin 9 isoform a IPI00784614 65 kDa 
SERBP1 Isoform 1 of Plasminogen activator inhibitor 1 RNA-binding protein IPI00410693 45 kDa 
SERPINA1 Isoform 1 of Alpha-1-antitrypsin IPI00553177 47 kDa 
SERPINA3 cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-
ANTICHYMOTRYPSIN IPI00550991 51 kDa 
SERPINB1 Leukocyte elastase inhibitor IPI00027444 43 kDa 
SERPINB5 Serpin B5 IPI00783625 42 kDa 
SERPINB6 Putative uncharacterized protein DKFZp686I04222 IPI00413451 46 kDa 
SERPINH1 Serpin H1 IPI00032140 46 kDa 
SET Isoform 1 of Protein SET IPI00072377 33 kDa 
SF3A1 Splicing factor 3 subunit 1 IPI00017451 89 kDa 
SF3B1 Splicing factor 3B subunit 1 IPI00026089 146 kDa 
SF3B2 splicing factor 3B subunit 2 IPI00221106 100 kDa 
SF3B3 Isoform 1 of Splicing factor 3B subunit 3 IPI00300371 136 kDa 
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SFN Isoform 1 of 14-3-3 protein sigma IPI00013890 28 kDa 
SFPQ Isoform Long of Splicing factor, proline- and glutamine-rich IPI00010740 76 kDa 
SFRS1 Isoform ASF-1 of Splicing factor, arginine/serine-rich 1 IPI00215884 28 kDa 
SFRS2 Splicing factor, arginine/serine-rich 2 IPI00005978 25 kDa 
SFRS6 Isoform SRP55-3 of Splicing factor, arginine/serine-rich 6 IPI00215879 38 kDa 
SFXN3 sideroflexin 3 IPI00793874 36 kDa 
SH3BGRL SH3 domain-binding glutamic acid-rich-like protein IPI00025318 13 kDa 
SHMT2 Serine hydroxymethyltransferase, mitochondrial IPI00002520 56 kDa 
SLC12A2 Isoform 1 of Solute carrier family 12 member 2 IPI00022649 131 kDa 
SLC25A24 Isoform 1 of Calcium-binding mitochondrial carrier protein 
SCaMC-1 IPI00337494 53 kDa 
SLC25A3 Isoform A of Phosphate carrier protein, mitochondrial IPI00022202 40 kDa 
SLC25A5 ADP/ATP translocase 2 IPI00007188 33 kDa 
SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 IPI00220194 54 kDa 
SLC9A3R1 Ezrin-radixin-moesin-binding phosphoprotein 50 IPI00003527 39 kDa 
SMC1A Structural maintenance of chromosomes protein 1A IPI00291939 143 kDa 
SNCG Gamma-synuclein IPI00297714 13 kDa 
SND1 Staphylococcal nuclease domain-containing protein 1 IPI00140420 102 kDa 
SNRNP200 Isoform 1 of U5 small nuclear ribonucleoprotein 200 kDa helicase IPI00420014 245 kDa 
SNRNP70 Isoform 2 of U1 small nuclear ribonucleoprotein 70 kDa IPI00219483 51 kDa 
SNRPB Isoform SM-B' of Small nuclear ribonucleoprotein-associated proteins 
B and B' IPI00027285 25 kDa 
SNRPD1 Small nuclear ribonucleoprotein Sm D1 IPI00302850 13 kDa 
SNRPD3 Small nuclear ribonucleoprotein Sm D3 IPI00017964 14 kDa 
SNX27 Isoform 2 of Sorting nexin-27 IPI00640980 60 kDa 
SORBS1 Isoform 9 of Sorbin and SH3 domain-containing protein 1 IPI00002491 87 kDa 
SORD Sorbitol dehydrogenase IPI00216057 38 kDa 
SPR Sepiapterin reductase IPI00017469 28 kDa 
SPTAN1 Isoform 1 of Spectrin alpha chain, brain IPI00844215 285 kDa 
SPTBN1 Isoform Long of Spectrin beta chain, brain 1 IPI00005614 275 kDa 
SQRDL Sulfide:quinone oxidoreductase, mitochondrial IPI00009634 50 kDa 
SRC Isoform 2 of Proto-oncogene tyrosine-protein kinase Src IPI00328867 61 kDa 
SRI Sorcin IPI00027175 22 kDa 
SRRM2 Isoform 1 of Serine/arginine repetitive matrix protein 2 IPI00782992 300 kDa 
SSB Lupus La protein IPI00009032 47 kDa 
SSR4 Translocon-associated protein subunit delta precursor IPI00019385 20 kDa 
STAT1 Isoform Alpha of Signal transducer and activator of transcription 1-
alpha/beta IPI00030781 87 kDa 
STAT6 Isoform 1 of Signal transducer and activator of transcription 6 IPI00030782 94 kDa 
STIM1 Stromal interaction molecule 1 IPI00299063 77 kDa 
STIP1 Stress-induced-phosphoprotein 1 IPI00013894 63 kDa 
STOM Erythrocyte band 7 integral membrane protein IPI00219682 32 kDa 
STOML2 Stomatin-like protein 2 IPI00334190 39 kDa 
STT3A Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit STT3A IPI00297492 81 kDa 
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SUB1 Activated RNA polymerase II transcriptional coactivator p15 IPI00221222 14 kDa 
SUPT16H FACT complex subunit SPT16 IPI00026970 120 kDa 
SYNCRIP Isoform 1 of Heterogeneous nuclear ribonucleoprotein Q IPI00018140 70 kDa 
TAGLN Transgelin IPI00216138 23 kDa 
TAGLN2 Transgelin-2 IPI00550363 22 kDa 
TALDO1 Transaldolase IPI00744692 38 kDa 
TAP2 Antigen peptide transporter 2 IPI00328112 76 kDa 
TCP1 T-complex protein 1 subunit alpha IPI00290566 60 kDa 
TF Serotransferrin IPI00022463 77 kDa 
TGFBI Transforming growth factor-beta-induced protein ig-h3 IPI00018219 75 kDa 
TGM2 Isoform 1 of Protein-glutamine gamma-glutamyltransferase 2 IPI00294578 77 kDa 
THBS1 Thrombospondin-1 IPI00296099 129 kDa 
THRAP3 Thyroid hormone receptor-associated protein 3 IPI00104050 109 kDa 
TJP1 Isoform Long of Tight junction protein ZO-1 IPI00216219 195 kDa 
TJP2 Isoform A1 of Tight junction protein ZO-2 IPI00003843 134 kDa 
TJP3 TJP3 protein IPI00744036 105 kDa 
TKT cDNA FLJ54957, highly similar to Transketolase IPI00643920 69 kDa 
TLN1 Talin-1 IPI00298994 270 kDa 
TMED10 Transmembrane emp24 domain-containing protein 10 IPI00028055 25 kDa 
TMED2 Transmembrane emp24 domain-containing protein 2 IPI00016608 23 kDa 
TMED4 Isoform 1 of Transmembrane emp24 domain-containing protein 4 IPI00296259 26 kDa 
TMEM43 Transmembrane protein 43 IPI00301280 45 kDa 
TMEM63A Transmembrane protein 63A IPI00006006 92 kDa 
TMOD3 Tropomodulin-3 IPI00005087 40 kDa 
TMPO Isoform Beta of Lamina-associated polypeptide 2, isoforms 
beta/gamma IPI00030131 51 kDa 
TMSB4X Thymosin beta-4 IPI00220828 5 kDa 
TNC Isoform 1 of Tenascin IPI00031008 241 kDa 
TNKS1BP1 Isoform 1 of 182 kDa tankyrase 1-binding protein IPI00304589 182 kDa 
TNS1 Tensin-1 IPI00307545 186 kDa 
TNXB Isoform XB of Tenascin-X IPI00025276 464 kDa 
TOR1AIP1 Similar to Torsin-1A-interacting protein 1 IPI00644766 48 kDa 
TPD52L2 Isoform 2 of Tumor protein D54 IPI00221178 20 kDa 
TPM1 Isoform 3 of Tropomyosin alpha-1 chain IPI00216135 33 kDa 
TPM1 tropomyosin 1 alpha chain isoform 7 IPI00216134 29 kDa 
TPM2 Isoform 2 of Tropomyosin beta chain IPI00220709 33 kDa 
TPM3 Isoform 2 of Tropomyosin alpha-3 chain IPI00218319 29 kDa 
TPM4 Isoform 1 of Tropomyosin alpha-4 chain IPI00010779 29 kDa 
TPM4 Isoform 2 of Tropomyosin alpha-4 chain IPI00216975 33 kDa 
TPP2 Tripeptidyl-peptidase 2 IPI00020416 138 kDa 
TPR Nucleoprotein TPR IPI00742682 267 kDa 
TRAP1 Heat shock protein 75 kDa, mitochondrial IPI00030275 80 kDa 
TRIM25 Tripartite motif-containing protein 25 IPI00029629 71 kDa 
TRIM28 Isoform 1 of Transcription intermediary factor 1-beta IPI00438229 89 kDa 
TRIM29 Isoform Alpha of Tripartite motif-containing protein 29 IPI00073096 66 kDa 
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TSN Translin IPI00018768 26 kDa 
TST Thiosulfate sulfurtransferase IPI00216293 33 kDa 
TSTA3 GDP-L-fucose synthetase IPI00014361 36 kDa 
TTC38 Tetratricopeptide repeat protein 38 IPI00550644 53 kDa 
TTLL3;ARPC4 Actin-related protein 2/3 complex subunit 4 IPI00554811 20 kDa 
TTN Isoform 2 of Titin IPI00023283 
3806 
kDa 
TUBA4A Tubulin alpha-4A chain IPI00007750 50 kDa 
TUBB Tubulin beta chain IPI00011654 50 kDa 
TUBB2A Tubulin beta-2A chain IPI00013475 50 kDa 
TUBB2C Tubulin beta-2C chain IPI00007752 50 kDa 
TUFM Tu translation elongation factor, mitochondrial precursor IPI00027107 50 kDa 
TXNDC5 Thioredoxin domain-containing protein 5 IPI00171438 48 kDa 
TXNL1 Thioredoxin-like protein 1 IPI00305692 32 kDa 
TXNRD1 Isoform 5 of Thioredoxin reductase 1, cytoplasmic IPI00554786 55 kDa 
TYMP Thymidine phosphorylase IPI00292858 50 kDa 
UBA1 Ubiquitin-like modifier-activating enzyme 1 IPI00645078 118 kDa 
UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 
IPI00179330 
(+22) 18 kDa 
UBR4 Isoform 4 of E3 ubiquitin-protein ligase UBR4 IPI00640981 574 kDa 
UCHL3 Ubiquitin carboxyl-terminal hydrolase isozyme L3 IPI00011250 26 kDa 
UGDH UDP-glucose 6-dehydrogenase IPI00031420 55 kDa 
UGP2 Isoform 1 of UTP--glucose-1-phosphate uridylyltransferase IPI00329331 57 kDa 
UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial IPI00013847 53 kDa 
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial IPI00305383 48 kDa 
UQCRFS1 Cytochrome b-c1 complex subunit Rieske, mitochondrial IPI00026964 30 kDa 
USO1 Putative uncharacterized protein DKFZp451D234 IPI00031583 109 kDa 
USP14 Ubiquitin carboxyl-terminal hydrolase 14 IPI00219913 56 kDa 
VAPA Vesicle-associated membrane protein-associated protein A IPI00170692 28 kDa 
VARS Valyl-tRNA synthetase IPI00000873 140 kDa 
VASP Vasodilator-stimulated phosphoprotein IPI00301058 40 kDa 
VAT1 Synaptic vesicle membrane protein VAT-1 homolog IPI00156689 42 kDa 
VCAN Isoform V0 of Versican core protein IPI00009802 373 kDa 
VCL Isoform 1 of Vinculin IPI00291175 117 kDa 
VCP Transitional endoplasmic reticulum ATPase IPI00022774 89 kDa 
VDAC1 Voltage-dependent anion-selective channel protein 1 IPI00216308 31 kDa 
VIL1 Villin-1 IPI00218852 93 kDa 
VILL Isoform 2 of Villin-like protein IPI00215851 94 kDa 
VIM Vimentin IPI00418471 54 kDa 
VPS26A Vacuolar protein sorting-associated protein 26A IPI00411426 38 kDa 
VPS35 Vacuolar protein sorting-associated protein 35 IPI00018931 92 kDa 
VTN Vitronectin IPI00298971 54 kDa 
VWA5A Isoform 1 of Loss of heterozygosity 11 chromosomal region 2 gene A 
protein IPI00005609 86 kDa 
WDR1 Isoform 2 of WD repeat-containing protein 1 IPI00216256 58 kDa 
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WIBG Isoform 1 of Protein wibg homolog IPI00305092 23 kDa 
XPO1 Exportin-1 IPI00298961 123 kDa 
XPO7 Exportin-7 IPI00302458 124 kDa 
XRCC5 ATP-dependent DNA helicase 2 subunit 2 IPI00220834 83 kDa 
XRCC6 ATP-dependent DNA helicase 2 subunit 1 IPI00644712 70 kDa 
YBX1 Nuclease-sensitive element-binding protein 1 IPI00031812 36 kDa 
YWHAB Isoform Long of 14-3-3 protein beta/alpha IPI00216318 28 kDa 
YWHAE 14-3-3 protein epsilon IPI00000816 29 kDa 
YWHAG 14-3-3 protein gamma IPI00220642 28 kDa 
YWHAH 14-3-3 protein eta IPI00216319 28 kDa 
YWHAQ 14-3-3 protein theta IPI00018146 28 kDa 
YWHAZ 14-3-3 protein zeta/delta IPI00021263 28 kDa 
ZNF185 Isoform 1 of Zinc finger protein 185 IPI00005688 49 kDa 
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Appendix II 
 
Appendix II tabulates the comparison of the 854 proteome with previous published 
proteomic studies on pancreatic juice, blood and urine, and shows those proteins 
common to all studies analysed. This comparison was performed using the 
Pancreatic Expression Database (http://www.pancreaticexpression.org) (188). 
 
Emsembl Gene ID Ensembl Protein ID HNGC Symbol 
ENSG00000121410 ENSP00000263100 A1BG 
ENSG00000175899 ENSP00000323929 A2M 
ENSG00000114779 ENSP00000378455 ABHD14B 
ENSG00000072778 ENSP00000349297 ACADVL 
ENSG00000075239 ENSP00000265838 ACAT1 
ENSG00000100412 ENSP00000216254 ACO2 
ENSG00000075624 ENSP00000349960 ACTB 
ENSG00000072110 ENSP00000193403 ACTN1 
ENSG00000130402 ENSP00000252699 ACTN4 
ENSG00000138071 ENSP00000260641 ACTR2 
ENSG00000115091 ENSP00000263238 ACTR3 
ENSG00000106624 ENSP00000223357 AEBP1 
ENSG00000124942 ENSP00000367263 AHNAK 
ENSG00000063438 ENSP00000264933 AHRR 
ENSG00000117448 ENSP00000397013 AKR1A1 
ENSG00000198074 ENSP00000352584 AKR1B10 
ENSG00000162482 ENSP00000355377 AKR7A3 
ENSG00000163631 ENSP00000295897 ALB 
ENSG00000165092 ENSP00000297785 ALDH1A1 
ENSG00000149925 ENSP00000400452 ALDOA 
ENSG00000135046 ENSP00000366109 ANXA1 
ENSG00000182718 ENSP00000387545 ANXA2 
ENSG00000138772 ENSP00000264908 ANXA3 
ENSG00000196975 ENSP00000377833 ANXA4 
ENSG00000164111 ENSP00000296511 ANXA5 
ENSG00000118137 ENSP00000236850 APOA1 
ENSG00000198931 ENSP00000367615 APRT 
ENSG00000130429 ENSP00000389631 ARPC1B 
ENSG00000138363 ENSP00000236959 ATIC 
ENSG00000152234 ENSP00000282050 ATP5A1 
ENSG00000110955 ENSP00000262030 ATP5B 
ENSG00000166710 ENSP00000340858 B2M 
ENSG00000182492 ENSP00000327336 BGN 
ENSG00000090013 ENSP00000263368 BLVRB 
ENSG00000100220 ENSP00000216038 C22orf28 
ENSG00000125730 ENSP00000245907 C3 
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ENSG00000104267 ENSP00000285379 CA2 
ENSG00000198668 ENSP00000349467 CALM1 
ENSG00000143933 ENSP00000272298 CALM2 
ENSG00000160014 ENSP00000291295 CALM3 
ENSG00000179218 ENSP00000320866 CALR 
ENSG00000127022 ENSP00000394817 CANX 
ENSG00000131236 ENSP00000361883 CAP1 
ENSG00000042493 ENSP00000386315 CAPG 
ENSG00000116489 ENSP00000263168 CAPZA1 
ENSG00000121691 ENSP00000241052 CAT 
ENSG00000159228 ENSP00000290349 CBR1 
ENSG00000166226 ENSP00000299300 CCT2 
ENSG00000150753 ENSP00000280326 CCT5 
ENSG00000146731 ENSP00000275603 CCT6A 
ENSG00000135624 ENSP00000258091 CCT7 
ENSG00000105388 ENSP00000402431 CEACAM5 
ENSG00000172757 ENSP00000309629 CFL1 
ENSG00000230685 ENSP00000409979 CLIC1 
ENSG00000187955 ENSP00000297848 COL14A1 
ENSG00000134871 ENSP00000353654 COL4A2 
ENSG00000142156 ENSP00000355180 COL6A1 
ENSG00000142173 ENSP00000300527 COL6A2 
ENSG00000163359 ENSP00000295550 COL6A3 
ENSG00000047457 ENSP00000264613 CP 
ENSG00000116791 ENSP00000339399 CRYZ 
ENSG00000117984 ENSP00000384947 CTSD 
ENSG00000100448 ENSP00000216336 CTSG 
ENSG00000100243 ENSP00000379603 CYB5R3 
ENSG00000011465 ENSP00000376862 DCN 
ENSG00000153904 ENSP00000284031 DDAH1 
ENSG00000206395 ENSP00000382936 DDAH2 
ENSG00000091140 ENSP00000205402 DLD 
ENSG00000187908 ENSP00000342210 DMBT1 
ENSG00000132002 ENSP00000254322 DNAJB1 
ENSG00000092964 ENSP00000309539 DPYSL2 
ENSG00000104823 ENSP00000221418 ECH1 
ENSG00000127884 ENSP00000357535 ECHS1 
ENSG00000104529 ENSP00000317399 EEF1D 
ENSG00000167658 ENSP00000307940 EEF2 
ENSG00000084623 ENSP00000362688 EIF3I 
ENSG00000143924 ENSP00000320663 EML4 
ENSG00000074800 ENSP00000234590 ENO1 
ENSG00000136628 ENSP00000355890 EPRS 
ENSG00000166147 ENSP00000325527 FBN1 
ENSG00000165140 ENSP00000364475 FBP1 
ENSG00000171560 ENSP00000306361 FGA 
ENSG00000171564 ENSP00000306099 FGB 
ENSG00000171557 ENSP00000336829 FGG 
ENSG00000091483 ENSP00000355518 FH 
ENSG00000136068 ENSP00000295956 FLNB 
ENSG00000115414 ENSP00000352696 FN1 
ENSG00000075618 ENSP00000371798 FSCN1 
241 
 
ENSG00000087086 ENSP00000366525 FTL 
ENSG00000111640 ENSP00000384819 GAPDH 
ENSG00000171766 ENSP00000388809 GATM 
ENSG00000148672 ENSP00000277865 GLUD1 
ENSG00000172354 ENSP00000305260 GNB2 
ENSG00000090615 ENSP00000204726 GOLGA3 
ENSG00000148180 ENSP00000362924 GSN 
ENSG00000100983 ENSP00000216951 GSS 
ENSG00000148834 ENSP00000358727 GSTO1 
ENSG00000084207 ENSP00000381607 GSTP1 
ENSG00000206172 ENSP00000322421 HBA1 
ENSG00000188536 ENSP00000251595 HBA2 
ENSG00000244734 ENSP00000333994 HBB 
ENSG00000143321 ENSP00000349878 HDGF 
ENSG00000115677 ENSP00000312042 HDLBP 
ENSG00000189403 ENSP00000343040 HMGB1 
ENSG00000169045 ENSP00000377082 HNRNPH1 
ENSG00000104824 ENSP00000221419 HNRNPL 
ENSG00000153187 ENSP00000393151 HNRNPU 
ENSG00000072506 ENSP00000168216 HSD17B10 
ENSG00000080824 ENSP00000335153 HSP90AA1 
ENSG00000096384 ENSP00000360609 HSP90AB1 
ENSG00000166598 ENSP00000299767 HSP90B1 
ENSG00000204389 ENSP00000364802 HSPA1A 
ENSG00000232804 ENSP00000393087 HSPA1B 
ENSG00000170606 ENSP00000302961 HSPA4 
ENSG00000044574 ENSP00000324173 HSPA5 
ENSG00000109971 ENSP00000227378 HSPA8 
ENSG00000113013 ENSP00000297185 HSPA9 
ENSG00000106211 ENSP00000248553 HSPB1 
ENSG00000144381 ENSP00000373620 HSPD1 
ENSG00000149428 ENSP00000384144 HYOU1 
ENSG00000138413 ENSP00000260985 IDH1 
ENSG00000182054 ENSP00000331897 IDH2 
ENSG00000166411 ENSP00000299518 IDH3A 
ENSG00000132465 ENSP00000254801 IGJ 
ENSG00000132305 ENSP00000387262 IMMT 
ENSG00000140575 ENSP00000268182 IQGAP1 
ENSG00000151655 ENSP00000351190 ITIH2 
ENSG00000167768 ENSP00000252244 KRT1 
ENSG00000186395 ENSP00000269576 KRT10 
ENSG00000111057 ENSP00000373489 KRT18 
ENSG00000171345 ENSP00000355124 KRT19 
ENSG00000172867 ENSP00000310861 KRT2 
ENSG00000135480 ENSP00000329243 KRT7 
ENSG00000170421 ENSP00000293308 KRT8 
ENSG00000171403 ENSP00000246662 KRT9 
ENSG00000002549 ENSP00000226299 LAP3 
ENSG00000136167 ENSP00000315757 LCP1 
ENSG00000134333 ENSP00000395337 LDHA 
ENSG00000111716 ENSP00000229319 LDHB 
ENSG00000100097 ENSP00000215909 LGALS1 
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ENSG00000131981 ENSP00000254301 LGALS3 
ENSG00000108679 ENSP00000262776 LGALS3BP 
ENSG00000071282 ENSP00000157600 LMCD1 
ENSG00000160789 ENSP00000357283 LMNA 
ENSG00000113368 ENSP00000261366 LMNB1 
ENSG00000139329 ENSP00000266718 LUM 
ENSG00000120992 ENSP00000397807 LYPLA1 
ENSG00000090382 ENSP00000261267 LYZ 
ENSG00000102882 ENSP00000263025 MAPK3 
ENSG00000168906 ENSP00000303147 MAT2A 
ENSG00000014641 ENSP00000233114 MDH1 
ENSG00000146701 ENSP00000327070 MDH2 
ENSG00000240972 ENSP00000215754 MIF 
ENSG00000005381 ENSP00000225275 MPO 
ENSG00000128309 ENSP00000411719 MPST 
ENSG00000013364 ENSP00000378760 MVP 
ENSG00000100345 ENSP00000216181 MYH9 
ENSG00000105835 ENSP00000222553 NAMPT 
ENSG00000104419 ENSP00000404854 NDRG1 
ENSG00000023228 ENSP00000392709 NDUFS1 
ENSG00000198805 ENSP00000354532 NP 
ENSG00000105953 ENSP00000222673 OGDH 
ENSG00000102837 ENSP00000219022 OLFM4 
ENSG00000185624 ENSP00000327801 P4HB 
ENSG00000116288 ENSP00000418770 PARK7 
ENSG00000169564 ENSP00000305556 PCBP1 
ENSG00000100889 ENSP00000216780 PCK2 
ENSG00000063438 ENSP00000264933 PDCD6 
ENSG00000170248 ENSP00000307387 PDCD6IP 
ENSG00000168291 ENSP00000307241 PDHB 
ENSG00000167004 ENSP00000300289 PDIA3 
ENSG00000089220 ENSP00000261313 PEBP1 
ENSG00000108518 ENSP00000225655 PFN1 
ENSG00000102144 ENSP00000362413 PGK1 
ENSG00000079739 ENSP00000360125 PGM1 
ENSG00000167085 ENSP00000300408 PHB 
ENSG00000133110 ENSP00000369071 POSTN 
ENSG00000180817 ENSP00000362329 PPA1 
ENSG00000196262 ENSP00000419425 PPIA 
ENSG00000166794 ENSP00000300026 PPIB 
ENSG00000213639 ENSP00000378769 PPP1CB 
ENSG00000105568 ENSP00000324804 PPP2R1A 
ENSG00000117450 ENSP00000361152 PRDX1 
ENSG00000167815 ENSP00000301522 PRDX2 
ENSG00000165672 ENSP00000298510 PRDX3 
ENSG00000123131 ENSP00000368646 PRDX4 
ENSG00000117592 ENSP00000342026 PRDX6 
ENSG00000188783 ENSP00000411768 PRELP 
ENSG00000204983 ENSP00000308720 PRSS1 
ENSG00000197746 ENSP00000378394 PSAP 
ENSG00000129084 ENSP00000379675 PSMA1 
ENSG00000161057 ENSP00000391211 PSMC2 
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ENSG00000161057 ENSP00000292644 PSMC2 
ENSG00000165916 ENSP00000298852 PSMC3 
ENSG00000092010 ENSP00000206451 PSME1 
ENSG00000132341 ENSP00000376176 RAN 
ENSG00000114115 ENSP00000232219 RBP1 
ENSG00000198755 ENSP00000363018 RPL10A 
ENSG00000198755 ENSP00000363018 RPL10AP9 
ENSG00000142676 ENSP00000363676 RPL11 
ENSG00000161016 ENSP00000262584 RPL8 
ENSG00000112306 ENSP00000230050 RPS12 
ENSG00000140988 ENSP00000341885 RPS2 
ENSG00000008988 ENSP00000009589 RPS20 
ENSG00000171858 ENSP00000345957 RPS21 
ENSG00000143947 ENSP00000385659 RPS27A 
ENSG00000140988 ENSP00000341885 RPS2P11 
ENSG00000149273 ENSP00000278572 RPS3 
ENSG00000198034 ENSP00000362744 RPS4X 
ENSG00000137154 ENSP00000369757 RPS6 
ENSG00000143546 ENSP00000357721 S100A8 
ENSG00000163220 ENSP00000357727 S100A9 
ENSG00000163993 ENSP00000296370 S100P 
ENSG00000101347 ENSP00000262878 SAMHD1 
ENSG00000109072 ENSP00000226218 SEBOX 
ENSG00000168385 ENSP00000385387 SEPT2 
ENSG00000197249 ENSP00000390299 SERPINA1 
ENSG00000196136 ENSP00000376795 SERPINA3 
ENSG00000021355 ENSP00000370115 SERPINB1 
ENSG00000149257 ENSP00000350894 SERPINH1 
ENSG00000072501 ENSP00000323421 SMC1A 
ENSG00000197157 ENSP00000346762 SND1 
ENSG00000137767 ENSP00000260324 SQRDL 
ENSG00000148175 ENSP00000286713 STOM 
ENSG00000165283 ENSP00000348886 STOML2 
ENSG00000149591 ENSP00000278968 TAGLN 
ENSG00000158710 ENSP00000357077 TAGLN2 
ENSG00000177156 ENSP00000321259 TALDO1 
ENSG00000091513 ENSP00000385834 TF 
ENSG00000120708 ENSP00000416330 TGFBI 
ENSG00000198959 ENSP00000355330 TGM2 
ENSG00000137801 ENSP00000260356 THBS1 
ENSG00000137076 ENSP00000316029 TLN1 
ENSG00000167460 ENSP00000300933 TPM4 
ENSG00000232575 ENSP00000410071 TUBB 
ENSG00000235067 ENSP00000401317 TUBBP1 
ENSG00000183311 ENSP00000373058 TUBBP2 
ENSG00000178952 ENSP00000322439 TUFM 
ENSG00000239264 ENSP00000369081 TXNDC5 
ENSG00000025708 ENSP00000252029 TYMP 
ENSG00000130985 ENSP00000366568 UBA1 
ENSG00000169764 ENSP00000338703 UGP2 
ENSG00000010256 ENSP00000203407 UQCRC1 
ENSG00000140740 ENSP00000268379 UQCRC2 
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ENSG00000165280 ENSP00000351777 VCP 
ENSG00000213585 ENSP00000378484 VDAC1 
ENSG00000026025 ENSP00000224237 VIM 
ENSG00000109072 ENSP00000226218 VTN 
ENSG00000071127 ENSP00000371890 WDR1 
ENSG00000166913 ENSP00000300161 YWHAB 
ENSG00000164924 ENSP00000379287 YWHAZ 
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